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Abstract

BETA 2 NICOTINIC ACETYLCHOLINE RECEPTOR CONTRIBUTIONS TO ANXIETYLIKE BEHAVIOR
By Rev. Shawn Matthew Anderson, O.S.B., B.S. Pharm., M.Div.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2013.
Major Director, Darlene H. Brunzell, Ph.D., Associate Professor, Pharmacology and Toxicology

Nicotine is a major psychoactive ingredient in tobacco that is thought to promote smoking
behavior via nicotinic acetylcholine receptors (nAChRs) in the brain. Given reports that people
smoke to relieve anxiety and that anxiety precipitates relapse, the overarching goal of this
dissertation research is to assess β2 subunit containing nAChR (β2*nAChR) contributions to
anxiety-like behavior. Nicotine’s activity at β2*nAChRs is concentration-dependent, with high
concentrations facilitating activation followed by rapid desensitization and low concentrations
preferentially desensitizing β2*nAChRs; hence, activation or inhibition of β2*nAChRs may
support smoking behavior. Rodent studies reveal that nicotine affects anxiety-like behavior
dose-dependently: low doses promote anxiolysis- and high doses support anxiogenic-like
behavior. These pharmacological and genetic studies in mice test the hypothesis that nicotine
administration promotes anxiolysis via inactivation of β2*nAChRs and begin to identify which
subunits, namely α4 and α6, work in concert with β2 to affect anxiety-like behavior. Low dose
xvii

nicotine and inhibition of β2*nAChRs supported anxiolysis-like behavior in a number of tasks
with predictive validity for anxiolysis efficacy. These studies further suggest that activation of
α6β2*nAChRs is sufficient to produce anxiogenic-like behavior and that inhibition of
α4β2*nAChRs supports anxiolysis-like behavior. A secondary goal of these studies is to assess
if β2*nAChRs affect anxiety-like behavior during aging. Dysregulation of cholinergic tone can
increase anxiety in the elderly, but little is known regarding β2*nAChR contributions to anxiety
in this population or where in the brain this may take place. These studies show that
α4β2*nAChR expression differentially affects anxiety-like behavior in adult and aged mice.
With a focus on the lateral septum, a GABA-ergic limbic nucleus thought to regulate anxietylike responses to external stimuli, a third goal of these studies is to elucidate the neuroanatomical
and intracellular underpinnings of anxiety-like behavior that are affected by β2*nAChR
inhibition and expression. Previous studies demonstrate that exposure to stressors reduces
phosphorylation of extracellular regulated kinase (ERK) in the lateral septum. In these studies,
levels of pERK in the lateral septum were inversely associated with α4β2*nAChR expression as
well as anxiogenic-like behavior. In sum, these preclinical studies suggest that inhibition
α4β2*nAChRs may support cessation in those who smoke to relieve anxiety.

xviii

Chapter 1 – Introduction

Tobacco use remains the leading cause of preventable death in the US and is a growing global
health concern (WHO, 2008). Some 443,000 deaths were attributed to tobacco use and another
49,000 were linked to secondhand smoke exposure in the United States in 2011 (CDC, 2011;
NIH, 2011). Studies in human smokers reveal that multiple factors contribute to tobacco use; as
well as the pleasure received from smoking, many report that they use tobacco to relieve anxiety
(Berlin et al., 2003; Fidler & West, 2009; Livson & Leino, 1988; Perkins & Grobe, 1992;
Shiffman et al., 1997; Shiffman & Waters, 2004; Skara, Sussman, & Dent, 2001). Studies
further show that perceived stress contributes both to failed smoking cessation attempts and
escalation of smoking behaviors (Byrne, Byrne, & Reinhart, 1995; Byrne & Mazanov, 2003;
Finkelstein, Kubzansky, & Goodman, 2006; McCabe et al., 2004; Shiffman et al., 1997;
Siqueira, Diab, Bodian, & Rolnitzky, 2000; Skara et al., 2001; Zvolensky, Marshall, et al., 2009;
Zvolensky, Stewart, Vujanovic, Gavric, & Steeves, 2009). The exact mechanism underlying
reported reductions in anxiety by smokers is not clearly understood. The preclinical studies in
this dissertation aim to elucidate the mechanisms by which nicotine exerts its effects on anxietylike behavior.

History of Nicotine
Nicotine is the principal alkaloid in tobacco, comprising some 1.5% of the weight and 95% of
the cumulative alkaloid content of commercially available cigarette tobacco. The average
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tobacco rod contains about 10-14 mg of nicotine, and approximately 1-1.5 mg of nicotine is
absorbed during smoking (Benowitz & Jacob, 1984; Kozlowski et al., 1998). The tobacco plant
is a member of the nightshade family. Other than its known use as a drug for recreational
purposes, nicotine is also an effective insecticide, which is its endogenous role in the tobacco
plant. Tobacco was used for centuries by the indigenous peoples of North and South America,
chiefly in religious ceremonies and as a treatment for many ailments, including diarrhea, pain,
wounds and burns. Nicotiana tobacum, the species of tobacco plant most commonly used in
commercial tobacco products, is likely of South American origin, while another species,
Nicotiana rusticum, is native to North America. Jean Nicot de Villemain, a French ambassador
to Portugal, grew tobacco and observed the healing properties of extracts of the leaves. His
enthusiasm for the healing properties of the plant grew and his sharing of tobacco was so liberal
that the plant became known as the ambassador’s plant, or nicotiane, by which it is known today.

In 1807 Gaspare Cerioli and in 1809 Louis-Nicolas Vauquelin independently isolated nicotine
from the tobacco plant. Later, in 1828, Wilhelm Heinrich Posselt and Karl Ludwig Reimann
first isolated pure nicotine from the tobacco plant. Louise Melsens, a Belgian chemist and
physicist, described nicotine's empirical formula in 1843, and Adolf Pinner and Richard
Wolffenstein, described its structure in 1893. The first synthesis of nicotine occurred in 1904 by
A. Pictet and P. Crepieux.

Nicotinic Acetylcholine Receptors (nAChRs)
Nicotine binds to pentameric nicotinic acetylcholine receptors (nAChRs), which are members of
the Cys-loop superfamily of ligand-gated ion channels (Karlin, 1993; Le Novere & Changeux,
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1995). The earliest studies that led to the discovery of nAChRs were performed on skeletal
muscle by John Langley. In skeletal muscle, α1, β1, δ and γ or ε subunits assemble to form a
functional nAChR. He observed that nicotine and curare had opposing effects on skeletal muscle
activity and that they continued to exert their effects in the absence of innervation (Langley,
1905). From this he theorized that nicotine and curare acted via a “receptive substance” other
than the muscle that was able to affect the contractile activity of the muscle (Langley, 1907) and
change its properties. Langley also discovered that the application of nicotine resulted in
paralysis of peripheral ganglia (Langley & Dickinson, 1890). Although they did not realize it at
the time, nicotine was exerting these effects via desensitization or inactivation of the nAChRs.

The activity of nicotine at nAChRs is dose-dependent; micromolar concentrations of nicotine
activate nAChRs (Fenster, Rains, Noerager, Quick, & Lester, 1997; Grady, Wageman, Patzlaff,
& Marks, 2012; Kuryatov, Berrettini, & Lindstrom, 2011; R. A. Lester & Dani, 1995; Lu, Marks,
& Collins, 1999; Mansvelder, Keath, & McGehee, 2002; Pidoplichko, DeBiasi, Williams, &
Dani, 1997), whereas nM concentrations of nicotine support preferential desensitization of most
heteromeric nAChRs (Fenster et al., 1997; Grady et al., 2012; Kuryatov et al., 2011; Lu et al.,
1999; Mansvelder et al., 2002; Pidoplichko et al., 1997). The binding of two agonist molecules
to nAChRs generally promotes a conformational change in the nAChR protein, facilitating
opening of the central pore, which allows the passage of the cations sodium and calcium into the
cell. Following activation, nAChRs become desensitized, wherein they are resistant to
subsequent activation by either endogenous or exogenous agonists (Fenster et al., 1997; R. A.
Lester & Dani, 1995; Mansvelder et al., 2002; Pidoplichko et al., 1997). Consequently, nAChRs
can exist in at least 3 distinct stoichiometries: Unbound and Resting, Bound and Activated (with
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ligand bound to nAChR) and Bound and Desensitized (with ligand still bound) (Katz & Thesleff,
1957). nAChRs in the Bound and Desensitized state are in the thermodynamically preferred
state (Changeux, Devillers-Thiery, & Chemouilli, 1984), with α4β2*nAChRs requiring upwards
of 90 min washout time before returning to the Unbound and Resting state (Fenster et al., 1997).
In contrast to the effects of micromolar concentrations of nicotine, which activate and
subsequently desensitize nAChRs, nanomolar concentrations of nicotine at least 62 fold lower
than the EC50 value of nicotine preferentially desensitize nAChRs without activation (Fenster et
al., 1997; Grady et al., 2012; Kuryatov et al., 2011; Lu et al., 1999). However, since nicotine is
an agonist, nAChRs are not statically in the Bound and Desensitized state, but are said to be in an
intermediate “smoldering” state. Higher nicotine concentrations favor transition of nAChRs
from Bound and Desensitized to the Bound and Activated state, whereas lower agonist
concentrations are likely to result in nAChRs remaining Bound and Desensitized until nicotine is
cleared from the receptor site (Kuryatov et al., 2011). Peak concentrations of nicotine in the
brains of smokers reach micomolar levels, while they are likely maintained between 200-500 nM
throughout the day (Rose et al., 2010). Consequently, fluctuating concentrations of nicotine in
the brains of smokers have the potential to activate or desensitize nAChRs. Although the
phenomenon of nAChR receptor desensitization was first observed following prolonged
exposure of the endogenous ligand acetylcholine (ACh) at the neuromuscular junction, the
activity of acetylcholinesterase (AChE), the degradative enzyme of ACh, normally prevents
ACh-mediated nAChR desensitization (G. L. Brown, Dale, & Feldberg, 1936; Katz & Thesleff,
1957; Thesleff, 1955).
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In the central nervous system, the affinity and activity of both ACh and exogenous agonists such
as nicotine upon nAChRs further depend upon the subunit composition of the particular nAChR
subclass that is the target of the ligand’s activity. α7nAChRs, the only homomeric nAChRs
known to exist in the mammalian brain, have a high binding affinity for the antagonist αbungarotoxin (Clarke, Schwartz, Paul, Pert, & Pert, 1985; Marks & Collins, 1982). Heteromeric
nAChRs are comprised of a combination of alpha (α2-α6) and beta (β2-β4) subunits. β2
subunit-containing nAChRs (β2*nAChRs; * denotes other subunits may co-assemble to form a
functional receptor) have the highest binding affinity and lowest EC50 for ACh and nicotine, at
least 15 fold lower than other subclasses of nAChRs (Grady et al., 2010; Pauly, Marks, Gross, &
Collins, 1991; Whiting & Lindstrom, 1988; Y. Xiao & Kellar, 2004), and are widely distributed
throughout the brain (Clarke et al., 1985; Court & Clementi, 1995; Fujita et al., 2000; Grady et
al., 2010; Kimes et al., 2008; Marks et al., 2010; Marks et al., 1992; Pauly & Collins, 1993;
Picciotto et al., 1995; Rubboli et al., 1994; Staley et al., 2005; Y. Xiao & Kellar, 2004), where
they are enriched on the soma or terminals of neurons residing in limbic brain regions known to
regulate appetitive and affective behaviors (Clarke et al., 1985; Court & Clementi, 1995; Fujita
et al., 2000; Grady et al., 2010; Kimes et al., 2008; Marks et al., 2010; Marks et al., 1992; Pauly
& Collins, 1993; Picciotto et al., 1995; Rubboli et al., 1994; Staley et al., 2005; Y. Xiao &
Kellar, 2004), suggesting that modifying the activity of α4β2*nAChRs could affect both rewardlike and anxiety-like behaviors. This is in contrast to a subclass of β2*nAChRs, which is
sensitive to α-conotoxin MII, those that contain an α3 or α6 subunit. (α3β2*nAChRs and
α6β2*nAChRs). Studies in α6 subunit knockout mice (α6KO) reveal that α6β2*nAChRs are
more selectively expressed than other β2*nAChRs, being predominantly enriched on the soma
and neuron terminals of catecholaminergic neurons, as well as in brain areas associated with the
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visual circuit, including the superior colliculus (Champtiaux et al., 2002; Marks et al., 2010;
Whiteaker, McIntosh, Luo, Collins, & Marks, 2000). α-conotoxin MII binding studies further
show that α6β2*nAChRs are highly expressed on terminals of dopamine (DA) neurons
projecting from the ventral tegmental area (VTA) to the dorsal striatum and nucleus accumbens
(NAcc). This is in contrast to the α4β2*nAChRs, which in addition to their expression in the
VTA and are also highly expressed in other DA projection regions including the amygdala,
hippocampus, lateral septum and anterior cingulate cortex (Cartier et al., 1996; Champtiaux et
al., 2002; Marks et al., 2010; Mineur et al., 2009; Whiteaker et al., 2000). In making a
distinction between α4β2*nAChRs and α6β2*nAChRs, it should be noted that a subclass of
receptors expresses both α4 and α6 subunits (α4α6β2*nAChRs). The α4α6β2*nAChRs are
highly implicated in nicotine reinforcement and reward and compared to other heteroreceptors
are resistant to desensitization in response to nM concentrations of nicotine that are achieved in
the brains of smokers (Brunzell, Boschen, Hendrick, Beardsley, & McIntosh, 2010; Jackson,
McIntosh, Brunzell, Sanjakdar, & Damaj, 2009; L. Liu, Zhao-Shea, McIntosh, Gardner, &
Tapper, 2012; Pons et al., 2008; Tapper et al., 2004).

nAChR agonists bind at the juncture of the “front” of an α subunit and the “back” of the adjacent
subunit. Heteromeric nAChRs only have two binding sites, at the junction of an α and β subunit,
which is in contrast to the homomeric α7nAChRs which may have a ligand binding site at each
of the five subunit junctures. In heteromeric nAChRs, the fifth or accessory subunit does not
participate in binding but does contribute to the receptor binding and channel function (Bailey,
De Biasi, Fletcher, & Lambe, 2010; Grady et al., 2012; Kuryatov, Onksen, & Lindstrom, 2008).
The α5 and β3 subunits are thought to only function as accessory subunits, whereas α2-4, α6,
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α7, β2 and β4 may act as binding or accessory subunits (Briggs et al., 2006; R. W. Brown,
Collins, Lindstrom, & Whiteaker, 2007; Drenan, Nashmi, et al., 2008; Gerzanich, Wang,
Kuryatov, & Lindstrom, 1998; Kuryatov, Luo, Cooper, & Lindstrom, 2005; Nelson, Kuryatov,
Choi, Zhou, & Lindstrom, 2003; Tumkosit, Kuryatov, Luo, & Lindstrom, 2006). Additionally,
studies in xenopus oocytes show that an increased expression ratio of α4:β2 subunits favors
assembly of a lower sensitivity α4(3)β2(2) stoichiometry, whereas higher expression of β2:α4
favors the α4(2)β2(3) stoichiometry of α4β2*nAChRs with higher sensitivity for nAChR ligands
(Anand, Conroy, Schoepfer, Whiting, & Lindstrom, 1991; Buisson & Bertrand, 2001; Cooper,
Couturier, & Ballivet, 1991; Covernton & Connolly, 2000; Khiroug, Khiroug, & Yakel, 2004;
Moroni, Zwart, Sher, Cassels, & Bermudez, 2006; Nelson et al., 2003; Zwart & Vijverberg,
1998). In vitro studies show that 86Rb+ efflux from striatal synaptosomes taken from mice with
50% reduction of the β2 subunit (β2HET), favoring the α4(3)β2(2) stoichiometry, is reduced
following exposure to low ACh concentrations compared to synaptosomes harvested from mice
with a 50% reduction of the α4 subunit (α4HET), which would more likely assemble in the
higher sensitivity α4(2)β2(3) stoichiometry (Gotti et al., 2008). This suggests that assembly of
α4β2*nAChRs with both high and low sensitivity modifies endogenous ACh tone in in vivo as
well. The “front” of the binding pocket requires the Cys-Cys loop of the α subunit as well as a
number of predominantly hydrophobic amino acids, including Tyr 93, Trp 149, Tyr 190 and Tyr
198 and the “back” of the binding site requires 3 amino acids (L112, M114, and Trp53) found on
the adjacent subunit (Celie et al., 2004; Karlin et al., 1986; Sine & Engel, 2006).

Unlike other neurotransmitters which are largely expressed post-synaptically opposite the release
site, nAChRs are predominantly expressed extrasynaptically, on pre-synaptic terminals, and on
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cell bodies (Arroyo-Jiminez et al., 1999; Hill, Zoli, Bourgeois, & Changeux, 1993; Kawai,
Lazar, & Metherate, 2007; McGehee, Heath, Gelber, Devay, & Role, 1995; Rice & Cragg, 2004;
Vidal & Changeux, 1993; Wonnacott, 1997; H. Zhang & Sulzer, 2004). Rather, nAChRs act as
neuromodulators. Positioned on neurons that release many different neurotransmitters,
stimulation of nAChRs can facilitate the release of glutamate, GABA, DA, ACh, norepinephrine
and serotonin, suggestive of pre-synaptic activity (McGehee et al., 1995; Wonnacott, 1997).
Facilitation of neurotransmitter release via nAChRs is subclass specific and it varies between
brain regions. For example, activation of α7nAChRs facilitates glutamate release and activation
of α4β2 nAChRs facilitates GABA release in the VTA, whereas glutamate release is increased
after β2*nAChR activation in thalamo-cortical neurons. (Mansvelder & McGehee, 2000; Parikh,
Ji, Decker, & Sarter, 2010; Poorthuis, Bloem, Verhoog, & Mansvelder, 2013). Additionally, the
release of ACh is enhanced following activation of α3β4*nAChRs on cholinergic neuron
terminals (Grady et al., 2001). In support of ACh synaptic transmission, there is evidence
demonstrating that nicotine and ACh can stimulate excitatory post-synaptic potentials
(Alkondon, Pereira, & Albuquerque, 1998; Jones, Sudweeks, & Yakel, 1999; Lena & Changeux,
1999; Picciotto et al., 1995; Picciotto et al., 1998), but other studies suggest that ACh exerts its
effects primarily through volume transmission (Arroyo, Bennett, Aziz, Brown, & Hestrin, 2012;
Bell, Shim, Chen, & McQuiston, 2011; Yamasaki, Matsui, & Watanabe, 2010). The effect of
nAChR activation on neuronal plasticity is also contingent upon the nAChR subclass involved
and brain region investigated. For example, activation of α7nAChRs on glutamate terminals
promotes long-term potentiation (LTP) via activation of DA neurons in the VTA (Mansvelder &
McGehee, 2000). By contrast, activation of α4β2*nAChRs on GABA terminals reduces postsynaptic calcium levels (Couey et al., 2007). Furthermore, by activation of the protein
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phosphatase calcineurin and subsequent inactivation of L-type calcium channels, activation of
high affinity β2*nAChRs can reduce calcium entry into post-synaptic neurons following the
release of glutamate (Stevens, Krueger, Fitzsimonds, & Picciotto, 2003). These studies
demonstrate that the disruption of cholinergic activity by nicotine and/or nicotinic antagonists or
partial agonists has the potential to alter the valence of an external stimulus.

Considering that activation of pre-synaptic β2*nAChRs can facilitate neurotransmitter release
and that activation of post-synaptic β2*nAChRs can result in either elevated or reduced levels of
intracellular calcium, preferential desensitization of β2*nAChRs also has the potential to
profoundly modify the central nervous system response to both ACh and nicotine. Currently
approved pharmacotherapies for smoking cessation include the β2*nAChR partial agonist
varenicline and the nicotine patch, which has nicotine pharmacokinetics that would support
desensitization of β2*nAChRs (Benowitz, Jacob, Fong, & Gupta, 1994). Thus, it is possible that
these therapies derive their efficacy by reducing the activity of β2*nAChRs during the release of
ACh. Varenicline is also a full agonist at α7nAChRs, and local infusions of the selective
α7nAChR agonist PNU 282987 into the NAcc shell reduce the motivation to self-administer
nicotine in preclinical models, making it difficult to determine if the efficacy of varenicline is
promoted primarily via β2*nAChRs or α7nAChRs (Brunzell & McIntosh, 2012).

Similar to nicotine’s dose-dependent effects at nAChRs, behavioral studies show that nicotine
administration also has a bimodal effect on anxiety-like behavior; low doses of nicotine promote
an anxiolytic-like phenotype (Cheeta, Irvine, Kenny, & File, 2001; File, Kenny, & Ouagazzal,
1998; Irvine, Cheeta, & File, 1999; McGranahan, Patzlaff, Grady, Heinemann, & Booker, 2011),
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whereas high doses of nicotine result in an increase in anxiety-like behavior (Cheeta, Tucci, &
File, 2001; File, Kenny, & Cheeta, 2000; File et al., 1998; Ouagazzal, Kenny, & File, 1999;
Zarrindast, Solati, Oryan, & Parivar, 2008). Evidence suggests that inhibition of the β2*nAChRs
with selective antagonists or partial agonists supports anxiolysis in animal models (Anderson &
Brunzell, 2012; Dawson, Miles, & Damaj, 2013; Roni & Rahman, 2011; Turner, Castellano, &
Blendy, 2010, 2011). This is in contrast to nicotine’s “reward-like” and reinforcing properties,
which require activation of the high affinity β2*nAChRs (Brunzell et al., 2010; Corrigall, Coen,
& Adamson, 1994; Gotti et al., 2010; Grabus, Martin, Brown, & Damaj, 2006; Jackson et al.,
2009; Maskos et al., 2005; McGranahan et al., 2011; Mineur et al., 2009; Picciotto et al., 1998;
Pons et al., 2008; Tapper et al., 2004; Walters, Brown, Changeux, Martin, & Damaj, 2006) (but
see (Exley & Cragg, 2008). Nicotine self-administration and nicotine conditioned place
preference are absent in α4, α6 and β2 null mutant mice (α4KO, α6KO, β2KO) (Jackson et al.,
2009; McGranahan et al., 2011; Mineur et al., 2009; Orejarena et al., 2012; Picciotto et al., 1998;
Pons et al., 2008; Walters et al., 2006). These rodent models of nicotine reinforcement and
reward are also blocked by pre-injection of the β2*nAChR antagonist dihydro-beta-erythroidine
(DHβE), which selectively antagonizes α4β2*nAChRs as well as α6β2*nAChRs, and by
selective antagonists of α6β2*nAChRs (Brunzell et al., 2010; Corrigall et al., 1994; Gotti et al.,
2010; Grabus et al., 2006; Jackson et al., 2009; Maskos et al., 2005; McGranahan et al., 2011;
Mineur et al., 2009; Picciotto et al., 1998; Pons et al., 2008; Tapper et al., 2004; Walters et al.,
2006) (but see (Exley & Cragg, 2008)). Studies utilizing gain-of-function mice with an L9’A
single point mutation in the M2 pore-forming region of the α4 subunit (L9A) further show that
activation of the α4 subunit is sufficient to support nicotine conditioned place preference (CPP)
(Tapper et al., 2004). Furthermore, activation of α6β2*nAChRs on the soma of DA neurons
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originating in the VTA is sufficient to stimulate release of DA in the NAcc (Drenan et al., 2010;
Drenan, Grady, et al., 2008; Exley & Cragg, 2008; Pons et al., 2008; Zhao-Shea et al., 2011).
Together these studies suggest that activation of α4α6β2*nAChRs supports nicotine reward and
nicotine self-administration. DA release in the dorsal striatum is thought to mediate nicotinemediated locomotor activation (Cohen et al., 2012; Drenan et al., 2010; Drenan, Grady, et al.,
2008; McGranahan et al., 2011; Mineur et al., 2009). However, in vivo microdialysis and cyclic
voltammetry studies show that DA release is also increased in the NAcc following an aversive
footshock and is predictive of execution of lever pressing behavior to avoid reception of a
footshock (Kalivas & Duffy, 1995; Oleson, Gentry, Chioma, & Cheer, 2012; Takahashi, Takada,
Nagai, Urano, & Takada, 1998). Thus, increased accumbal DA release is not ubiquitous with the
rewarding properties of a reinforcer, but is also associated with determining the salience of
aversive external stimuli.

Neuroanatomy of nAChRs: pathways relevant to addiction phenotype
Binding studies show that nAChRs are expressed in brain regions such as the NAcc and VTA
that regulate the rewarding/reinforcing properties of drugs of abuse and natural reinforcers, such
as food, as well as brain nuclei associated with emotive responses to environmental stimuli, such
as the amygdala, hippocampus, prefrontal cortex (PFC) and lateral septum (Baddick & Marks,
2011; Clarke et al., 1985; Marks et al., 2010). Binding studies using the selective α6/α3*nAChR
antagonist α-conotoxin MII further demonstrate that α7nAChRs and α4β2*nAChRs, but not
α6β2*nAChRs are expressed in the amygdala, hippocampus, PFC and lateral septum (Baddick
& Marks, 2011; Champtiaux et al., 2002; Clarke et al., 1985; Marks et al., 2010; Mineur et al.,
2009; Whiteaker et al., 2000). The activation of the amygdala promotes anxiety and fear, as
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evidenced by reduced anxiety-like behaviors in rodents, non-human primates and humans
following either excitotoxic lesions of the amygdala or amygdalar damage (Drevets, 2003; Kalin,
Shelton, & Davidson, 2004; Masaoka, Hirasawa, Yamane, Hori, & Homma, 2003; Ventura-Silva
et al., 2013). Additionally, human imaging studies show that amygdala activity is increased in
individuals presenting with trait anxiety and anxiety related to dementia (Britton, Lissek, Grillon,
Norcross, & Pine, 2011; Sehlmeyer et al., 2011). The selective removal of cholinergic input to
the basolateral amygdala (BLA), where α4β2*nAChRs prevail, results in reduced anxiety-like
behavior (Power & McGaugh, 2002), suggesting that reduced activity of α4β2*nAChRs in the
amygdala would attenuate anxiety-like behavior.

The lateral septum is a GABA-ergic nucleus that receives a convergence of neuronal input from
various brain regions known to regulate the motivational valence of external stimuli (e.g., DA
from the VTA, the neuropeptide CRF indirectly from the amygdala via the bed nucleus of the
stria terminalis, glutamate from the hippocampus and the PFC and ACh from the lateral dorsal
tegmental nucleus (Risold & Swanson, 1997a, 1997b). Together with the hippocampus, the
lateral and medial septal nuclei comprise the “septo-hippocampal” circuit that is thought to
regulate anxiety-like behavior, with the hippocampus integrating information that is predictive of
a real or perceived threat, and the lateral septum regulating the emotive anxiety response to an
environmental stimulus (Gray, 1982; Risold & Swanson, 1997a, 1997b). Among primates, the
septum achieves its maximal size in the human species, making it an appealing brain region to
evaluate the anxiolytic-like properties of nicotine (Andy & Stephan, 1968). Excitotoxic lesions
to the lateral septum result in the expression of an anxiogenic-like phenotype classified as the
“septal rage syndrome” (Albert & Chew, 1980; Albert & Walsh, 1982; Brady & Nauta, 1953;
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Olton & III, 1976). Activation of corticotropin releasing factor subtype 2 receptors (CRFR2) in
the lateral septum, which increases anxiety-like behavior, also inhibits lateral septum activity,
possibly via inhibition of excitatory glutamate release in the lateral septum from the PFC or
hippocampus (Eberly, Dudley, & Moss, 1983; J. Liu et al., 2004). Pharmacological antagonism
of both corticotropin releasing factor subtype 1 receptor (CRFR1) and CRFR2 in the lateral
septum attenuates anxiogenic-like behavior following restraint stress (Radulovic, Ruhmann,
Liepold, & Spiess, 1999).

A preponderance of the evidence suggests that stimulation of the lateral septum promotes
anxiolysis-like behavior. Electrical stimulation of the lateral septum results in increased water
consumption despite the reception of lick-contingent shocks and has been shown to reduce
gastric ulceration following chronic stress (Yadin & Thomas, 1996; Yadin, Thomas, Grishkat, &
Strickland, 1993). The lateral septum gives rise to GABA-ergic outputs to several brain areas
thought to regulate anxiety and arousal and thus is positioned to inhibit these brain areas. The
infusion of the benzodiazepine chlordiazepoxide results in activation of the lateral septum and
reduced activity within the amygdala (Yadin & Thomas, 1998), suggesting that opposing
activation of these two brain regions may be coordinated to regulate the emotive response to an
aversive stimulus. Additionally, electrical stimulation of the lateral septum reduces activity of
the paraventricular nucleus of the hypothalamus (PVN) by 50% and neurotoxic lesions in the
lateral septum resulted in increased HPA-axis activation and expression of c-Fos in the PVN
following forced swim stress than sham-lesioned controls, suggesting the activation of lateral
septal nuclei results in an attenuation of the response of the PVN to stressors (Herman,
Marciano, & Gash, 1986; Herman, Ostrander, Mueller, & Figueiredo, 2005; Pittman, Blume, &
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Renaud, 1981; Saphier & Feldman, 1987; Singewald, Rjabokon, Singewald, & Ebner, 2011).
Taken together, these studies indicate that activation of the lateral septum reduces anxiety-like
behaviors, and suggest that lateral septum inhibition may promote anxiogenic-like behavior (Fig
1.1).

Nicotine effects on intracellular signaling: extracellular regulated kinase (ERK)
ERK is a serine/threonine kinase critical for neuronal plasticity related to learning and memory
and to the rewarding properties of drugs of abuse, including nicotine (Brunzell, Mineur, Neve, &
Picciotto, 2009; Brunzell, Russell, & Picciotto, 2003; S. Davis, Vanhoutte, Pages, Caboche, &
Laroche, 2000; Schafe et al., 2000; Schafe, Swank, Rodrigues, Debiec, & Doyere, 2008; Sweatt,
2001; Valjent et al., 2006; Valjent, Pages, Herve, Girault, & Caboche, 2004). Nicotine-mediated
activation of nAChRs facilitates the release of neurotrophins such as nerve growth factor (NGF)
and brain-derived neurotrophic factor (BDNF), which activate the Ras/Raf/MEK pathway via
receptor tyrosine kinases (Belluardo, Mudo, Blum, et al., 1999; Belluardo, Mudo, Blum, & Fuxe,
2000; Belluardo, Mudo, Caniglia, et al., 1999; Ying et al., 2002). Activation of nAChRs also
facilitates increased levels of intracellular calcium, leading to releases of intracellular stores of
calcium or phosphorylation of protein kinase C (PKC), calcium modulated kinase II (CaMKII),
or proline-rich tyrosine kinase (Pyk-2), which in turn may phosphorylate (activate) ERK (Chang
& Berg, 2001; Dajas-Bailador, Soliakov, & Wonnacott, 2002; Fenster et al., 1999; Konu et al.,
2001; Messing, Stevens, Kiyasu, & Sneade, 1989; Nakayama, Numakawa, Ikeuchi, & Hatanaka,
2001; Tahara et al., 2001; Tuominen et al., 1992).
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The effect of external stressors on ERK phosphorylation is brain region specific. In rats exposed
to restraint stress, pERK was significantly increased in the hippocampus, PFC and hypothalamus
(Kwon et al., 2006; Meller et al., 2003; Sananbenesi, Fischer, Schrick, Spiess, & Radulovic,
2003; H. T. Wang, Han, Gao, & Shi, 2010), (however, see (ElBatsh, Assareh, Marsden, &
Kendall, 2012)). An intracerebroventricular infusion of corticotropin releasing factor (CRF),
associated with anxiogenic-like behavior, induced significant increases in pERK in the
hippocampus and BLA respectively (Refojo et al., 2005). In contrast with the increased
phosphorylation of ERK in these excitatory nuclei, levels of pERK were reduced in the lateral
septum following restraint and chronic housing stress (Sheehan, Neve, Duman, & Russell, 2003;
Singewald, Nguyen, Neumann, Singewald, & Reber, 2009). Additionally, overexpression of
Pyk-2, which can activate Ras, leading to ERK phosphorylation, in the lateral septum led to a
reduction in depression-like behavior (Sheehan et al., 2003). ERK, like c-Fos, can act as a
biomarker for cellular activity. The studies above suggest that elevated levels of pERK, similarly
to increased lateral septum neuronal activity, is associated with reductions in stress-like behavior
whereas decreases are associated with increases in anxiety-like and depression-like behavior
(Sheehan et al., 2003; Singewald et al., 2009; E. Thomas, Strickland, Yadin, & Burock, 2005; E.
Thomas & Yadin, 1980; E. Thomas, Yadin, & Strickland, 1991; Yadin & Thomas, 1996, 1998;
Yadin et al., 1993).

In addition to acting as a biomarker for anxiety-like behavior, lateral septum ERK may play a
functional role in regulation of anxiety-like behavior. pERK can be translocated to the nucleus,
where it activates the transcription factor CREB. The overexpression of CREB in the NAcc

15

Figure 1.1 - Promotion of increased neuronal activity in the lateral septum via elevations in
pERK may result in reduced expression of anxiety-like behavior. Adapted from (Sheehan,
Chambers, & Russell, 2004).
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regulates the motivational salience of rewarding and aversive external stimuli (Barrot et al.,
2002; Barrot et al., 2005). Like ERK, CREB activation is region specific as it associates to
anxiety-like behavior. The expression of pCREB in the hippocampus and PFC is inversely
associated with changes in anxiety-like behavior (Rubino et al., 2007; J. Zhang et al., 2010),
whereas the opposite is found regarding pCREB expression in the periaqueductal gray (Adamec,
Berton, & Abdul Razek, 2009). Increased expression of inducible cAMP early repressor is
associated with increased anxiety-like behavior in the elevated plus maze (Green et al., 2006).
Furthermore, increased pCREB in the hippocampus is associated with improved cognitive
function in preclinical experiments (Trofimiuk, Holownia, & Braszko, 2010).

Intracellular changes in ERK phosphorylation may result from downregulation of ERK
activation pathways (Raf/Ras/MEK) or upregulation of phosphatase activity, which would
inactivate pERK. The phosphatase striatal enriched phosphatase (STEP) can dephosphorylate, or
inactivate ERK (M. A. Johnson & Lombroso, 2012; Lombroso, Murdoch, & Lerner, 1991;
Munoz, Tarrega, Blanco-Aparicio, & Pulido, 2003; Odagaki et al., 2001; Paul, Nairn, Wang, &
Lombroso, 2003; Xu, Kurup, Bartos, et al., 2012). Outside of the striatum, STEP expression is
the highest in the lateral septum, suggesting that it may be an important regulator of ERK
phosphorylation in this brain region (Boulanger et al., 1995; Lombroso, Naegele, Sharma, &
Lerner, 1993). STEP is increased in several neuropsychiatric disorders, including Alzheimer’s
Disease (AD) and schizophrenia, disorders also known to involve dysregulation of nAChRs
(Chin et al., 2005; Kurup et al., 2010; Xu, Kurup, Nairn, & Lombroso, 2012; Y. Zhang et al.,
2010). Furthermore, the overexpression of a “substrate trapping” form of STEP that irreversibly
binds to molecular targets such as ERK prevents fear conditioning when locally infused into the
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amygdala (Paul et al., 2007); hence altering the activity of phosphatases that control pERK can
regulate the motivational salience of external stimuli.

Little is known about how

α4β2*nAChRs may contribute to changes in lateral septum ERK that could support changes in
anxiety behaviors.

Nicotine and smoking behavior
Human and animal studies demonstrate that nicotine exerts its psychoactive properties by
binding to nAChRs in brain (Brunzell et al., 2010; Corrigall et al., 1994; DeNoble & Mele, 2006;
Gotti et al., 2010; Pons et al., 2008). Like most drugs of abuse, nicotine activates DA projection
neurons of the mesocorticlimbic reward pathway that originate in the VTA, resulting in the
release of the neurotransmitter DA in brain areas known to be critical in determining the
motivational salience of external stimuli, such as the NAcc, PFC and lateral septum (Brody,
Mandelkern, Olmstead, et al., 2009; Brody et al., 2004; Domino et al., 2013; Domino, Tsukada,
& Harada, 2009; Kleijn et al., 2011; Mansvelder et al., 2002; Mineur et al., 2009; Perez, Bordia,
McIntosh, Grady, & Quik, 2008; Perez, Ly, McIntosh, & Quik, 2012; Perez, McIntosh, & Quik,
2013; Pidoplichko et al., 1997; Takahashi et al., 2008). Consequently, the majority of preclinical
and clinical research has been directed at understanding the neuronal and molecular mechanisms
regulating the pleasurable or “rewarding” effects exerted by nicotine.

The Fagerstrom Test for Nicotine Dependence (Table 1.1) is the most widely used instrument to
determine the degree of nicotine dependence in smokers (Fagerstrom, 1978). Time elapsed
before smoking the first cigarette of the day is the greatest predictor of nicotine dependence
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Table 1.1 – Fagerstrom Test for Nicotine Dependence
Fagerstrom Test for Nicotine Dependence
1. How soon after you wake up do
Less than 5 min 3 pt
you smoke your first cigarette?
6-30 min 2 pt
30-60 min 1 pt
2. Do you find it difficult to refrain
Yes 1 pt
from smoking in places where it is
No 0 pt
prohibited?
3. Which cigarette would you hate
First one of the day 1 pt
to give up?
Any other 0 pt
4. How many cigarettes a day do
10 or less 0 pt
you smoke?
11-20 1 pt
21-30 2 pt
31 or more 3 pt
5. Do you smoke more frequently
Yes 1 pt
in the morning?
No 0 pt
6. Do you smoke even if you are
Yes 1 pt
sick in bed most of the day?
No 0 pt
Total score
Score
1-2 = Low dependence
5-7 = Moderate dependence
3-4 = Low to moderate dependence 8+ = High dependence
(Adapted from (Fagerstrom, 1978)).
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using this test, indicating that nicotine dependence is thought to be primarily driven by the
reward-like experience of smoking the first cigarette of the day, which is reported by many
smokers to be the most pleasurable. An emerging theory of drug dependence is that the positive
reinforcing effects of drugs of abuse likely contribute to the onset of drug use, whereas
avoidance of the negative effects of withdrawal underlie escalation of drug use, leading to
dependency and addiction (Koob & Volkow, 2010).

While this may also hold true for tobacco use, there is a high concordance between tobacco use
and affective disorders, including the range of anxiety-related disorders (Evatt & Kassel, 2010;
Gilbert et al., 2008; Grillon, Avenevoli, Daurignac, & Merikangas, 2007; John, Meyer, Rumpf,
& Hapke, 2004; J. L. Johnson, Eaton, Pederson, & Lowry, 2009; McCabe et al., 2004;
Morissette, Brown, Kamholz, & Gulliver, 2006; Tsuda, Steptoe, West, Fieldman, & Kirschbaum,
1996; Vujanovic, Marshall, Gibson, & Zvolensky, 2010; Vujanovic, Marshall-Berenz, Beckham,
Bernstein, & Zvolensky, 2010; Zvolensky, Marshall, et al., 2009; Zvolensky, Stewart, et al.,
2009). Furthermore, stress and anxiety are cited as primary factors contributing to relapse during
smoking cessation attempts and to the escalation of cigarette use (Byrne et al., 1995; Byrne &
Mazanov, 2003; Finkelstein et al., 2006; McCabe et al., 2004; Shiffman et al., 1997; Siqueira et
al., 2000; Skara et al., 2001; Zvolensky, Marshall, et al., 2009; Zvolensky, Stewart, et al., 2009).
In light of this, clinical trials are evaluating subjects for trait anxiety scores using instruments
such as the Anxiety Sensitivity Index (ASI) to help identify other factors contributing to the
onset and maintenance of tobacco use. Various preclinical models of anxiety-like behavior are
also being employed to determine the genetic and molecular factors that underlie initial
sensitization to the interoceptive effects of acute nicotine that ultimately lead to escalation of
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tobacco use and dependence. The studies described herein attempt to address the question of
what subclass of nAChRs contributes to the anxiolytic-like effects of acute nicotine
administration, to pharmacologically test if nicotine exerts anxiolytic-like effects via activation
or inhibition of these nAChRs, and to identify the neurochemical substrates downstream of
nAChRs that may contribute to these anxiolytic effects.

In smokers, daily concentrations of nicotine in the brains of average smokers are estimated to be
as high as 1-3 µM, but thought to be maintained in the 200 - 450 nM range (Rose et al., 2010),
which would favor desensitization of the high affinity β2*nAChRs. Nicotine absorption via the
alveolar membrane is delayed due to sequestration of nicotine in the lung tissues of smokers
(Rose et al., 2010). Nonetheless, the lag time between taking a puff of a cigarette to nicotine
reaching crossing the blood-brain barrier is only 10-20 seconds (Rose, Behm, Westman, &
Coleman, 1999). This relatively short time between cigarette smoking and nicotine delivery in
the central nervous system affords the smoker the ability to titrate the desired dose, increasing
the reinforcing properties of cigarette smoking and the addiction potential of cigarette use. In the
morning, consumption of the first cigarette of the day, which many smokers report to be the most
pleasurable, would result in a sharp increase in nicotine concentrations, facilitating activation of
β2*nAChRs and nicotine-stimulated DA release, as is reported in human smokers during PET
imaging studies (Benowitz, 1988; Benowitz & Jacob, 1984; Brody, Mandelkern, Olmstead, et
al., 2009; Brody et al., 2004; Domino et al., 2013; Domino et al., 2009; Fagerstrom, 1978;
Fagerstrom, Heatherton, & Kozlowski, 1990; Takahashi et al., 2008). When considered along
with the fact that a single cigarette contains enough nicotine to occupy at least 75% of the high
affinity β2*nAChRs for upwards of 4 hours, it is possible that many of these β2*nAChRs are in
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a desensitized state for much of the day (Brody, Mandelkern, Costello, et al., 2009; Brody et al.,
2006). Since the activation of β2*nAChRs regulates the release of DA in the NAcc, factors
other than the reinforcing properties of nicotine may also contribute to the maintenance of
smoking behavior. One possibility is that in susceptible populations, cigarette use may be
employed as a means of self-medication to relieve anxiety.

Anxiety and smoking
Anxiety has been described as an emotional state arising from the anticipation of a future event
and has been distinguished from fear, in that fear is often tied to a clearly identified threat, while
anxiety lacks an objective threatening object or event (Estes, 1948; Grillon, 2002). In the human
subject, anxiety can result from a seminal precipitating event, as occurs in post-traumatic stress
disorder, or it can manifest itself as heightened worry and concern over every day events in
general anxiety disorders or social phobias.

Although human imaging studies do not reveal a correspondence between the expression of
β2*nAChRs and anxiety, there is a significant correlation between cigarette smoking and
anxiety-related disorders such as panic attacks, specific phobias, social phobias and posttraumatic stress disorder (Evatt & Kassel, 2010; Gilbert et al., 2008; Grillon et al., 2007; John et
al., 2004; J. L. Johnson et al., 2009; McCabe et al., 2004; Morissette et al., 2006; Tsuda et al.,
1996; Vujanovic, Marshall, et al., 2010; Vujanovic, Marshall-Berenz, et al., 2010; Zvolensky,
Marshall, et al., 2009; Zvolensky, Stewart, et al., 2009). Additionally, post-mortem [3H] nicotine
binding and SPECT imaging studies show that cigarette smokers have a significantly higher
number of high affinity β2*nAChRs than non-smokers (Benwell, Balfour, & Anderson, 1988;
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Breese et al., 1997; Cosgrove et al., 2009; Gilbert et al., 2008; Staley et al., 2006; Staley et al.,
2005; Tsuda et al., 1996). There is also a high concordance between cigarette smoking and other
psychiatric disorders, such as depression (John et al., 2004; Kalman, Morissette, & George,
2005; Lasser et al., 2000; Leonard et al., 2000; Leonard et al., 1998).

Anxiety sensitivity (AS) is defined as the fear of behaviors or emotions related to anxiety.
Individuals rating higher on the ASI assessment are more likely to experience improvement in
positive affect following smoking, have lower smoking cessation success rates and are more
likely to relapse in order to relieve negative affect than subjects who rate low on this scale (R. A.
Brown, Kahler, Zvolensky, Lejuez, & Ramsey, 2001; Evatt & Kassel, 2010; Gonzalez,
Zvolensky, Vujanovic, Leyro, & Marshall, 2008; K. A. Johnson, Farris, Schmidt, & Zvolensky,
2012; K. A. Johnson, Stewart, Rosenfield, Steeves, & Zvolensky, 2012; Wong et al., 2013).
These data suggest that individuals exhibiting heightened trait anxiety may be more sensitive to
the anxiety relief following tobacco use. Although prospective studies have not demonstrated
causality between cigarette smoking and development of anxiety-related disorders, the high
concordance between chronic tobacco use and anxiety disorders also has implications for
longevity and well-being, as individuals with chronic anxiety have a higher risk of developing
cardiovascular and cognitive degenerative diseases related to aging, as well as premature death
(Benninghoven et al., 2006; Bjorngaard et al., 2013; Carroll et al., 2011; Eaker, Sullivan, KellyHayes, D'Agostino, & Benjamin, 2005; Goodwin, Perkonigg, Hofler, & Wittchen, 2013;
Kubzansky & Kawachi, 2000; C. Li et al., 2008; Shahab, Andrew, & West, 2013; Wong et al.,
2013). Finally, since cigarette smoking is a risk factor for many chronic diseases, including
cardiovascular and respiratory diseases, as well as cancer, it is not a desirable treatment for
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anxiety. Understanding how nicotine relieves anxiety may not only help smokers to quit, but
could identify a novel therapeutic target for anxiety disorders.

Anxiety and Aging
The preponderance of data suggests that although anxiety rates are lower in the geriatric
population compared with the general population, they are increased in elderly subjects
presenting with co-morbidities of AD or dementia (Baune et al., 2012; Beaudreau & O'Hara,
2009; Boralingaiah, Bettappa, & Kashyap, 2012; Bunce, Batterham, Mackinnon, & Christensen,
2012; Cairney, Corna, Veldhuizen, Herrmann, & Streiner, 2008; D'Onofrio et al., 2012; Flint,
1994; Goncalves, Pachana, & Byrne, 2011; Higgins et al., 2012; Hynninen, Breitve, Rongve,
Aarsland, & Nordhus, 2012; Kvaal, McDougall, Brayne, Matthews, & Dewey, 2008; Ni
Mhaolain et al., 2012; Nilsson et al., 2012; O'Connor, 2006; Panza et al., 2012; Potvin, Forget,
Grenier, Preville, & Hudon, 2011; Prina, Ferri, Guerra, Brayne, & Prince, 2011a, 2011b; Rozzini
et al., 2009; Samuelsson, McCamish-Svensson, Hagberg, Sundstrom, & Dehlin, 2005; Seby,
Chaudhury, & Chakraborty, 2011; Sinoff & Werner, 2003; Skoog, 2011; Smalbrugge,
Jongenelis, Pot, Beekman, & Eefsting, 2005; Wolitzky-Taylor, Castriotta, Lenze, Stanley, &
Craske, 2010; Yochim, Mueller, & Segal, 2013), (but see (Mehta et al., 2007; Prina et al., 2011a,
2011b; Wolitzky-Taylor et al., 2010)). Nevertheless, a diagnosis of general anxiety disorder is
correlated with increased mortality and the onset of geriatric anxiety may be an early indicator of
the development of cognitive neurodegenerative disorders such as AD or advanced dementia
(Nilsson et al., 2012). Post-mortem epibatidine binding and SPECT imaging studies show that
reductions in high affinity nAChRs in the human brain appear to coincide with normal aging,
whereas pathologic reductions in this nAChR subclass are associated with cognitive declines and
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the emergence of psychological co-morbidities, such as increased anxiety and depression
(Brodaty et al., 2012; Mitsis et al., 2009; Sabbagh et al., 2006). FDA-approved
pharmacotherapies for AD alleviate the symptoms of AD, including anxiety by increasing the
endogenous ACh tone via inhibition of AChE (S. L. Rogers, Doody, Mohs, & Friedhoff, 1998).
In addition to in vitro studies showing that β2*nAChRs serve a neuroprotective role, postmortem epibatidine binding and western blot analyses, as well as imaging studies show that
cognitive neurodegeneration is associated with reduced expression of β2*nAChRs (Gotti et al.,
2006; Martin-Ruiz et al., 1999; Pimlott et al., 2004; Warpman & Nordberg, 1995; Wevers et al.,
1999; Zanardi et al., 2007; Zoli, Picciotto, Ferrari, Cocchi, & Changeux, 1999). In summary,
these data concerning anxiety-related behavior and the elderly population underscore the need to
develop novel methods to improve treatment and early detection of anxiety in susceptible
individuals.

Experimental Aims
In light of these data, Specific Aim 1 tested the hypothesis that nicotine supports anxiolysis-like
behavior via inhibition of β2*nAChRs. These studies used a combination of genetic,
pharmacological and behavioral manipulations to test this hypothesis. In Chapter 2, we
evaluated the effects of a range of doses of nicotine (0, 0.0032, 0.01, 0.032, 0.1 mg/kg) and the
selective β2*nAChR antagonist DHβE (0, 0.01 0.032, 0.1, 0.32 mg/kg) in multiple behavioral
assays that have predictive and/or face validity for testing the anxiolytic efficacy of drugs,
including the conditioned emotional response (CER), marble burying task and elevated plus
maze assay. The anxiolytic efficacies were determined by the ability of nicotine and DHβE to
increase behavior, as measured by increased exploration of the aversive open arms of an elevated
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plus maze, or increased lever pressing in the presence of an aversive conditioned stimulus or
reduce behavior, as measured by less digging behavior in the marble burying task. We predict
that the administration of both a low dose of nicotine and the selective β2*nAChR antagonist
DHβE will similarly attenuate anxiety-like behavior in these behavioral assays without
significantly affecting locomotor activity. In Chapter 3, we expanded upon these
pharmacological studies in mice lacking β2*nAChRs (Picciotto et al., 1995). We tested if
β2*nAChRs are necessary for the anxiolytic-like and anxiogenic-like efficacies of nicotine by
evaluating low and high doses of nicotine (0, 0.01, 0.05, 0.1, 0.5 mg/kg) in WT and null mutant
β2KO mice in the light-dark assay. By expanding the range of doses administered in the lightdark assay, we predict that we will observe both an anxiolytic and anxiogenic-like dose of
nicotine. In support of the hypothesis that β2*nAChRs are required for the anxiolytic and
anxiogenic-like effects of acute nicotine, we predict that the effects of these doses of nicotine on
anxiety-like behavior will be absent in β2KO mice. The observation of an anxiolytic or
anxiogenic-like effect of nicotine in β2KO mice would suggest that some other subclass of
nAChRs contributed to the observed effects. A third experiment assessed the effects of the
selective β2*nAChR agonist 5I-A85380 (0, 0.001, 0.0032, 0.01, 0.032 mg/kg) in the light-dark
and elevated plus maze assays. We predict that the administration of 5I-A85380 will also reduce
anxiety-like behavior at low doses and promote anxiogenic-like behavior at high doses. Failure
to observe either anxiolytic or anxiogenic efficacy of 5I-A85380 may result from not testing a
wide enough range of doses. It may also suggest that other subclasses of nAChRs mediated the
effects of nicotine observed in earlier experiments. The pharmacologic and genetic studies
described thus far are correlative, and inform us whether the β2*nAChRs are required for the
effects of nicotine, or whether nicotinic agonists and selective antagonism of β2*nAChRs
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similarly promote anxiolytic-like behavior. We therefore directly tested whether pre-injections
of 2 mg/kg DHβE would block or accumulate with an anxiolytic low dose (0.05 mg/kg) or
anxiogenic high dose (0.5 mg/kg) of nicotine in the light-dark assay. We also evaluated if 0.01 or
0.05 mg/kg doses of nicotine would accumulate with or also block the anxiogenic-like effects of
0.5 mg/kg during the light-dark and elevated-plus maze assays. In support of the hypothesis that
low doses of nicotine promote anxiolysis via inhibition of β2*nAChRs, we predict that preinjections of both DHβE and nicotine will significantly attenuate the anxiogenic-like effects of
0.5 mg/kg i.p. nicotine. If low doses of nicotine promote anxiolysis via activation of
β2*nAChRs, these effects ought to be similarly blocked by DHβE and nicotine. In support of
the hypothesis that the anxiolytic-like effects are promoted via inhibition of β2*nAChRs, we
predict that neither DHβE nor nicotine pretreatment will significantly attenuate the anxiolyticlike effects of 0.05 mg/kg nicotine. If we do observe a significant attenuation of the anxiolyticlike effects of 0.05 mg/kg nicotine, this would suggest that reductions in anxiety-like behavior
are in part mediated via activation of β2*nAChRs, and may necessitate the evaluation of 0.032
mg/kg nicotine in these assays.

The focus of Specific Aim 2 is to identify which subclass of β2*nAChRs is likely responsible for
mediating the anxiolytic-like efficacy of acute nicotine. In contrast to in vitro and in vivo assays
suggesting that low doses of nicotine may reduce anxiety-like behavior via activation of
α4α6β2*nAChRs, we hypothesize that activation of α6β2*nAChRs will promote an anxiogenic
phenotype (L. Liu et al., 2012; McGranahan et al., 2011). In order to test this hypothesis, in
Chapter 4, we compared the anxiety-like behaviors of L9S mice with hypersensitive
α6β2*nAChRs as well as null mutant α6KO mice with their WT controls in the ethological
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light-dark, elevated plus maze and open field assays. To support the hypothesis that activation of
α4α6β2*nAChRs promotes anxiety, we predict that anxiety-like behavior will be higher in L9S
than WT mice in the behavioral tests used. We further predict that α6KO mice will show an
anxiolytic-like phenotype compared to WT controls. Should L9S mice demonstrate reduced
anxiety-like behavior, it may suggest that nicotine is promoting anxiolysis via activation of
α4α6β2*nAChRs. Failure of α6KO mice to show reduced anxiety-like behavior may suggest
that the behavioral assays were not sufficiently stressful to render them sensitive to changes in
anxiety-like behavior in this genotype. It may also reflect that other tasks, such as CER or the
marble burying task, may be better assays to detect changes in basal anxiety-like behavior in
these mice. It is also possible that neuroadaptations during development compensated for the
deletion of α6β2*nAChRs. In Chapter 5, using α4HET mice with a 50% reduction in
α4β2*nAChRs, we also evaluated whether reduced expression of α4β2*nAChRs would promote
anxiolytic-like behavior in the light-dark, elevated plus and open field assays. In support of the
hypothesis that nicotine promotes anxiolysis-like behavior via inactivation of α4β2*nAChRs, we
predict that α4HET mice will show reduced levels of anxiety-like behavior following a saline
injection compared to WT controls.

The preponderance of evidence shows that anxiety rates are lower in the geriatric than the
general population but higher in those with neurodegenerative diseases (Baune et al., 2012;
Beaudreau & O'Hara, 2009; Boralingaiah et al., 2012; Bunce et al., 2012; Cairney et al., 2008;
D'Onofrio et al., 2012; Flint, 1994; Goncalves et al., 2011; Higgins et al., 2012; Hynninen et al.,
2012; Kvaal et al., 2008; Ni Mhaolain et al., 2012; Nilsson et al., 2012; O'Connor, 2006; Panza
et al., 2012; Potvin et al., 2011; Prina et al., 2011a, 2011b; Rozzini et al., 2009; Samuelsson et
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al., 2005; Seby et al., 2011; Sinoff & Werner, 2003; Skoog, 2011; Smalbrugge et al., 2005;
Wolitzky-Taylor et al., 2010; Yochim et al., 2013), and that α4β2*nAChRs may protect against
age-dependent neurodegeneration (Gotti et al., 2006; Martin-Ruiz et al., 1999; Pimlott et al.,
2004; Warpman & Nordberg, 1995; Wevers et al., 1999; Zanardi et al., 2007; Zoli et al., 1999).
In light of these data, Specific Aim 3 is to determine how α4β2*nAChRs may regulate agerelated changes in anxiety-like behavior. Previous immunohistochemistry and [3H] nicotine
binding studies show age-dependent reductions in α4β2*nAChRs in mice (Gahring, Persiyanov,
& Rogers, 2005; S. W. Rogers, Gahring, Collins, & Marks, 1998). We further predict, using
immunoprecipitation assays, that we will observe age-dependent reductions in levels of α4
subunit protein. Alternatively, expression of the α4 subunit may not decline, but may stay the
same or increase in older animals. This may indicate increased sequestration of the α4 subunit in
the endoplasmic reticulum, the assembly of α4β2*nAChRs in the lower sensitivity α4(3)β2(2)
stoichiometry, or that the antibodies used in our studies are more selective for the α4 subunit
than previous experiments (Anand et al., 1991; Buisson & Bertrand, 2001; Cooper et al., 1991;
Covernton & Connolly, 2000; Gahring et al., 2005; Khiroug et al., 2004; H. A. Lester et al.,
2009; Moroni et al., 2006; Nelson et al., 2003; S. W. Rogers et al., 1998; Wanamaker & Green,
2007; Zwart & Vijverberg, 1998). Finally, we desired to identify potential brain regions and
cellular signaling molecules downstream of α4β2*nAChR activity related to age-dependent
changes in anxiety-like behavior. Since ERK phosphorylation in the lateral septum is negatively
correlated with exposure to both restraint and chronic housing stress (Sheehan et al., 2003;
Singewald et al., 2009), we predict that western blot analyses of brain punches taken from the

lateral septum will reveal that levels of ERK phosphorylation will be inversely associated with
changes in anxiety-like behavior in Adult and Aged WT and α4HET mice. Failure to detect
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significant changes in pERK are possible, since ERK phosphorylation is tightly regulated. We
may need to repeat these studies at a different time point to detect relevant changes in pERK in
the lateral septum.
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Chapter 2 - Low dose nicotine and antagonism of β2 subunit containing nicotinic
acetylcholine receptors have similar effects on affective behavior in mice

INTRODUCTION

Human and animal studies indicate that nicotine exerts its psychoactive effects by binding to
nicotinic acetylcholine receptors (nAChRs) in the brain (DeNoble & Mele, 2006; Rose et al.,
2003). nAChRs comprised of the β2 subunit (β2*nAChRs; *denotes assembly with other
subunits) have high binding affinity for nicotine and the endogenous neurotransmitter,
acetylcholine (ACh) (Grady et al., 2010; Pauly et al., 1991; Whiting & Lindstrom, 1988; Y. Xiao
& Kellar, 2004). β2*nAChRs are enriched on neurons in limbic system brain areas that regulate
both affect and reward (Clarke et al., 1985; Court & Clementi, 1995; Fujita et al., 2000; Grady et
al., 2010; Kimes et al., 2008; Marks et al., 2010; Marks et al., 1992; Pauly & Collins, 1993;
Picciotto et al., 1995; Rubboli et al., 1994; Staley et al., 2005; Y. Xiao & Kellar, 2004)
suggesting that these nAChR subtypes may serve a dual role in supporting reward-like behavior
and relieving negative affect. nAChRs are ion channels that can be activated as well as
desensitized (inactivated) by nicotine (Fenster et al., 1997; R. A. Lester & Dani, 1995;
Mansvelder et al., 2002; Pidoplichko et al., 1997). A preponderance of the evidence suggests that
activation of β2*nAChRs supports nicotine conditioned place preference and nicotine selfadministration, models of nicotine reward and reinforcement (Brunzell et al., 2010; Corrigall et
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al., 1994; Gotti et al., 2010; Grabus et al., 2006; Jackson et al., 2009; Maskos et al., 2005;
McGranahan et al., 2011; Mineur et al., 2009; Picciotto et al., 1998; Pons et al., 2008; Tapper et
al., 2004; Walters et al., 2006) (but see (Exley & Cragg, 2008)). The studies herein used a
conditioned emotional response (CER) assay, a marble burying task and an elevated plus maze
experiment to test the hypothesis that inactivation of β2*nAChRs attenuates fear and anxiety-like
behavior in mice.

CER is an appetitive, operant task in which lever pressing maintained by a positive reinforcer
(saccharin solution) is interrupted by presentation of a conditioned stimulus (CS, light and tone)
that co-terminates with an aversive unconditioned stimulus (US, 0.1 or 0.3 mA, 0.5 s mild
footshock). This study tested if nicotine and a selective antagonist of β2*nAChRs, dihydro-betaerythroidine (DHβE) would attenuate conditioned suppression of responding in the presence of
an aversive CS in the absence of footshock. During CER, subjects serve as their own controls
within sessions to return a suppression ratio (SR) score = A/(A+B) where A is lever pressing
during the 60 s CS period and B is lever pressing during the 60 s prior to CS presentation. An
SR ≈ 0 is indicative of conditioned suppression whereas SR ≈ 0.5 indicates that rodent
responding is unaffected by presentation of the CS. The CER assay has good face validity for
tobacco users who experience stressors during goal-oriented behavior on a daily basis. Separate
groups of mice were tested using an ethological marble burying task where increased digging,
rather than suppression of activity, is thought to be interpretive of negative affective behavior,
and in an elevated plus maze assay where increased activity in the open arms, relative to the
enclosed arms of the maze, is thought to reflect anxiolysis-like behavior. As a follow-up to
experiments that evaluated affective-like phenotype, a locomotor activity assay using a beam-
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break apparatus confirmed that doses of nicotine and DHβE in these experiments did not affect
locomotor activity.

MATERIALS AND METHODS

Subjects
Twenty-nine C57BL/6J, adult, male mice from Jackson Labs (Bar Harbor, ME) or derived in a
Virginia Commonwealth University (VCU) breeding colony were used in these studies. Mice
had ad libitum access to both food and water in their home cages. Animals were group-housed
(2-5 per cage) with 1/8 inch corn cob bedding in a vivarium with a 12h light/dark cycle (lights on
0600). Mice were habituated to the test room and experimenter handling for 3 days prior to any
training or testing.

Ethics Statement
Efforts were made to minimize mouse discomfort in these experiments. Mild footshock without
analgesia and experimenter injections were necessary to perform these studies that model
affective-like behavior in mice. Experiments were approved by the VCU Institutional Animal
Care and Use Committee (Protocol Number: AM-10163) and were in compliance with the Guide
for Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 2010).

Apparatus
CER experiments were conducted in mouse operant chambers (21.6 cm x 17.8 cm x 12.7 cm;
Med Associates, St. Albans, VT). An LED cue light with an opaque cover was positioned 5.5
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cm above the operant lever with a liquid dipper receptacle centered on the same wall. A speaker
and a 2.24 watt incandescent house-light were positioned 9.5 cm from the floor on the opposite
wall of the operant chamber. The floor consisted of steel rods (0.32 cm in diameter placed 0.79
cm apart) connected to a Med Associates shock generator/scrambler. All data were collected via
Med PC software. Marble burying took place in a polycarbonate cage (33 cm× 21 cm × 9 cm
high) filled with 5 cm of loose wood chip bedding (Harlan Sani-Chip, Indianapolis, IN). The
elevated plus maze was constructed of wood with white laminated flooring on two (5 x 30 cm)
open arms that were perpendicular to two equivalent, white, laminated, enclosed arms with 15.25
cm black Plexiglas wall enclosures. The entire apparatus was elevated 68 cm above the floor.
Experimentation took place under fluorescent light illumination. A ceiling-mounted camera was
interfaced to a PC for collection of data using ANY-maze tracking software by Stoelting (Wood
Dale, IL). Locomotor testing was conducted in two adjoining chambers (measuring 26.5 cm x
12.7 cm x 26.2 cm and 16.8 cm x 12.7 cm x 12.7 cm). A locomotor unit was defined as the
breaking of two adjacent light beams (3 cm apart). Illumination was provided by a single 23
watt fluorescent light bulb. Data was collected using Med Associates software. All experimental
chambers were cleaned between animals with 2% Nolvosan (Pfizer Animal Health, Madison,
NJ).

Drugs
Nicotine hydrogen tartrate (Sigma Aldrich, St. Louis, MO) was dissolved in 0.9 % sterile saline
with pH adjusted to 7.1-7.3. DHβE (Sigma Aldrich, St. Louis, MO) was dissolved in 0.9 %
sterile saline. Nicotine doses are expressed as freebase and DHβE doses are expressed as
hydrogen bromide salt. As with previous nicotine place conditioning studies (Brunzell et al.,
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2009; Mineur et al., 2009), injections were delivered i.p. in volumes of 0.1 ml/30 g. Nicotine
was administered immediately prior to CER, marble burying and locomotor tests. After DHβE
injection, animals were returned to their home cages for 15 minutes before CER, elevated plus
maze and locomotor testing and for 30 minutes prior to the marble burying task. Weights were
measured approximately 1 h prior to behavioral assays.

Behavioral Procedures
Conditioned Emotional Response (CER)
The CER paradigm consisted of several phases of operant and Pavlovian training followed by
drug testing sessions where operant responding was tested in the presence of a footshock-paired
CS but in the absence of the US footshock (Figure 2.1).

Magazine Training
Subjects received eighty presentations of 10 mMol saccharin solution according to a variable
interval 30 second (VI-30s) schedule. Mice met criteria when they entered the magazine for
20% of the dipper presentations. Animals failing to meet this criteria were given a second, and if
necessary, a third exposure to magazine training before moving on to acquisition of operant
responding during overnight sessions.

CER Acquisition of Lever-Pressing Behavior
Mice were trained to lever press for 0.01 ml of 10 mMol saccharin solution via a liquid dipper in
a single 16 hour overnight session (adapted from (Morris, Dawson, Reynolds, Atack, &
Stephens, 2006)). Responding for saccharin reinforcement was maintained on increasing fixed

35

Figure 2.1 - CER training and drug testing schedule. To introduce mice to the location of
saccharin delivery, magazine training (Phase I) occurred over days 1-3. CER acquisition of lever
pressing maintained by 10 mMol saccharin solution took place during overnight sessions with
increasingly demanding schedules of reinforcement (Phase II; days 4-9) until mice reached
criteria of 70 reinforcers and 100 s of correct magazine entries in a session. This was followed by
daily 30 minute sessions (Phase III) where mice lever pressing was maintained by saccharin
under a variable schedule of reinforcement. Mice moved onto the next Phase of training when
they reached criteria of 40 lever presses and 10 reinforcers during a single 30 minute session
(days 10-13). During CER training mice continued operant training but also received 2 explicit
pairings of a light and tone conditioned stimulus (CS) which co-terminated with a 0.1 or 0.3 mA
footshock unconditioned stimulus (US) (Phase IV; days 14-43). Phase IV continued until all
mice showed a stable level of CS and NON-CS responding over 3 days. Drug testing (Phase V)
consisted of lever pressing maintained by saccharin in the presence of the CS but in the absence
of the US. For these studies that used a within-subject, Latin square design, there were at least 2
CER training days in between drug testing sessions to assure that mice returned to baseline prior
to the next injection of drug.
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ratio (FR) schedules, FR 1 up to 10 reinforcers, FR 2 up to the subsequent 10 reinforcers and FR
4 for the subsequent 20 reinforcers. This was followed by a variable ratio (VR) 5 or variable
interval (VI) 15 second schedule of reinforcement until the end of the session. Mice were next
trained to lever press during 30 minute daily sessions (1400-1800 h) for a saccharin reinforcer at
the assigned variable schedule of reinforcement for which they were trained. Mice meeting a
criterion of 10 reinforcers and 40 lever presses in a single session advanced to CER training.
The house light was on during all acquisition and CER procedures in the absence of the CS.

CER Training (Operant responding with Pavlovian CS + US footshock conditioning)
During 30 minute CER sessions, saccharin continued to be available according to the variable
schedule of reinforcement presented during acquisition. Pseudo-random presentation of two 60
s, compound CSs (house light off + cue light on + 70 dB, 2000 Hz tone) co-terminated with a 0.5
s, 0.3 mA footshock US. A second cohort of animals received all the same conditions but was
administered a 0.1 mA footshock US shown previously to not significantly affect suppression
ratios (Dixon, Rosahl, & Stephens, 2008). The first CS presentation occurred between min 3 and
12 and the second CS between min 18 and 27. The number of lever presses were recorded both
for the 60 s immediately preceding the onset of the CS (Pre-CS) as well as during the CS. The
suppression ratio was calculated using the equation A/(A+B), where A is the number of
responses during the CS and B equals lever presses in the Pre-CS period (Annau & Kamin,
1961). A suppression ratio of 0.5 indicates no suppression of responding during the CS and a
suppression ratio of 0 reflects total suppression of responding during the CS. All active leverpressing in the absence of the CS was also evaluated (NON-CS). Increases in suppression ratio
following drug treatment were interpreted as anxiolytic-like behavior. Once stable baseline
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responding and suppression ratios (≤ 0.1 for the 0.3 mA condition) were established for 3
consecutive days, mice proceeded to drug testing.

CER Drug Testing
Drug testing took place in the absence of footshock US using a within-subject Latin square
design. Animals received 0, 0.0032, 0.01, 0.032 or 0.1 mg/kg i.p. nicotine or 0, 0.1, 0.3, 1 or 3
mg/kg i.p. DHβE before CER. At least 2 days of CER training were administered between doses
to allow for wash-out of drug. These intermediate training sessions further assured that
responding returned to baseline between doses of drug.

Marble Burying
Using a within-subject, Latin Square design, separate groups of mice received 0, 0.01 and 0.032
mg/kg i.p. nicotine or 0 and 3 mg/kg i.p. DHβE. Marble burying sessions were separated by at
least 5 days as has been demonstrated to provide a steady level of digging behavior in the
absence of treatment (Broekkamp, Rijk, Joly-Gelouin, & Lloyd, 1986; A. Thomas et al., 2009).
Prior to each test, 20 green, glass marbles (10 mm diameter) were evenly arranged in a 4 x 5 grid
on loose sawdust bedding. Individual mice were placed into the side of the experimental cage so
as to not disturb any of the marbles. At the conclusion of the 15 minute test, mice were returned
to the home cage; marbles at least 50% covered by the bedding were counted as buried.

Elevated Plus Maze
Using a between-subject design, mice receiving 0, 0.03 or 3 mg/kg i.p. DHβE were returned to
their home cage for a 15 min wait period and subsequently placed on the center of an elevated
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plus maze apparatus (n = 9 - 11 per dose). Behavior was evaluated for a period of 10 minutes.
Subjects were scored for open arm entries, time spent in the open arms and latency to explore the
terminal zones (the extreme 5 cm) of the open arms.

Locomotor Test
Using a between-subject design, animals received nicotine (0, 0.01 or 0.032 mg/kg i.p. by weight
of freebase) immediately prior to placement into the small chamber of the Med Associates
apparatus. The door separating the two chambers was opened, allowing animals free mobility
throughout the apparatus. Breaking of two adjacent beams (3 cm equidistant apart) constituted a
locomotor activity count. Behavior was assessed for ten minutes. Mice that received DHβE (0,
0.3 or 3 mg/kg i.p.) were placed in their home cages for 15 min following injections with the
other locomotor procedures as described for nicotine subjects.

Statistical Analysis
For CER experiments, repeated measures ANOVA assessed the effect of nicotine and DHβE on
suppression ratio, lever presses/minute during the CS period and lever presses/min during the
NON-CS period. Paired t-tests were used as post-hoc tests where appropriate. Student’s t-test
was used to assess the effect of footshock intensity on suppression ratios. Repeated measures
ANOVA and paired t-tests were used to evaluate the effect of nicotine and DHβE on number of
marbles buried. ANOVA tests assessed elevated plus maze activity as measured by open arm
entries, time on the open arms and latency to reach the end terminal 5cm of the open arms. Posthoc t-tests and planned comparisons were performed between vehicle and drug-injected subjects.
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One-way ANOVA tested the effects of drug doses on locomotor activity. Confidence intervals
of P < 0.05 were reported as significant.

RESULTS

On the 3 days of CER training prior to CER testing, NON-CS responding was stable (F’s < 1)
and suppression ratios were consistently lower than 0.1 for mice trained to a 0.3 mA footshock.
The suppression ratios for mice receiving 0.1 mA footshock US were significantly higher than
mice exposed to 0.3 mA footshock US following saline injection (0.1 mA = 0.69 ± 0.15; 0.3 mA
= 0.03 ± 0.02) (t14 = 5.691, P < 0.001). In contrast to mice that received a 0.3 mA footshock,
mice trained with a 0.1 mA footshock did not show a suppression of responding during the CS,
indicating that this suppression of behavior in 0.3 mA-trained mice was a conditioned response
to an aversive CS and not due to a more generalized orienting response to the compound
stimulus CS used in these experiments. There was no effect of footshock intensity on overall
NON-CS or Pre-CS lever pressing (F’s < 1). Supplemental Figure 2.1 shows average lever
presses per minute during the entire 30 minute sessions. There was no significant effect of
schedule of reinforcement on suppression ratios in 0.3 mA mice receiving 0.01 ml saccharin
solution according to VI-15 sec or VR5 schedules of operant reinforcement following nicotine
(F1,8 = 0.060, P = 0.812) or DHβE (F1,5 = 0.290, P = 0.613), so these groups were combined
during subsequent analyses. Administration of nicotine resulted in a dose-dependent increase in
suppression ratio (F4,9 = 3.101, P < 0.05) for mice exposed to the 0.3 mA US. Post hoc t-tests
revealed that low doses of nicotine (0.01 and 0.032 mg/kg) significantly reversed conditioned
suppression of responding in comparison to when animals received saline (t9 = 2.663 and 2.331,
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P’s < 0.05; Fig 2.2a). Despite consistent trends for elevated responding at doses of nicotine that
reversed conditioned suppression, raw scores for CS lever pressing failed to reach significance
following nicotine injection (F4,9 = 0.867, P > 0.05; Table 2.1). Unlike suppression ratios, there
was no effect of drug treatment on Pre-CS responding (F4,9 = 1.771, P > 0.05). There was an
effect of nicotine treatment observed for NON-CS responding, however (F4,9 = 9.832, P <
0.001). Post hoc tests showed that NON-CS lever pressing was elevated in mice following
0.0032 mg/kg (t9 = 3.820, P < 0.01), 0.032 mg/kg (t9 = 4.941, P < 0.001) and 0.1 mg/kg (t9 =
2.483, P < 0.05) compared to treatment with saline (Table 2.2). It is possible that nicotine was
enhancing the reinforcing efficacy of the saccharin stimulus as has been observed for a visual
cue (Caggiula et al., 2001; Donny et al., 2000). Further analysis comparing mice against their
responding prior to any injections indicated that this may have been due in part to anxiolytic
effects of nicotine as well. Compared to days when they had received no injection, there was a
significant decrease in NON-CS responding of mice following saline injection (t9 = 4.683, P <
0.001), suggesting that the stress of injection led to an overall reduction in lever pressing activity
(Table 2.2). Nicotine injection appeared to reverse this effect; low doses of nicotine (0.01 and
0.032 mg/kg i.p.) that elevated suppression ratio responding resulted in NON-CS lever pressing
that did not differ from pre-injection responding. A rewarding-like dose of nicotine (0.1 mg/kg
i.p.) (Brunzell et al., 2009; McGranahan et al., 2011; Mineur et al., 2009) resulted in a similar
elevation of responding compared to saline injection, however, there were also significantly
fewer lever presses during the NON-CS compared to when no injection was given, suggesting
that this dose was not effective at reversing suppression of overall responding that was
stimulated by the stress of injection.
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Figure 2.2 - Low dose nicotine and the β2*nAChR antagonist DHβΕ reverse conditioned
suppression. In mice conditioned to a 0.3 mA unconditioned stimulus footshock during CER
training, a) administration of nicotine resulted in a dose-dependent reversal of conditioned
suppression as measured by increased suppression ratios (F4,9 = 3.101, P < 0.05; n = 10). b) The
β2*nAChR antagonist DHβE also resulted in a significant increase in suppression ratios in these
mice (F4,6 = 2.934, P < 0.05; n = 7), suggesting that inhibition of β2*nAChRs supports
anxiolytic-like behavior in the CER assay. c, d) Neither nicotine (F4,5 = 1.991, P > 0.05; n = 6)
nor DHβE (F4,5 = 1.263, P > 0.05; n = 6) resulted in significant changes in suppression ratio
responding in mice exposed to 0.1 mA US footshock during CER training. Data are presented as
means ± SEM. *P < 0.05 compared to when mice received saline control injections.
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Table 2.1 - Lever pressing activity during the CS and Pre-CS period.

0.1 mA
Nicotine (mg/kg)
Pre-Drug
0
0.0032
0.01
0.032
0.1
DHβE (mg/kg)
Pre-Drug
0
0.1
0.3
1
3

Pre-CS
2.83±1.17
1.58±0.97
1.00±0.51
2.83±1.38
4.00±1.48
1.25±0.69

Pre-CS
2.75±1.33
1.58±0.97
3.50±1.48
0.75±0.34
2.80±0.88
1.75±0.48

0.3 mA
CS

1.50±0.26
1.50±0.47
1.50±0.47
1.58±0.52
1.58±0.97
1.17±0.54

CS
3.92±1.48
1.50±0.47
2.25±0.68
1.83±0.38
0.80±0.21
1.67±0.69

Pre-CS
1.60±0.40
0.80±0.40
2.07±0.11
1.90±0.49
3.86±1.79
2.25±0.68

Pre-CS
1.86±0.66
1.07±0.55
1.25±0.36
1.93±0.63
2.36±0.70
2.86±1.29

CS
0.30±0.17
0.10±0.07
0.21±0.12
0.45±0.16
0.36±0.14
0.20±0.20

CS
0.14±0.09
0.14±0.09
0.25±0.14
0.14±0.09
0.50±0.29
1.71±0.79

Lever presses per minute are depicted for mice during presentation of the
60 s conditioned stimulus (CS) and during the 60 s period prior to CS
presentation (Pre-CS). Pre-Drug levels of responding are depicted for the
last day of training prior to drug testing sessions (Pre-Drug) and during test
sessions following each of five i.p. doses of nicotine or DHβE. Data are
represented as means ± SEM.
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Table 2.2 - Lever pressing activity in the
absence of the CS.

0.1 mA

0.3 mA

NON-CS

NON-CS

Nicotine (mg/kg)
Pre Drug
0
0.0032
0.01
0.032
0.1

2.68±0.95
1.89±0.64
1.31±0.48
1.58±0.57
1.90±0.67
1.10±0.42

DHβE (mg/kg)
Pre Drug
0
0.1
0.3
1
3

NON-CS

NON-CS

3.33±0.98
1.89±0.64*
1.98±0.69
2.21±0.87
2.43±0.72
1.99±0.50

2.87±0.49
1.21±0.24*
2.30±0.41
1.83±0.30
2.17±0.26
2.41±0.51

1.92±0.28
0.94±0.22*
+
1.78±0.30
1.40±0.15
+
2.09±0.27
+
1.30±0.18*

Lever presses per minute are depicted for mice in the
absence of the conditioned stimulus (NON-CS) on the
day prior to drug testing sessions (Pre-Drug) and
during test sessions following each of five i.p. doses
of nicotine or DHβE. Data are represented as means
± SEM; *Significantly different from Pre-drug training
(P < 0.05); +Significantly different from test sessions
following saline injection (0 mg/kg; P < 0.05).
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Administration of nicotine did not significantly affect suppression ratios (F4,5 = 1.991, P =
0.135; Fig 2.2c), CS responding (F4,5 = 0.103, P > 0.05), Pre-CS responding (F4,5 = 2.245, P >
0.05; Table 2.1) or NON-CS responding (F4,5 = 1.46, P > 0.05; Table 2.2) in mice exposed to
the 0.1 mA footshock US. A dose-dependent reversal of conditioned suppression was also
observed following treatment with the selective β2*nAChR antagonist DHβE (F4,6 = 2.934, P <
0.05). Compared to when they received saline, mice showed a significant increase in suppression
ratios following injection of 3 mg/kg i.p. DHβE (t6 = 2.614, P < 0.05; Fig 2.2b) suggesting that
antagonism of the β2*nAChRs, like low dose nicotine, reverses conditioned inhibition of
behavior in this task. Pre-treatment with DHβE resulted in a dose-dependent increase in total
lever pressing in the presence of the CS (F4,6 = 3.338, P < 0.05) reflecting a trend for elevated
responding during the CS after administration of 3 mg/kg i.p. DHβE compared to saline (t9 =
2.049, P = 0.086; Table 2.1). As observed during the nicotine treatment regimen above, Pre-CS
responding was not significantly affected by DHβE exposure (F4,6 = 1.382, P > 0.05; Table 2.1),
but total NON-CS lever pressing was reduced in mice following saline injection compared to the
training session that immediately preceding the drug testing phase for DHβE (t6 = 3.113, P <
0.05; Table 2.2). Unlike nicotine, DHβE did not significantly affect responding in the absence of
the CS (Table 2.2). Similarly to nicotine, there were no effects of i.p. DHβE on suppression
ratios (F4,5 = 1.263, P = 0.317; Fig 2.2d), CS lever pressing (F4,5 = 1.334, P > 0.05), Pre-CS
responding (F4,5 = 2.274, P > 0.05; Table 2.1) or NON-CS responding (F4,5 = 1.112, P > 0.05;
Table 2.2) in mice trained with 0.1 mA footshock US. As observed with 0.3 mA-trained mice,
NON-CS responding was lower in mice following saline injection compared to responding
during training sessions immediately prior to DHβE drug testing (t5 = 3.451, P < 0.05; Table
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2.2), suggesting that the stress of injection may have led to a suppression of overall leverpressing activity.

A separate group of mice were tested in a marble burying task, an ethological measure of digging
behavior that is thought to reflect changes in rodent affect (Broekkamp et al., 1986; Bruins Slot,
Bardin, Auclair, Depoortere, & Newman-Tancredi, 2008; Deacon, 2006; Egashira et al., 2008;
Ichimaru, Egawa, & Sawa, 1995; Kinsey, O'Neal, Long, Cravatt, & Lichtman, 2011; Nicolas,
Kolb, & Prinssen, 2006; Njung'e & Handley, 1991; Pelleymounter, Joppa, Ling, & Foster, 2002;
Turner et al., 2010). Doses of i.p. nicotine (0.01 and 0.032 mg/kg) and i.p. DHβE (3 mg/kg) that
were capable of increasing lever pressing maintained by saccharin during presentation of an
aversive CS also led to a significant decrease of marble burying in an open, exposed
environment. Repeated measures ANOVA revealed a significant effect of nicotine exposure on
digging behavior as measured by marbles buried (F2,13 = 4.022, P < 0.05). Consistent with
results from CER, post hoc t-tests revealed that mice buried fewer marbles after 0.01 and 0.032
mg/kg i.p. nicotine than when they received saline (t13 = 2.747, P < 0.05 and t13 = 2.376, P <
0.05, respectively; Fig 2.3a). DHβE-injected mice also buried significantly fewer marbles than
after saline vehicle in the marble burying task (t14 = 1.781, P < 0.05; Fig 2.3b).

Antagonism of β2*nAChRs also affected the behavior of mice in the elevated plus maze.
ANOVA analysis revealed a significant effect of DHβE treatment on latency to reach the
terminus of the open arms (F2,30 = 4.449, P < 0.05). Post-hoc tests revealed that mice receiving
0.3 mg/kg i.p. DHβE required significantly less time to explore the terminal ends of the open
arms compared to mice receiving saline (t17.341 = 2.769, P < 0.05; Fig 2.4a). Despite similar
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Figure 2.3 - Nicotine and DHβE resulted in fewer marbles buried. a) The 0.01 and 0.032
mg/kg i.p. nicotine that promoted anxiolytic-like behavior in the CER task also resulted in a
significant reduction in digging behavior as measured by fewer marbles buried compared to
when mice were administered saline (n = 14). b) Similarly, mice treated with 3 mg/kg i.p.
DHβE also buried less marbles compared to when they received saline treatment (n = 15). Data
are presented as means ± SEM; *P < 0.05 compared to when mice received saline control
injections.
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Figure 2.4. Antagonism of β2*nAChRs promoted anxiolysis-like behavior in the elevated
plus maze. a) Mice receiving 0.3 mg/kg i.p. DHβE required less time to explore the end
terminus of the open arms of an elevated plus maze, b) to enter the open arms of the maze and c)
spent more time in the open arms than saline-injected mice. Data are presented as means ±
SEM; *P < 0.05, #P = 0.067 compared to saline controls.
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trends for DHβE-associated increases in open arm entries and total time spent in the open arms,
ANOVA tests failed to return a significant effect of treatment for these respective measures (F2,30
= 2.258, P > 0.05; F2,30 = 2.219, P > 0.05; Fig 2.4b), but planned comparisons revealed that
mice receiving 0.3 mg/kg i.p. DHβE had significantly greater number of open arm entries than
saline-injected mice (t12.682 = 2.610, P < 0.05; Fig 2.4b) and spent significantly more time in the
open arms of the maze compared to saline controls (t13.490 = 2.753, P < 0.05; Fig 2.4c). Although
there was a trend for mice receiving 3 mg/kg DHβE to spend more time in the open arms (t10.992
= 2.034, P = 0.068), behavioral measures for this dose of DHβE failed to reach significance for
any behavioral measure in the elevated plus maze.

To further determine if the observed behavioral effects of nicotine and DHβE were due in part to
non-specific changes in locomotion, mice were tested in a locomotor activity beam-break
apparatus following administration of saline and doses of nicotine (0.01 and 0.032 mg/kg) and
DHβE (0.3 and 3 mg/kg) that reversed conditioned suppression in the CER assay, decreased
digging in the marble burying task, or that increased open arm activity during the elevated plus
maze test. In comparison to saline-injected animals, there were no observable effects of i.p.
nicotine (F2,14 = 0.072, P > 0.05) or i.p. DHβE (F2,13 = 1.451, P > 0.05) on locomotor activity
(Fig 2.5).

DISCUSSION

In the present experiments, low dose nicotine and a selective antagonist of β2*nAChRs
decreased fear- and anxiety-like behavior in three separate animal models of affect. There was a
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Figure 2.5 - Nicotine and DHβE did not affect locomotor activity. a) Doses of nicotine (n = 5
- 6) and b) DHβE (n = 4 - 5) that promoted anxiolytic-like behavior in the CER and marble
burying tasks did not affect locomotor activity as measured by beam breaks (F’s = 0.072, 1.451,
P’s > 0.05). Data are presented as means ± SEM.
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significant reversal of conditioned suppression of lever pressing in mice treated with 0.01 and
0.032 mg/kg i.p. nicotine but a 0.1 mg/kg i.p. dose of nicotine that has been shown to be
rewarding during conditioned place preference (Brunzell et al., 2009; McGranahan et al., 2011;
Mineur et al., 2009) had no effect. Mice treated with these low doses of nicotine also buried
fewer marbles compared to when they were treated with saline in an ethological marble burying
task, and previous studies show that similarly low doses of nicotine decrease anxiety-like
behavior as measured by increases in open arm activity in an elevated plus maze (McGranahan et
al., 2011; Varani, Moutinho, Bettler, & Balerio, 2012). The present findings expand on previous
data to show that inactivation of the high affinity β2*nAChRs has similar effects of low dose
nicotine on these affective tasks. DHβE dose dependently increased responding for a saccharin
reinforcer during the presentation of an aversive CS, significantly decreased marble burying in
an open, exposed environment and significantly increased exploration of the open arms of an
elevated plus maze. These divergent behavior-stimulating and behavior-inhibiting measures
indicate that these observations were not due to non-selective effects of DHβE or nicotine on
activity. Neither effective doses of nicotine nor DHβE showed any change in beam break activity
during a locomotor task. Together these findings suggest that low dose nicotine and DHβE
attenuate negative affective and anxiety-like behavior.

Together with previous findings, these studies identify a dual role for β2*nAChRs in regulating
nicotine reinforcement and relieving negative affective behavior. Whereas nicotine
reinforcement and reward-like behavior requires activation of β2*nAChRs (Brunzell et al., 2010;
Corrigall et al., 1994; Gotti et al., 2010; Grabus et al., 2006; Jackson et al., 2009; X. Liu et al.,
2003; Maskos et al., 2005; McGranahan et al., 2011; Picciotto et al., 1998; Pons et al., 2008;
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Tapper et al., 2004; Walters et al., 2006), the studies described herein suggest that inactivation of
β2*nAChRs decreases fear-like and anxiety-like behavior as measured by increased suppression
ratios during CER, decreased digging behavior in a marble burying task, and increased
exploratory behavior in the open arms of an elevated plus maze. Rats will self-administer A85830, a selective agonist of β2*nAChRs (X. Liu et al., 2003). Administration of selective
β2*nAChR antagonists blocks nicotine conditioned place preference and greatly attenuates
nicotine self-administration (Brunzell et al., 2010; Corrigall et al., 1994; Gotti et al., 2010;
Grabus et al., 2006; Jackson et al., 2009). This is in contrast to the current studies which show
that systemic administration of DHβE promotes lever pressing maintained by saccharin during
presentation of a stressful cue. The current studies also showed that subthreshold doses for
nicotine conditioned place preference, but not a reward-like dose, were capable of increasing
suppression ratios during the CER operant task. The non-selective nAChR antagonist
mecamylamine has been shown to have anxiolytic efficacy in the elevated plus maze, social
interaction and marble burying tasks (Hall, Pearson, & Buccafusco, 2010; Newman, Manresa,
Sanberg, & Shytle, 2002; Newman, Nazian, Sanberg, Diamond, & Shytle, 2001; Roni &
Rahman, 2011l). The present findings expand on this work to show that inhibition of
β2*nAChRs is sufficient to decrease fear-like behavior and increase anxiolytic-like behavior in
both operant and ethological tasks.

Low dose nicotine had similar effects as DHβE to decrease negative affective behavior.
Although the mechanism of how DHβE and nicotine act at nAChRs has not been clearly
elucidated in an awake, behaving animal, in vitro and ex vivo studies show that nicotine
promotes both activation and desensitization of nAChRs (Fenster et al., 1997; Grady et al., 2012;
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Kuryatov et al., 2011; R. A. Lester & Dani, 1995; Lu et al., 1999; Mansvelder et al., 2002;
Pidoplichko et al., 1997); hence nicotine-associated desensitization could result in a behavioral
phenotype that is similar to nAChR antagonism. Micromolar concentrations of nicotine activate
β2*nAChRs, facilitating neurotransmitter release (Fenster et al., 1997; R. A. Lester & Dani,
1995; Mansvelder et al., 2002; Pidoplichko et al., 1997). This is followed by rapid
desensitization of the β2*nAChRs (Fenster et al., 1997; R. A. Lester & Dani, 1995; Mansvelder
et al., 2002; Pidoplichko et al., 1997). In vitro studies further show that nanomolar
concentrations of nicotine can result in preferential desensitization of β2*nAChRs (Fenster et al.,
1997; Grady et al., 2012; Kuryatov et al., 2011; Lu et al., 1999). Low levels of nicotine increase
the likelihood that β2*nAChR stoichiometry will favor the desensitized state. Consistent with
these observations, reductions in marble burying are also observed following administration of
partial agonists of β2*nAChRs, including varenicline and sazetidine-a (Levin et al., 2010;
Newman et al., 2002; Turner et al., 2010; Y. Xiao et al., 2006). The present data suggest that
behavioral effects of partial agonists in the marble burying and CER tasks are likely due to
inhibition rather than activation of the β2*nAChRs.

It is not clear from these studies which nAChR subunits in combination with β2 might require
inactivation to promote the anxiolytic-like effects of nicotine. DHβE has high affinity for
α6β2*nAChRs and α4β2*nAChRs (Grady et al., 2010; Papke et al., 2008) although a large part
of the sensitivity appears to be driven by the α4 subunit (Papke et al., 2008). Recent work using
the elevated plus maze as a measure of anxiety reported that α4 knockout mice fail to show
nicotine-associated anxiolysis (McGranahan et al., 2011). There was no genotypic effect of the
α4 null mutation in the absence of drug, so it is not clear if activation or inhibition of
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α4β2*nAChRs or perhaps some other α4*nAChR is regulating open arm activity in this task
(Bencan & Levin, 2008; Decker et al., 1995; McGranahan et al., 2011). Selective deletion of the
α4 subunit in ventral tegmental area (VTA) DA neurons attenuated the effects of nicotine on
open arm entries in the elevated plus maze, suggesting a possible role for the mesolimbic DA
pathway in support of anxiolysis-like behavior (McGranahan et al., 2011). Given recent data to
suggest that VTA GABA neurons promote conditioned aversion and counter appetitive behavior
via inhibition of DA neuron signaling (Tan et al., 2012; van Zessen, Phillips, Budygin, & Stuber,
2012), it is possible that blockade of α4β2*nAChR activity on GABA terminals could promote
anxiolysis-like behavior via disinhibition of DA neurons (Mansvelder et al., 2002; Mineur et al.,
2009; Pidoplichko et al., 1997). It is not clear if α6β2*nAChRs, which are enriched in
catecholaminergic nuclei (Champtiaux et al., 2002; Marks et al., 2010; Whiteaker et al., 2000)
(but see (Yang et al., 2011)) might contribute to anxiety-like behavior. Slice electrophysiology
studies show that α4α6β2*nAChRs on DA neurons in the posterior VTA are highly sensitive to
even nM concentrations of nicotine and are resistant to desensitization (L. Liu et al., 2012)
suggesting their activity, rather than their inhibition, may promote nicotine-associated anxiolysis
in response to low doses of nicotine. As further support that desensitization of α4β2*nAChRs
promotes anxiolysis-like behavior, the α4β2*nAChRs, but not α6β2*nAChRs, are localized in
the basolateral amygdala where selective removal of ACh inputs decreases anxiety-like behavior
(Bahi, Mineur, & Picciotto, 2009; Champtiaux et al., 2002; Clarke et al., 1985; Marks et al.,
2010; Power & McGaugh, 2002; Whiteaker et al., 2000). A lack of compounds with selectivity
for α6β2*nAChRs that cross the blood brain barrier make it difficult to assess the stoichiometry
of the β2*nAChRs that support the systemic effects of nicotine; future studies using selective
peptide infusions in brain e.g. (Brunzell et al., 2010; Gotti et al., 2010; Jackson et al., 2009) will
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help parse the subunit configurations in combination with β2 that promote anxiolysis via
inhibition of β2*nAChRs.

Behaviorally, these nicotine findings are consistent with previous data. A preponderance of the
evidence suggests that low doses of nicotine promote anxiolysis-like behavior (Cheeta, Irvine, et
al., 2001; File et al., 1998; Irvine et al., 1999; McGranahan et al., 2011), moderate doses of
nicotine support reward-like behavior (Brunzell et al., 2009; McGranahan et al., 2011; Mineur et
al., 2009), and high doses of nicotine increase anxiety-like behaviors (Cheeta, Tucci, et al., 2001;
File et al., 2000; File et al., 1998; Ouagazzal et al., 1999). Similarly to low dose nicotine and
DHβE, anxiolytic drugs such as benzodiazepines increase lever pressing during a presentation of
an aversive CS compared to when saline is administered (Annau & Kamin, 1961; M. Davis,
1990; Dixon et al., 2008; Martin, Ballard, & Higgins, 2002; Mathiasen, Rodgers, & Mirza, 2007;
Morris et al., 2006; Scobie & Garske, 1970; Stanhope & Dourish, 1996), decrease digging in the
marble burying task (Broekkamp et al., 1986; Deacon, 2006; Kinsey et al., 2011; Nicolas et al.,
2006; Turner et al., 2010) and increase open arm activity in an elevated plus maze. Studies in
humans show that trait anxiety leads to elevated cued fear conditioning of aversive stimuli and
imaging studies show this behavioral tendency is positively correlated with an exaggerated
activation of the amygdala and anterior cingulate cortex, brain areas shown to regulate rodent
behavior during fear conditioning tasks (Britton et al., 2011; Craske et al., 2008; Delgado,
Olsson, & Phelps, 2006; Lang & McTeague, 2009; Sehlmeyer et al., 2011; Waters, Henry, &
Neumann, 2009). CER, marble burying and the elevated plus maze have good predictive
validity for anxiolytic drug efficacy (Annau & Kamin, 1961; Broekkamp et al., 1986; M. Davis,
1990; Deacon, 2006; Dixon et al., 2008; Garrett, Niekrasz, Haque, Parker, & Seale, 1998;
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Griebel, Belzung, Perrault, & Sanger, 2000; N. J. Johnson & Rodgers, 1996; Kinsey et al., 2011;
Martin et al., 2002; Mathiasen et al., 2007; Morris et al., 2006; Nicolas et al., 2006; Njung'e &
Handley, 1991; Pelleymounter et al., 2002; Pellow, Chopin, File, & Briley, 1985; Scobie &
Garske, 1970; Stanhope & Dourish, 1996; Turner et al., 2010; Wiley, Cristello, & Balster, 1995).
Together with previous data, the present studies suggest that inactivation of nAChRs may
promote anxiolysis-like behavior and may have mechanistic implications for why individuals
smoke to relieve anxiety.

These studies utilized CER, marble-burying and an elevated plus maze task to show that nicotine
and DHβE could both stimulate and suppress behavior in a way that is consistent with currently
available anxiolytic drugs (Broekkamp et al., 1986; Garrett et al., 1998; Griebel et al., 2000; N. J.
Johnson & Rodgers, 1996; Kinsey et al., 2011; Nicolas et al., 2006; Njung'e & Handley, 1991;
Pelleymounter et al., 2002; Pellow et al., 1985; Turner et al., 2010; Wiley et al., 1995). Marble
burying, however is also sensitive to antidepressant drugs and antipsychotics (Bruins Slot et al.,
2008; Egashira et al., 2008; Ichimaru et al., 1995; Nicolas et al., 2006) suggesting that digging
behavior in rodents may be driven by an underlying system that is common to the effects of these
diverse drug classes. Individuals diagnosed with anxiety disorder, depression or schizophrenia
all have a significantly elevated risk for tobacco dependence (Leonard et al., 2001; Ziedonis et
al., 2008). In addition to the high concordance with tobacco use, there is a high comorbidity for
diagnosis of anxiety with depression and schizophrenia, suggesting that there is a common
underlying etiology for these disorders (Buckley, Miller, Lehrer, & Castle, 2009). Some suggest
that the “non-purposeful” digging behavior in the marble burying task may model obsessive
compulsive disorder (Bruins Slot et al., 2008; Egashira et al., 2008; Ichimaru et al., 1995).
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Drugs such as clozapine, aripiprizole and risperidone that are used to augment the effects of
mood stabilizers also reduce marble burying activity (Bruins Slot et al., 2008; Egashira et al.,
2008). β2*nAChRs are ubiquitously expressed in the brain (Champtiaux et al., 2002; Chefer et
al., 1998; Marks et al., 2010; Vaupel et al., 1998; Whiteaker et al., 2000) where their activation
on the neuron soma and terminals promotes release of GABA, serotonin, DA, norepinephrine
and ACh, neurotransmitters that regulate mood and arousal and that are believed to contribute to
the etiology of anxiety, depression and schizophrenia (Picciotto et al., 2001). The β2*nAChRs
have also been implicated in contributing to rodent models of depression-like behavior with
mecamylamine and partial agonists of β2*nAChRs showing anti-depressant-like efficacy
(Mineur, Somenzi, & Picciotto, 2007; Rabenstein, Caldarone, & Picciotto, 2006; Rollema et al.,
2009). Unlike our observations in the marble burying task, however, administration of DHβE
blocks the antidepressant-like effects of the β2*nAChR partial agonists varenicline and
sazetidine in the forced swim task (Caldarone et al., 2011), showing a dichotomy with the
present results in the elevated plus maze which suggest that antagonism of β2*nAChRs promotes
anxiolysis-like behavior.

It is possible that our findings in the CER task reflect changes in learning that are independent of
fear and anxiety-like behavior. While it is possible that drug injection could result in statedependent learning effects, we do not believe this was the case given that animals showed dosedependent effects of nicotine and DHβE using a within-subject, Latin Square design. Place
conditioning and drug discrimination studies clearly demonstrate that mice can physiologically
detect the 0.1 mg/kg dose of nicotine (Brunzell et al., 2009; Chance, Murfin, Krynock, &
Rosecrans, 1977; Le Foll, Justinova, Wertheim, Barnes, & Goldberg, 2008; Le Foll, Wertheim,
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& Goldberg, 2008; McGranahan et al., 2011; Mineur et al., 2009; Palmatier, Wilkinson,
Metschke, & Bevins, 2005) yet this dose did not reverse conditioned suppression as low doses
did in these studies, suggesting that the effects of nicotine and DHβE on suppression ratios
during CER were not due to a generalized decrement caused by state-dependent learning. It is
also possible that the injection itself could have served as an occasion-setter to indicate that no
shock would occur during these test sessions. This was not the case. Rather, saline injection led
to a decrease in NON-CS responding during these test sessions, suggesting that the stress of
injection led to a reduction in goal-oriented behavior as measured by lever pressing for
saccharin. Several doses of nicotine, including a rewarding-like dose, reversed this suppression
of NON-CS responding. Whereas it is possible that this behavior was stimulated by anxiolyticlike effects of nicotine, it is equally plausible that nicotine exposure promoted stimulus
enhancing effects of the saccharin reinforcer as has been shown for an unconditioned stimulus
light and a conditioned stimulus associated with an appetitive stimulus (Brunzell et al., 2006;
Caggiula et al., 2001; Donny et al., 2000; Olausson, Jentsch, & Taylor, 2004). The present
results also showed an interesting contrast to findings using Pavlovian fear conditioning without
an operant component. Unlike our observations in the CER task, systemic administration of
nicotine enhances freezing in a footshock-paired context with no effect on explicit cue
conditioning (Gould, 2003; Gould & Wehner, 1999). These dichotomies may be due in part to
the use of a more mild footshock and extended explicit cue CS training used during CER
compared to traditional Pavlovian fear conditioning procedures. A significant difference in CS
but not NON-CS lever pressing between mice trained to a 0.1 mA and 0.3 mA footshock
suggests that the contextual fear did not contribute to CER behavior in these studies. In addition,
systemic administration of DHβE alone does not affect either context or explicit cue CS-freezing
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following fear conditioning (J. A. Davis & Gould, 2006), drawing a further contrast between
these procedures. Together these findings suggest that basic Pavlovian fear conditioning and
CER are modeling different behaviors. These data further suggest that CER, but not Pavlovian
fear conditioning, is sensitive to inactivation of the high affinity β2*nAChRs. Whereas the CER
paradigm is a complex animal model that involves fear learning and operant behavior, this
procedure benefits from subjects acting as their own controls both within and between sessions.
The fact that mice showed similar effects in the marble-burying task and elevated plus maze,
which do not have a learning components to them, supports the hypothesis that affective
behavior was modified by nicotine and DHβE during CER.

Studies in human smokers reveal that multiple factors contribute to tobacco use; as well as the
pleasure received from smoking, many report that they use tobacco to relieve anxiety or to relax
(Berlin et al., 2003; Fidler & West, 2009; Livson & Leino, 1988; Perkins & Grobe, 1992;
Shiffman et al., 1997; Shiffman & Waters, 2004; Skara et al., 2001). The first cigarette of the
day results in an abrupt increase in nicotine plasma concentrations that smokers associate with
the rewarding effects of the drug (Benowitz, 1988; Benowitz & Jacob, 1984; Fagerstrom et al.,
1990). The nicotine ingested from a single cigarette is sufficient to occupy 80% of β2*nAChRs
(Brody, Mandelkern, Costello, et al., 2009; Brody et al., 2006). During subsequent smoking
episodes, smokers achieve smaller increases in nicotine that ought to preferentially favor
desensitization of nAChRs (Benowitz, 1988; Benowitz & Jacob, 1984) if slice electrophysiology,
Xenopus oocyte, tissue culture and synaptosome studies are predictive of how nAChRs function
in vivo (Fenster et al., 1997; Grady et al., 2012; Kuryatov et al., 2011; R. A. Lester & Dani,
1995; Lu et al., 1999; Mansvelder et al., 2002; Pidoplichko et al., 1997). Nicotine reaches daily
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steady-state concentrations in the brains of human smokers between 200-400 nM. ACh is a
major neuromodulator in brain that is thought to regulate anxiety-like behavior (DeBiasi, 2010;
Power & McGaugh, 2002). As nicotine levels drop, populations of β2*nAChRs in brain regions
that regulate anxiety become available for activation by ACh in response to stressful stimuli such
as cigarette/tobacco cues (Carter et al., 2006; Lazev, Herzog, & Brandon, 1999; Littel &
Franken, 2007; McDonough & Warren, 2001). Hence, in addition to smoking to activate their
β2*nAChRs, tobacco users may also be titrating ACh signals via desensitization of the
β2*nAChRs, particularly after the first cigarette of the day. Human imaging studies suggest that
β2*nAChRs may be critical for nicotine’s ability to curb anxiety in smokers (Benowitz, 2008;
Sharma & Brody, 2009) but presently available compounds that assess β2*nAChR occupancy in
humans cannot differentiate between receptors in the activated or desensitized state.

To conclude, low dose nicotine and DHβE had similar effects on affective behavior in the CER,
marble burying and elevated plus maze tasks. These studies support the hypothesis that nicotine
may reduce negative affect and anxiety via desensitization of the high affinity β2*nAChRs.
These data further suggest that antagonism of β2*nAChRs may be an effective strategy for
promoting tobacco cessation or for relieving anxiety in non-tobacco users. The conclusions of
these studies would be strengthened by evaluating whether β2*nAChRs are necessary for the
anxiolytic-like effects of low-dose nicotine using mice with genetic deletion of β2*nAChRs
(β2KO). Furthermore, if the anxiolytic-like effects of low-dose nicotine are promoted via
inactivation of β2*nAChRs, then an anxiolytic-like dose of nicotine ought to block the
behavioral effects of a high dose of nicotine.
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Chapter 3 - Anxiolytic- and anxiogenic-like effects of nicotine are regulated via diverse
action at β2*nAChRs

INTRODUCTION
Tobacco use is a major global risk factor for cancer and cardiopulmonary diseases (WHO, 2008).
Many smokers indicate that they smoke to relieve anxiety and studies suggest that smokers
experience anxiety more intensely than non-smokers (Fidler & West, 2009; Parrott, 1999;
Perkins & Grobe, 1992). Stress is also a major precipitating factor in relapse to smoking
(Shiffman et al., 1997) and for escalation of cigarette use (Skara et al., 2001). The exact
mechanism of nicotine-mediated relief of anxiety experienced by smokers is not clearly
understood.

Using a combination of genetic and pharmacological approaches, these studies sought to
determine the role of β2 subunit containing nicotinic acetylcholine receptors (β2*nAChRs;
*other subunits assemble with β2 to form a functional receptor) in the anxiolytic-like and
anxiogenic-like effects of nicotine in the light-dark and elevated plus maze assays, rodent models
with good predictive validity for FDA-approved pharmacological agents for treatment of anxiety
in humans (Crawley & Goodwin, 1980; Wiley et al., 1995). Neurons in limbic system brain
regions that regulate both affect and reward are enriched with β2*nAChRs (Clarke et al., 1985;
Court & Clementi, 1995; Fujita et al., 2000; Grady et al., 2010; Kimes et al., 2008; Marks et al.,
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2010; Marks et al., 1992; Pauly & Collins, 1993; Picciotto et al., 1995; Rubboli et al., 1994;
Staley et al., 2005; Y. Xiao & Kellar, 2004) suggesting that this nAChR subtype may serve a role
in the relief of negative affect. In Experiment 1, β2*nAChR null mutant mice (β2KO) were
compared to their wild type (WT) littermate controls across a range of doses of nicotine (0, 0.01,
0.05, 0.1 or 0.5 mg/kg i.p. by weight of freebase) on measures of latency, percent time in the
light chamber and movements per second in the light and dark chambers. Preclinical studies
demonstrate that low doses of nicotine promote anxiolysis-like behavior and high doses lead to
anxiogenic-like behavior (Picciotto, Brunzell, & Caldarone, 2002). It is well known that high
doses of nicotine promote anxiogenic-like behavior in a variety of rodent behavioral assays
(Cheeta, Tucci, et al., 2001; File et al., 2000; File et al., 1998; Ouagazzal et al., 1999; Zarrindast
et al., 2008), but it is not clear if this is due to activation or inhibition of nAChRs. Experiment 2
utilized a selective agonist of β2*nAChRs, 5-Iodo-A85380 (5I-A85380), to test if selective
targeting of β2*nAChRs is sufficient to promote anxiolysis-like and anxiogenic-like behavior in
the light-dark and elevated plus maze assays. Experiment 3 assessed if a pre-injection of the
selective β2*nAChR antagonist DHβE would block or augment the anxiolytic-like effects of
low-dose nicotine (0.05 mg/kg i.p.) or the anxiogenic effects of high dose nicotine (0.5 mg/kg
i.p.).

In vitro and in vivo studies show that nicotine both activates and desensitizes nAChRs and that
low concentrations may preferentially desensitize nAChRs, rendering them unavailable for
further activation by nicotine or the endogenous neurotransmitter ACh (Buccafusco, Shuster, &
Terry, 2007; Fenster et al., 1997; R. A. Lester & Dani, 1995; Mansvelder et al., 2002;
Pidoplichko et al., 1997). Previously we showed that the administration of both low dose
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nicotine and the selective β2*nAChR antagonist DHβE similarly reduced anxiety-like behaviors
in various assays in mice, suggesting that the effective doses of nicotine may have exerted their
effects via inhibition rather than activation of the high affinity β2*nAChRs. Experiments 4 and
5 therefore directly assessed if pre-injection of a low dose of nicotine (0.01 or 0.05 mg/kg i.p.)
would effectively block or accumulate with doses of nicotine that promote anxiolytic-like (0.05
mg/kg i.p.) and anxiogenic-like (0.5 mg/kg i.p.) behavior in the light-dark and elevated plus
maze assays.

MATERIALS AND METHODS
Subjects
64 adult male WT mice and 42 β2KO mice (Picciotto et al., 1995) backcrossed at least 10
generations on a C57BL/6J background were derived in a Virginia Commonwealth University
(VCU) vivarium using heterozygous matings. Genotypes were confirmed as described
previously (Salminen et al., 2004) using the following primers for the β2 nAChR subunit (β2
wild-type 5′, 5′-GCTTCAAACCTCTCCACGTC-3′; β2 wild-type 3′,
5′CGCCATAGAGTTGGAGCACC-3′) and the LacZ cassette reporter (LacZ 5′, 5′
CACTACGTCTGAACGTCGAAAA-3′; and LacZ 3′, 5′-CGGGCAAATAATATCGGTGGC3′). 121 C57BL/6J mice were obtained from Jackson Laboratory (Bar Harbor, ME) for these
experiments. Animals were group-housed (2-5 per cage), maintained in an AAALAC approved
facility on a 12h light/dark cycle (lights on at 0600) and were provided ad libitum access to food
and water throughout these studies. Animals purchased from Jackson labs were given 3 days to
habituate to the vivarium prior to handling or experimentation. Mice were habituated to
experimenter handling for 3 days and to the experimental room for 1 day prior to any
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experimentation. Every effort was taken to minimize any pain and discomfort the animals may
have experienced during these studies. All experiments were conducted during the light cycle
and were approved by the VCU Institutional Animal Care and Use Committee and were in
compliance with the Guide for Care and Use of Laboratory Animals.

Apparatus
Light-dark experiments were conducted in modified place conditioning chambers (Med
Associates, St. Albans, VT). A small, enclosed, dark chamber with a black ceiling (L 16.8 cm x
W 12.7 cm x H 12.7 cm) was directly adjacent to a larger, open, brightly-lit chamber (L 26.5 cm
x W 12.7 cm x H 26.2 cm) that was illuminated by a single 23W fluorescent light bulb. A door
between chambers (W 5 cm x H 5.9 cm) enabled mice to move freely throughout the apparatus.
White and black plastic inserts (L 16.8 cm x W 12.7 cm) were placed in the stainless steel
dropping trays in the respective light and dark chambers. Photocells placed 3 cm apart recorded
mouse location and movement. Data were collected on a PC computer and calculated using Med
Associates software. An elevated plus maze 68 cm above the floor was constructed of wood
with white plastic flooring on two (5 x 30 cm) open arms that were perpendicular to two
equivalent, white, plastic enclosed arms with 15.25 cm black Plexiglas wall enclosures.
Experiments were conducted under fluorescent light illumination. Data was collected with a
ceiling-mounted camera that was interfaced to a PC for collection of data using ANY-maze
tracking software (Stoelting, Wood Dale, IL).

Drugs
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Nicotine hydrogen tartrate (Sigma Aldrich, St. Louis, MO), the selective β2*nAChR antagonist,
DHβE and the selective β2*nAChR agonist 5I-A85380 (Tocris, Bristol, United Kingdom) were
diluted in 0.9% sterile saline vehicle for these experiments. Injections were delivered i.p. in
volumes of 0.1 ml/30 g. Doses are presented as freebase.

Behavioral Procedures
Experiment 1: Genetic Assessment of β2*nAChR contributions to Light-Dark Behavior
On test day, the experimental room was dark other than illumination required for the light-dark
apparatus. β2KO and WT mice received between-subject delivery of 0, 0.01, 0.05, 0.1 or 0.5
mg/kg i.p. nicotine (n = 8-13 for each dose and genotype) immediately prior to placement in the
dark, enclosed chamber of the apparatus. Mice were evaluated for latency to leave the dark
chamber, % time spent in the light chamber and movement counts per second in the light and
dark chambers for a period of 10 min. Chambers were cleaned of debris and thoroughly wiped
with 2% Nolvasan (Pfizer Animal Health, Madison, NJ) between trials. Mouse weights were
taken approximately 1 h before testing.

Experiment 2: Evaluation of the selective β2*nAChR agonist 5I-A85380 on Anxiety-like
Behavior in the Elevated Plus Maze and Light-Dark assays
C57BL/6J male mice received between-subject delivery of 0, 0.001, 0.0032, 0.01 or 0.032 mg/kg
i.p. 5I-A85380 15 min prior to behavioral evaluation in the light-dark assay as described above
or the elevated plus maze assay (n = 7-9 per dose). In the elevated plus maze assay, after
between-subject delivery of 0, 0.001, 0.0032, 0.01 or 0.032 mg/kg i.p. 5I-A85380 15 min prior to
experimentation, mice were evaluated for the number of entries made into the open arms, time
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spent in the open arms, latency to explore the terminal 5 cm of the open arms and time spent in
the closed arms. The effect of drug administration on the number of entries made into the closed
arms was also evaluated to measure drug effects on locomotor activity.

Experiment 3: Pharmacological Assessment of β2*nAChR contributions to Light-Dark Behavior
Behavioral Procedures were as described for Experiment 1 except that 15 min prior to vehicle (0
mg/kg), low dose (0.05 mg/kg) or high dose (0.5 mg/kg) nicotine, WT mice received a preinjection of 0.9% saline or 2 mg/kg i.p. DHβE (n = 7-9 for each group). This dose of DHβE has
been shown previously to promote anxiolysis-like behavior in other assays without affecting
locomotor activity (Anderson & Brunzell, 2012), and to block nicotine conditioned place
preference (CPP), which requires activation of β2*nAChRs (Walters et al., 2006). The DHβE
given in the CPP study was delivered s.c., which would likely render it less potent than the dose
administered i.p. in these experiments.

Experiment 4: Evaluation of the effects of low dose nicotine pre-injection on Light-Dark
Behavior
Procedures were as described for Experiment 2 except that mice received pre-injection of 0, 0.01
or 0.05 mg/kg i.p. nicotine 10 min prior to low dose (0.05 mg/kg) or high dose (0.5 mg/kg)
nicotine. Control mice in Experiments 2 and 4 received two injections of vehicle. Mice from
Experiment 2 and 4 for were run concomitantly to conserve vehicle controls (n = 7-9 per group).

Experiment 5: Assessment of the effects of low dose nicotine pre-injection on Behavior in the
Elevated Plus Maze Assay
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WT mice received a pre-injection of 0, 0.01 or 0.05 mg/kg i.p. nicotine 10 min before 0 or 0.5
mg/kg i.p. nicotine. After nicotine injection, mice were returned to home cage for 5 min prior to
evaluation on an elevated plus maze (n = 10-11 per group).

Statistical Analysis
Two-way, between-subject ANOVA tests compared animals across genotypes and drug
exposures in Experiments 1 and 2 and assessed interactions of pretreatment with nicotine
condition in Experiment 5. One-way ANOVA was used in Experiments 3 and 4. Dunnett’s or
Tukey’s post hoc tests assessed significant main effects and post hoc t-tests assessed significant
interactions. For all analyses, P values ≤ 0.05 were reported as significant. Planned comparisons
assessed genotypes independently of one another and assessed the stress of multiple injections by
comparing behaviors of WT vehicle controls in Experiment 1 to WT mice that received
VEH/VEH in Experiments 3 and 4.

RESULTS

Experiment 1: Genetic Assessment of β2*nAChR contributions to Light-Dark Behavior
Consistent with an anxiolytic-like phenotype, a main effect of nicotine treatment (F4,85 = 14.604,
P < 0.001) revealed that mice receiving a low dose of i.p. nicotine (0.05 mg/kg) spent more time
in the light chamber compared to vehicle-injected controls (P < 0.05; Fig 3.1a). In contrast, mice
administered a high dose of i.p. nicotine (0.5 mg/kg) spent significantly less time in the light
chamber compared to vehicle controls (P < 0.001; Fig 3.1a), suggestive of anxiogenic-like
behavior. Planned comparisons revealed that increased time spent in the light chamber following

67

Figure 3.1 - β2*nAChRs contribute to anxiolytic-like and anxiogenic-like effects of
nicotine. a) A main effect of treatment on time spent in the light chamber revealed that acute
nicotine treatment had a dichotomous effect on anxiety-like behavior. A low dose of nicotine
(0.05 mg/kg i.p.) resulted in reduced anxiety-like behavior in wild type (WT) mice only, which
spent more time in the light chamber than saline-treated WT mice. Mice receiving a high dose
(0.5 mg/kg i.p.) of nicotine spent less time in the light chamber than saline-injected mice
regardless of genotype, suggestive of an anxiogenic-like phenotype. There was a trend for
increased time spent in the light chamber in β2 knock-out (β2KO) mice compared to WT mice
receiving 0.5 mg/kg i.p. nicotine, suggesting that mice lacking the β2*nAChRs were protected
from the anxiogenic-like effects of the high dose of nicotine. b) Unlike β2KO mice, which were
not significantly affected by 0.5 mg/kg i.p. nicotine, WT mice receiving high dose nicotine
required more time to enter the light chamber than saline-treated controls. There was also a nonsignificant trend for lower latencies in β2KO mice administered 0.5 mg/kg i.p. nicotine
compared to WT mice receiving 0.5 mg/kg i.p. nicotine, further suggesting that β2KO mice were
protected from the anxiogenic-like effects of a high dose of nicotine. c) WT mice administered
0.5 mg/kg i.p. nicotine explored the light chamber less than saline-treated WT control mice as
measured by reduced movements per second spent in the light chamber. In contrast, light
chamber exploration was not significantly affected by nicotine dose in β2KO mice. Compared
to WT mice administered 0.5 mg/kg nicotine β2KO mice also showed higher movements per
second in the light chamber, suggesting that activation of β2*nAChRs is important for regulating
the anxiogenic-like effects of 0.5 mg/kg i.p. nicotine for this measure. d) Mice receiving 0.5
mg/kg i.p. nicotine moved less in the dark chamber compared to their saline-injected littermates
independent of genotype, suggesting that other nicotinic receptor sub-types contribute to reduced
locomotor activity in the dark chamber. Data are represented as means ± SEM. *P < 0.05
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compared to saline-treated mice of same genotype; **P < 0.05, #P < 0.09 compared to WT mice
receiving the same dose.
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0.05 mg/kg i.p. nicotine was only observed in WT mice (t20 = 2.293, P < 0.05; Fig 3.1a) and not
β2KO subjects compared to their saline controls (t16 = 1.383, P = 0.186), suggesting that
β2*nAChRs are important for the expression of the anxiolytic-like effects of low dose nicotine.
Both WT (t19 = 4.485, P < 0.001; Fig 3.1a) and β2KO mice (t16 = 2.851, P < 0.05; Fig 3.1a) spent
less time in the light chamber following the 0.5 mg/kg i.p. nicotine dose, suggesting that nAChR
receptor subtypes other than β2*nAChRs contribute to the anxiogenic effects of nicotine in this
assay. There was a non-significant trend for β2KO mice to spend more time in the light chamber
compared to WT mice receiving 0.5 mg/kg i.p. nicotine, however (t15 = 2.088, P = 0.054; Fig
3.1a), suggesting that β2*nAChRs contribute to nicotine’s anxiogenic effects as well. Similar
genotype x treatment interaction trends were observed for the measure of latency (F4,85 = 2.109,
P = 0.087), with main effects of genotype (F1,85 = 6.533, P < 0.05) and treatment (F4,85 = 13.339,
P < 0.001). WT mice receiving 0.5 mg/kg i.p. nicotine required significantly more time to enter
the light chamber than saline-injected mice (t19 = 3.908, P = 0.001; Fig 3.1b) with only trends for
delayed light chamber entry in 0.5 mg/kg β2KO mice compared to their vehicle-injected
counterparts (t16 = 1.870, P = 0.08; Fig 3.1b). Comparison across genotypes at the 0.5 mg/kg i.p.
dose revealed a non-significant trend for β2KO mice to exhibit shorter latencies to enter the light
chamber compared to their WT littermates (t15 = 1.873, P = 0.081; Fig 3.1b).

To assess locomotor activity in this assay, the effects of acute nicotine on movements per second
were separately assessed in the dark and light chambers. Changes in exploration that were
specific to the light chamber and not observed in the dark were interpreted as changes in anxietylike behavior whereas effects of movements per second observed in both chambers implicates a
likely locomotor component to the observed behavior. A significant interaction of genotype with
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treatment was specific to movements per second in the light chamber (F4,85 = 3.020, P < 0.05),
revealing that only WT mice showed a reduction in light chamber exploration at the highest dose
of nicotine (t19 = 4.592, P < 0.001; Fig 3.1c). In addition to not having significantly reduced
light chamber activity than β2KO controls (t16 = 1.508, P = 0.151), β2KO mice receiving the
high dose of nicotine showed increased movements per second in the light chamber than WT
mice injected with 0.5 mg/kg nicotine (t15 = 2.278, P < 0.05; Fig 3.1c). In contrast to light
chamber activity, there was no genotype x treatment interaction (F4,85 = 2.146, P > 0.05) and no
effect of genotype on dark chamber activity (F1,85 < 1, P = 0.456). A significant effect of
treatment (F4,85 = 14.756, P < 0.001) revealed that 0.5 mg/kg mice, overall, moved less in the
dark chamber compared to saline-injected mice independent of genotype (P < 0.001; Fig 3.1d).
Present in both genotypes, these general reductions in locomotor activity were likely driven by
nAChRs other than those that contain a β2 subunit.

Experiment 2: Evaluation of the selective β2*nAChR agonist 5I-A85380 on Anxiety-like
Behavior in the Elevated Plus Maze and Light-Dark assays
Significant effects of 5I-A85380 on elevated plus maze and light-dark behaviors revealed that
selective targeting of β2*nAChRs was sufficient to support anxiolysis-like and anxiogenic-like
phenotype. There were main effects of drug treatment for time spent in the open arms (F4,35 =
4.254, P = 0.007), time spent in the closed arms (F4,35 = 7.946, P < 0.001), number of entries into
the open arms (F4,35 = 5.131, P = 0.002), number of entries made into the closed arms (F4,35 =
3.129, P = 0.027) and latencies to explore the terminal 5cm of the open arms (F4,35 = 4.728, P =
0.004) of the elevated plus maze. Similar to nicotine, low dose 5I-A85380 supported anxiolysislike behavior and mice injected with high dose 5I-A85380 showed anxiogenic-like behavior.
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Compared to saline-injected controls, mice injected with 0.001 mg/kg i.p. 5I-A85380 spent more
time in the open arms and made more entries into the open arms (P < 0.05; Fig 3.2a, P < 0.05;
Figure 3.2c), whereas administration of a high 0.032 mg/kg i.p. dose of 5I-A85380 resulted in an
increase in time spent in the closed arms of an elevated plus maze (P < 0.05; Figure 3.2b). Post
hoc tests did not detect any dose-specific effects of 5I-A85380 administration on entries made
into the closed arms (P’s > 0.2; Table 3.1). Despite trends to show reduced latency to explore
the terminal 5cm of the open arms at the lowest dose of 5I-A85380, post hoc tests did not reveal
any dose-specific effects of 5I-A85380 administration on this measure (P’s > 0.1; Figure 3.2d).
There was a main effect of drug administration for % time spent in the light chamber (F4,36 =
5.120, P = 0.002) and latency to enter the light chamber (F4,36 = 17.453, P < 0.001). Consistent
with the high dose of 5I-A85380 supporting anxiogenic phenotype, post hoc tests revealed that
mice administered 0.032 mg/kg i.p. of the selective β2*nAChR agonist 5I-A85380 spent less
time in the light chamber (P = 0.005; Figure 3.3a) and showed increased latencies to enter the
light chamber than saline-injected mice (P < 0.001; Figure 3.3b). A main effect of treatment was
observed for light chamber (F4,36 = 7.604, P = 0.002), but not dark chamber activity (F4,36 =
2.599, P > 0.05) following selective agonism of β2*nAChRs with 5I-A85830. Mice injected
with 0.032 mg/kg i.p. 5I-A85380 showed reduced movements per second in the light chamber
compared to saline-injected controls (P < 0.001; Figure 3.3c). An absence of a significant effect
in the dark chamber suggests that changes in behavior observed during the light-dark assay
following the administration of 0.032 mg/kg 5I-A85380 reflected increased anxiety-like behavior
rather than reduced locomotor activity. In the light-dark assay, 5I-A85380 supported
anxiogenic-like behaviors at high doses but did not support anxiolysis-like behavior.
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Figure 3.2 - Administration of selective β2*nAChR agonist 5I-A85380 has bimodal effect
on anxiety-like behavior in elevated plus maze assay. a-b) Similar to nicotine, the selective
β2*nAChR agonist 5I-A85380 both reduced and increased anxiety-like behaviors, a) as mice
receiving a low dose (0.001 mg/kg i.p.) of 5I-A85380 spent more time in the open arms of an
elevated plus maze, b) whereas mice injected with a high dose (0.032 mg/kg i.p.) of 5I-A85380
spent more time in the closed arms than vehicle-injected controls. c) Mice injected with 0.001
mg/kg i.p. 5I-A85380 also made more entries into the open arms than saline-injected mice,
indicative of anxiolytic-like behavior. d) Although a main effect of drug treatment was revealed
for latency to explore the terminal 5cm of the open arms, post hoc tests did not detect any dosespecific effects for this measure.
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Table 3.1 - Effect of 5I-A85380 administration on number of entries made into the closed
arms.
5I-A85380
mg/kg i.p.
Closed arm
entries

0

0.001

0.0032

0.01

0.032

23.1 ± 2.2

28.8 ± 4.1

25.9 ± 3.3

18.3 ± 3.1

15.3 ± 2.5

Post hoc tests did not detect any significant dose-dependent effects of 5I-A85380 administration
on the number of entries made into the closed arms of an elevated plus maze, suggesting that
changes in observed behaviors were not solely driven by regulation of general locomotor
activity. Data are represented as Means ± SEM.
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Figure 3.3 - Administration of the selective β2*nAChR agonist 5I-A85380 also results in
anxiogenic-like behavior in the light-dark assay. a) Mice administered 0.032 mg/kg i.p. of
the selective β2*nAChR agonist 5-Iodo-A85380 (5I-A85380) showed longer latencies to enter
the light chamber and b) spent less time in the light chamber than mice receiving saline vehicle,
suggestive of an anxiogenic-like effect. c) A main effect of drug treatment for movements per
second in the light chamber revealed that mice injected with 0.032 mg/kg i.p. 5I-A85380 also
showed lower light chamber exploration than saline-injected mice. d) There was no effect of
drug treatment detected for dark chamber activity, suggesting that the behavioral effects of 0.032
mg/kg i.p. 5I-A85380 reflect increased anxiety-like behavior and not reductions in general
locomotor activity. Data are reported as means ± SEM; *P < 0.05 compared to saline vehicle.
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Table 3.2. Nicotine pre-injection time course.
PRE NIC
mg/kg
nicotine
i.p.

NIC
mg/kg
nicotine
i.p.

Pretreatment
time (min)

% Time light

Latency to enter
light chamber (s)

n size

No Pre-Injection
NO INJ
NO INJ
NO INJ

VEH
0.05 NIC
0.5 NIC

(12)
28.3 ± 3.6
113.4 ± 43.3
(10)
38.3 ± 2.7^
50.0 ± 12.4
(9)
5.4 ± 3.1^
421.8 ± 68.8^
Vehicle Pre-Injection Controls
VEH
VEH
10
(9)
15.6 ± 4.5^
164.2 ± 82.6
Pre-Injection prior to an Anxiolytic dose of 0.05 mg/kg i.p. nicotine
0.05 NIC
0.05 NIC 5
(7)
21.0 ± 5.1
147.1 ± 88.84
0.05 NIC
0.05 NIC 10
(7)
21.5 ± 6.1
69.0 ± 43.3
Pre-Injection prior to an Anxiogenic dose of 0.5 mg/kg i.p. nicotine
0.05 NIC
0.5 NIC
5
(7)
7.0 ± 2.7^
196.7 ± 104.3
,
0.05 NIC
0.5 NIC
10
(7)
23.5 ± 4.6*
28.4 ± 10.9 *
A nicotine pre-injection time course is shown for efficacy of pre-injection (PRE NIC) of a 0.05
mg/kg i.p. anxiolytic-like dose of nicotine to affect light-dark behaviors following a second
anxiolytic-like dose, or a 0.5 mg/kg i.p. anxiogenic-like dose of nicotine (NIC) in this task. In
mice receiving no pre-injection, 0.05 mg/kg i.p. nicotine (NO INJ/0.05 NIC) led to elevations in
percent time spent in the light chamber (t20 = 2.096) compared to NO INJ/VEH controls. In
contrast, mice receiving an anxiogenic-like dose of nicotine (NO INJ/0.5 NIC) showed significant
increases in latency to enter the light chamber (t19 = 3.908) and overall reductions in time spent in
this brightly-lit, exposed chamber compared to NO INJ/VEH controls (t19 = 4.485). The stress of
two injections (VEH/VEH) also led to significant decreases in % time spent in the light chamber
compared to NO INJ/VEH mice (t19 = 2.188). Despite the stress of multiple injections, mice preinjected with 0.05 mg/kg i.p. nicotine prior to an anxiogenic dose of 0.5 mg/kg i.p. nicotine (0.05
NIC/0.5 NIC) showed significantly shorter latencies than NO INJ/0.5 NIC (t14 = 4.967), but only
when injections were delivered 10 min and not 5 min prior to nicotine treatment. A time-course
revealed that pre-injection of 0.05 mg/kg i.p. low dose nicotine promoted anxiolysis-like behavior
only when given 10 min prior to subsequent nicotine injection and not at 5 min. 10 min preinjection also led to elevations in time spent in the light chamber compared to NO INJ/0.5 NIC
mice (t14 = 3.367). Data are represented as means ± SEM. ^P < 0.05 compared to NO INJ/VEH;
*P < 0.05 compared to NO INJ/0.5 NIC.
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Experiment 3: Pharmacological Assessment of β2*nAChR contributions to Light-Dark Behavior
The two injections required for this procedure increased anxiety-like behavioral measures (Table
3.2), but this did not preclude observation of anxiogenic or anxiolytic effects of nicotine in this
task. Planned comparisons revealed that mice receiving saline pre-injection before 0.5 mg/kg i.p.
nicotine (VEH/0.5 NIC) spent significantly less time in the light chamber than mice administered
saline followed by another saline vehicle injection (VEH/VEH; t14 = 2.789, P < 0.05; Fig 3.4a).
Latencies were not significantly affected (t14 = 1.396, P > 0.1; Fig 3.4b).

Experiment 3 evaluated whether pharmacological antagonism of β2*nAChRs would augment or
reduce the anxiogenic-like effects of 0.5 mg/kg i.p. high dose nicotine and the anxiolytic-like
effects of 0.05 mg/kg i.p. low dose nicotine. 0.5 mg/kg i.p. nicotine A pre-injection of DHβE
prior to 0.5 mg/kg nicotine (DHβE/0.5 NIC) blocked the anxiogenic-like effects of 0.5 mg/kg
nicotine and promoted an anxiolysis-like phenotype as measured by increased time spent in the
light chamber (P = 0.007; Fig 3.4a) and decreased latencies to enter the light chamber (P < 0.05;
Fig 3.4b) in these animals compared to VEH/0.5 NIC mice. Planned comparison analyses
revealed that mice administered 0.05 mg/kg i.p. nicotine following saline pre-injection
(VEH/0.05 NIC) spent more time in the light chamber (t14 = 2.131, P = 0.051; Fig 3.4c)
compared to VEH/VEH mice. There was no significant interaction of antagonist pre-exposure
with low dose nicotine treatment. Unlike anxiogenic-like effects of high dose nicotine, the
anxiolytic-like effects of low dose nicotine were neither augmented nor blocked by pre-injection
of DHβE.
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Figure 3.4 - Selective antagonism of β2*nAChRs with pretreatment of dihydro-betaerythroidine (PRE DHβE) blocks the anxiogenic-like effects of nicotine (NIC) in the lightdark assay. a) Consistent with Experiment 1, mice receiving saline pre-injection prior to a high
dose nicotine (VEH/0.5 NIC) spent less time in the light chamber than mice given two injections
of saline vehicle (VEH/VEH), suggestive of an anxiogenic-like effect at this dose. Although
mice receiving a pre-injection of 2 mg/kg i.p. DHβE (DHβE/VEH) did not show anxiolytic-like
behavior compared to VEH/VEH mice, a pre-injection of 2 mg/kg i.p. DHβE effectively blocked
the anxiogenic-like effects of 0.5 mg/kg i.p. nicotine treatment (DHβE/0.5 NIC). DHβE/0.5 NIC
mice spent more time in the light chamber and b) required less time to enter the light chamber
than VEH/0.5 NIC mice. c-d) Despite the added stress of two injections, consistent with
Experiment 1, pre-injection of saline vehicle prior to a low dose of nicotine (0.05 mg/kg i.p.)
resulted in elevated time spent in the light chamber and reduced latencies to enter the light
chamber following saline pre-injection. These effects were not further impacted by pre-injection
of 2 mg/kg i.p. DHβE, suggesting that the anxiolytic-like effects of low dose nicotine are not
mediated via activation of β2*nAChRs. Data are reported as means ± SEM; *P ≤ 0.05 compared
to VEH/VEH; **P < 0.05 compared to VEH/0.5 NIC.
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Planned comparisons between NO INJ/VEH and VEH/VEH mice revealed that multiple
injections did not significantly affect light or dark chamber activity (t19 = 0.335, P = 0.742; t19 =
1.681, P = 0.109). Two-way ANOVA analyses detected a trend for a pre-injection (PRE DHβE)
x nicotine (NIC) interaction in the light (F1,26 = 3.316, P = 0.08), but not the dark chamber (F1,26
< 1, P = 0.336) following pre-injections of vehicle (VEH) or 2 mg/kg i.p. DHβE (DHβE). Preinjections of DHβE blocked the effects of 0.5 mg/kg i.p. nicotine as evidenced by significantly
greater light chamber activity in DHβE/0.5 animals than VEH/0.5 NIC mice (P = 0.005; Fig
3.5a). Compared to VEH/VEH controls, animals injected with DHβE prior to saline vehicle
(DHβE/VEH) did not show increased light chamber activity.

Experiments 4 and 5: Evaluation of the effects of low dose nicotine pre-injection on nicotineassociated anxiogenic-like and anxiolytic-like behavior
A time course testing the effect of nicotine pre-injection on the anxiogenic effects of nicotine in
the light-dark assay showed that pre-injection with low dose nicotine dose-dependently blocked
the anxiogenic effects of high dose nicotine when given 10 min, but not 5 min, prior to
subsequent nicotine injection (Table 3.2). Data below are shown for 10 min pre-injections.
ANOVA analyses revealed main effects of treatment condition for time spent in the light
chamber (F6,44 = 5.509, P < 0.001) and latency to enter the light chamber (F6,44 = 4.092, P =
0.002). Pre-injection of saline vehicle prior to an anxiogenic 0.5 mg/kg i.p. dose of nicotine
(VEH/0.5 NIC) resulted in a significant reduction of time spent in the light chamber compared to
saline-injected controls receiving saline vehicle pre-treatment (VEH/VEH). Similar to preinjection with DHβE, this effect was blocked by pretreatment with an anxiolytic-like dose of
nicotine. 0.05 mg/kg nicotine prior to an anxiogenic dose of nicotine (0.05 NIC/0.5 NIC) resulted
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in significant elevations of time spent in the light chamber and reduced latencies to enter the light
chamber compared to VEH/0.5 NIC injected mice (P’s < 0.05; Fig 3.6a,b). Mice pre-injected
with vehicle prior to administration of the 0.05 mg/kg i.p. anxiolytic dose of nicotine showed a
significant increase in time spent in the light chamber compared to VEH/VEH mice, but were
unaffected by pre-injection with low-dose nicotine (0.05 NIC/0.05 NIC) for measures of % light
chamber time and latency (P’s > 0.1; Fig 3.6c,d). Together these data demonstrate that preinjection of nicotine did not accumulate with experimental doses to produce its effects, but rather
appeared to act like an antagonist when given at low doses 10 min prior to administration of an
anxiogenic dose of nicotine.

Similar to pre-injections of the selective β2*nAChR antagonist DHβE, significant effects of
treatment condition were observed following pretreatment of nicotine for movements per second
in the light (F6,44 = 4.22, P = 0.002) and dark chambers (F6,44 = 4.30, P = 0.002). VEH/VEH
mice showed greater exploration of the light chamber than VEH/0.5 NIC mice (P = 0.07), an
effect that was blocked by pre-injection of 0.05 mg/kg nicotine as evidenced by a non-significant
trend between 0.05 NIC/0.5 NIC and VEH/0.5 NIC mice (P = 0.07; Fig 3.5c) with no evident
difference between 0.05 NIC/0.5 NIC and VEH/VEH controls. Although post hoc tests did not
detect differences between VEH/VEH controls and VEH/0.5 NIC mice for dark chamber activity
(P = 0.334), 0.05 NIC/0.5 NIC mice showed greater dark chamber activity than VEH/0.5 NIC
mice (P = 0.009; Fig 3.5d).

In the elevated plus maze assay, planned comparison t-tests revealed that saline pre-injected mice
receiving 0.5 mg/kg i.p. nicotine (VEH/0.5 NIC) spent significantly more time in the closed arms
than vehicle pre-injected controls administered a second vehicle injection (VEH/VEH) (t19 =
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Figure 3.5 - Pre-injections of dihydro-beta-erythroidine (DHβE) and low dose nicotine
prior to 0.5 mg/kg i.p. nicotine similarly affect activity in both dark and light chambers. ab) Planned comparisons between mice from Experiment 1 given one saline injection (NO
INJ/VEH) and mice administered two injections of saline vehicle (VEH/VEH) did not detect any
significant differences for movements per second in either the light or dark chambers. Two-way
ANOVA analyses detected a trend for a pre-injection (PRE DHβE) x nicotine (NIC) interaction
in the light, but not the dark chamber following pre-injections of vehicle (VEH) or 2 mg/kg i.p.
DHβE (DHβE). VEH/0.5 NIC mice showed reduced movements per second than VEH/VEH
controls in the light chamber. Direct antagonism of β2*nAChRs blocked the behavioral effects
of 0.5 mg/kg i.p. nicotine in both chambers, as DHβE pre-injected mice (DHβE/0.5 NIC) had
higher movements per second in the light chamber than vehicle pre-injected mice (VEH/0.5
NIC). Compared to VEH/VEH controls, mice receiving pre-injections of DHβE prior to vehicle
(DHβE/VEH) did not show increased light chamber activity, suggesting that the effects observed
in DHβE/0.5 NIC were due to antagonism of 0.5 mg/kg i.p. nicotine. c-d) Similar to preinjections of DHβE, pre-injections of low dose nicotine also attenuated the behavioral effects of
high dose nicotine (VEH/0.5 NIC). c) Mice administered pre-injections of 0.05 mg/kg i.p.
nicotine (0.05 NIC/0.5 NIC) showed a trend for higher movements per second in the light
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chamber. d) 0.05 NIC/0.5 NIC mice showed higher dark chamber activity than VEH/0.5 NIC
controls. Taken together, these data suggest that pre-injections of 0.05 mg/kg i.p. nicotine may
have attenuated the anxiogenic-like effects of both 0.5 mg/kg i.p. nicotine and multiple injections
by reducing the activity of β2*nAChRs. Data are reported as means ± SEM. *P ≤ 0.05
compared to VEH/VEH; **P < 0.05, # < 0.09 compared to VEH/0.5 NIC.
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Figure 3.6 - Pretreatment with an anxiolytic-like low dose of nicotine (PRE NIC) blocks
anxiogenic-like effects of high dose nicotine (NIC) in the light-dark assay. a) Similar to
selective antagonism of β2*nAChRs, mice pretreated with an anxiolytic-like low dose of 0.05
mg/kg i.p. nicotine prior to 0.5 mg/kg i.p. nicotine (0.05 NIC/0.5 NIC) spent more time in the
light chamber and b) required less time to enter the light chamber than mice pre-injected with
saline vehicle prior to an anxiogenic dose of nicotine (VEH/0.5 NIC). c) Nicotine pretreatment
did not significantly alter the effects of an anxiolytic-like dose of i.p. nicotine (0.05 NIC/0.05
NIC). d) Latencies to enter the light chamber were also not significantly affected by i.p. nicotine
pretreatment; 0.05 NIC/0.05 NIC mice did not differ from VEH/0.05 NIC controls,
demonstrating that the administration of two injections of low dose i.p. nicotine did not
accumulate in this assay. Data are reported as means ± SEM; *P ≤ 0.05 compared to VEH/VEH;
**P < 0.05 compared to VEH/0.5 NIC.
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5.104, P < 0.001; Fig 3.7b). Two-way ANOVA analyses detected a main effect of anxiogenic
nicotine injection (F1,54 = 12.027, P = 0.001) and a trend for an interaction of nicotine preinjection x anxiogenic nicotine dosing for time spent in the closed arms (F2,54 = 2.942, P =
0.061). Student’s t-tests revealed that a pre-injection of 0.01 mg/kg i.p. nicotine blocked this
effect of 0.5 mg/kg i.p. nicotine to increase time spent in the closed arms; 0.01 NIC/0.5 NIC
mice spent less time in the closed arms compared to VEH/0.5 mice (t18 = 2.288, P < 0.05; Fig
3.7b). There was also a non-significant trend for 0.05 NIC/0.5 NIC mice to spend less time in the
closed arms than VEH/0.5 NIC mice (t20 = 1.794, P = 0.088; Fig 3.7b). Planned comparisons
also revealed that VEH/0.5 NIC mice spent less time in the open arms (t19 = 2.627, P < 0.05; Fig
3.7a), made fewer entries into the open arms (t19 = 3.012, P = 0.007; Fig 3.7c) and a nonsignificant trend for VEH/0.5 NIC mice to show increased latencies to explore the terminal 5cm
of the open arms than VEH/VEH mice (t19 = 2.051, P = 0.054; Fig 3.7d). A main effect of
nicotine pre-injection was also detected for time spent in the open arms (F2,54 = 4.235, P =
0.020), and for number of entries made into both the open arms (F1,54 = 8.089, P = 0.006) and
into the closed arms (F1,54 = 82.547, P < 0.001). There was no effect of nicotine administration
on latency to explore the terminal 5cm of the open arms (F2,54 = 1.207, P = 0.307). Nicotine preinjection had no effect on the number of closed arm entries (F2,54 = 1.158, P = 0.322; Table 3.3),
suggesting that the effects of low dose nicotine pre-treatment to reduce closed arm time
following 0.5 mg/kg nicotine injection was not due to increased locomotor activity.

DISCUSSION
These pharmacological and genetic studies support the hypothesis that β2*nAChRs are sufficient
and necessary for expression of anxiolytic-like effects of low dose nicotine in the light-dark and
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Figure 3.7 - Pre-injection of low-dose nicotine reverses anxiogenic-like effects of high dose
nicotine during elevated plus maze assay. a-d) Main effects of nicotine (NIC) administration
revealed that mice injected with 0.5 mg/kg i.p. nicotine (0.5 NIC) spent less time in the open
arms, more time in the closed arms and made fewer entries into the open arms of an elevated
plus maze than saline-injected controls (VEH). b) Vehicle pre-injected mice (PRE NIC)
administered 0.5 mg/kg i.p. nicotine (VEH/0.5 NIC) spent significantly more time in the closed
arms than VEH/VEH controls, suggesting that 0.5 mg/kg i.p. nicotine also promotes anxiogeniclike behavior in an elevated plus maze assay. Pre-injections of 0.01 mg/kg i.p. nicotine (0.01
NIC/0.5 NIC) blocked this effect, as 0.01 NIC/0.5 NIC mice spent less time in the closed arms
than VEH/0.5 NIC mice. There was also a trend for 0.05 NIC/0.5 NIC mice to spend less time in
the closed arms than VEH/0.5 NIC mice. These data suggest that pre-injections of low dose
nicotine are also effective at blocking the anxiogenic-like effects of 0.5 mg/kg i.p. nicotine in an
elevated plus maze assay. Data are reported as means ± SEM. *P ≤ 0.05 compared to
VEH/VEH; **P < 0.05, # < 0.09 compared to VEH/0.5 NIC.
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Table 3.3 - Effect of pre-injections of nicotine (PRE NIC) on
number of closed arm entries made during the elevated plus
maze assay.
Closed arm entries
NIC
(mg/kg) i.p.
VEH
0.5

VEH
21.1 ± 2.0
4.5 ± 1.6

PRE NIC (mg/kg) i.p.
0.01
0.05
23.6 ± 3.9
5.3 ± 1.4

25.3 ± 2.8
6.8 ± 1.5

All mice receiving 0.5 mg/kg i.p. nicotine (NIC = 0.5) made
fewer closed arm entries than saline-injected mice (NIC = VEH),
suggesting that 0.5 mg/kg i.p. nicotine resulted in locomotor suppression.
Pre-injections of nicotine (PRE NIC) did not affect number of closed
arm entries in 0.5 NIC mice, suggesting that attenuations in time spent
in the closed arms in 0.01 NIC/0.5 NIC and 0.05 NIC/0.5 NIC mice are
reflective of reduced anxiety-like behavior, not increased locomotor
activity.
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elevated plus maze tasks. These findings further suggest that β2*nAChRs are critically involved
in the anxiogenic-like effects of high dose nicotine. Our previous work showed that a selective
antagonist of β2*nAChRs had similar effects as low-dose nicotine to promote anxiolysis-like
behavior in the CER, marble burying and elevated plus maze tasks (Anderson, 2012 #1095).
Expanding upon this correlative data, which suggests that low dose nicotine exerts its anxiolyticlike effects via desensitization of the β2*nAChRs, the current experiments provide direct
pharmacological evidence that a low dose of nicotine can effectively block the anxiogenic effects
of a high dose of nicotine.

Similar to its bimodal effects on anxiety-like behaviors (Anderson & Brunzell, 2012; File et al.,
1998; McGranahan et al., 2011; Picciotto et al., 2002; Varani et al., 2012), nicotine activates and
desensitizes β2*nAChRs in a concentration-dependent manner. In vitro studies demonstrate that
micromolar concentrations of nicotine activate β2*nAChRs whereas pretreatment with
nanomolar concentrations of nicotine can preferentially desensitize β2*nAChRs, rendering them
unavailable for subsequent stimulation by ACh or nicotine (Fenster et al., 1997; Grady et al.,
2012; Kuryatov et al., 2011; R. A. Lester & Dani, 1995; Lu et al., 1999; Mansvelder et al., 2002;
Pidoplichko et al., 1997), but see Liu et al. on α6α4β2*nAChRs (L. Liu et al., 2012). Low
concentrations of nicotine have previously been shown to block the stimulatory effects of a
nicotinic ganglionic agonist on mean arterial pressure (Buccafusco et al., 2007), suggesting that
low doses of systemic nicotine are also capable of desensitizing nAChRs. The present studies
similarly show that in vivo pre-administration of low dose nicotine can attenuate the behavioral
effects of a nicotinic agonist. These findings are consistent with recent data showing that low
dose nicotine and DHβE reverse conditioned inhibition and promote anxiolysis-like behavior in a
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marble burying and elevated plus maze task (Anderson & Brunzell, 2012). Consistent with
previous models of anxiety-like behavior (Anderson & Brunzell, 2012; McGranahan et al., 2011;
Picciotto et al., 2002), treatment with a low dose of nicotine (0.05 mg/kg) resulted in anxiolyticlike behavior, whereas a high dose of nicotine (0.5 mg/kg) promoted anxiogenic-like behavior of
WT mice in the light-dark assay. The genetic study in Experiment 1 expands upon previous data
to show that β2*nAChRs promote anxiolysis-like behavior and contribute to anxiogenic-like
behavior (Anderson & Brunzell, 2012; McGranahan et al., 2011; Picciotto et al., 2002). Unlike
WT mice, β2KO mice failed to show elevated time spent in the light chamber when injected with
low dose nicotine and showed attenuated reductions of time spent in the light chamber and
increased latencies compared to WT controls following high dose nicotine. The selective
removal of cholinergic input to the BLA, where α4β2*nAChRs prevail, results in reduced
anxiety-like behavior (Power & McGaugh, 2002), further supporting the role for inactivation of
α4β2*nAChRs in the promotion of anxiolysis-like behaviors. As with the β2KO studies
performed herein, α4KO mice also failed to show nicotine-associated anxiolysis-like behavior in
an elevated plus maze (McGranahan et al., 2011), suggesting that α4β2*nAChRs support the
anxiolytic-like effects of nicotine, but the exact confirmation of these nAChRs and their
neuroanatomical location(s) remains to be determined. Pharmacological tests revealed that
activation of the β2*nAChRs is critical for nicotine’s anxiogenic-like effects, but not nicotine’s
anxiolytic-like effects during the light-dark assay; pre-injection of the β2*nAChR selective
antagonist, DHβE, blocked increases in latency to enter the light chamber and blocked decreases
of time spent in the light chamber following 0.5 mg/kg nicotine but had no effect on low dose
nicotine. Low-dose nicotine similarly blocked, rather than accumulated with the 0.5 mg/kg
anxiogenic nicotine dose without significantly affecting the anxiolytic-like effects of 0.05 mg/kg
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nicotine. A pre-injection of a low dose of nicotine also blocked the anxiogenic-like effects of 0.5
mg/kg nicotine in the elevated plus maze. In contrast to studies demonstrating that DHβE blocks
nicotine reward in mice and nicotine reinforcement in rats (Corrigall et al., 1994; Walters et al.,
2006), pre-injection with DHβE did not significantly affect the anxiolytic-like effects of a low
dose of nicotine in these studies, suggesting that activation of β2*nAChRs is not required for
nicotine-associated anxiolysis. Consistent with recent work using other anxiety models
(Anderson & Brunzell, 2012), a 0.1 mg/kg intermediate dose that supports nicotine CPP
(Brunzell et al., 2009; Mineur et al., 2009) did not promote anxiolysis-like behavior in the lightdark assay. Pre-injection of 0.05 mg/kg nicotine 10 min prior to another 0.05 mg/kg dose did not
accumulate to negate anxiolytic-like effects as was observed for 0.1 mg/kg nicotine. That
intermediate doses of nicotine promote reward-like behavior and high doses support
anxiogenesis is likely due to differences in neuroanatomical locale (Brunzell et al., 2010;
Corrigall et al., 1994; Gould & Wehner, 1999; Power & McGaugh, 2002) as well as recruitment
of nAChR subtypes other than β2*nAChRs (e.g. α3β4*nAChRs) at higher doses (Fenster et al.,
1997; Nelson & Lindstrom, 1999; Petersen, Norris, & Thompson, 1984). Together these
findings suggest that high doses of nicotine promote anxiogenesis via activation of β2*nAChRs
and that low doses of nicotine promote anxiolysis via inhibition of β2*nAChRs.

As further evidence that β2*nAChRs contribute to anxiety-like behavior, 5I-A85380, like
nicotine, promoted anxiolysis-like behavior at low doses and supported anxiogenic-like behavior
at the highest dose tested. 5I-A85380 is 25,000 x more selective for β2*nAChRs than other
nAChR subtypes (Mukhin et al., 2000), suggesting that β2*nAChRs are sufficient to support
bimodal anxiety-like behavioral effects. The administration of 0.001 mg/kg 5I-A85380
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promoted anxiolysis-like behavior in the elevated plus maze, whereas 0.032 mg/kg 5I-A85380
resulted in an increase in anxiety-like behavior in both the light-dark and elevated plus maze
assays. Like ACh and nicotine, sub-activating concentrations of 5I-A85380 also preferentially
desensitize β2*nAChRs (Wageman, Marks, & Grady, 2013). Therefore, it is possible that the
anxiolytic-like effects of 5I-A85380 were also promoted via inactivation of β2*nAChRs.

High doses of nicotine that support anxiogenic-like behavior can also reduce locomotor activity
(Clarke & Kumar, 1983; Jackson et al., 2010; Marubio et al., 2003; Salas et al., 2003; Tritto et
al., 2004). Independent assessment of light and dark chamber activity revealed no difference in
locomotor activity of WT compared to β2KO mice injected with vehicle in either chamber or in
the dark chamber when injected with any dose of nicotine, suggesting that β2*nAChRs did not
support gross changes in locomotor activity in this assay. Following 0.5 mg/kg i.p. nicotine,
WT, but not β2KO mice showed reduced exploration of the light chamber, however,
demonstrating that genetic deletion of β2*nAChRs protected against nicotine-induced increases
in anxiety-like activity for this measure. The high dose of nicotine in these studies produced
locomotor suppression of dark chamber activity independent of genotype, suggesting the
contributions of nAChRs other than β2*nAChRs affected locomotor activity. β4 null mutants
are less sensitive to the locomotor suppressive effects of 0.5mg/kg i.p. nicotine than WT mice
and also show reduced anxiety-like behavior in the elevated-plus and staircase maze assays
(Salas et al., 2003). Early studies showed that β2KO mice expressed elevated passive avoidance
learning (Picciotto et al., 1995). β2KO mice in the present study showed partial attenuation of
the anxiogenic effects of nicotine, suggesting that activation of other nAChRs, likely
α3β4*nAChRs, contributed to behaviors observed following 0.5 mg/kg nicotine. Mice with a
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deletion of the α4 subunit are less sensitive to the locomotor suppressive effects of high dose
nicotine (Marubio et al., 2003) and administration of the α4β2*nAChR partial agonist,
varenicline (Ortiz, O'Neill, Marks, & Grady, 2012), blocks nicotine-induced suppression of
locomotor activity. Previous studies suggest that α4α6β2*nAChRs, which are more resistant to
desensitization than α4β2*nAChRs (non-α6) (L. Liu et al., 2012), predominantly regulate the
locomotor effects of nicotine (Drenan et al., 2010). DHβE pre-injection, which antagonizes
α4β2*nAChR and α4α6β2*nAChRs also reversed “locomotor-suppressant” effects of 0.5 mg/kg
nicotine in these studies. Both 0.01 NIC/0.5 NIC and 0.05 NIC/0.5 NIC mice showed reductions
in time spent in the closed arms of an elevated plus maze compared to VEH/0.5 NIC mice.
There was no effect of nicotine pretreatment on the number of entries made into the closed arms
in mice administered 0.5 mg/kg nicotine, suggesting that the behavioral effects of pre-injections
of 0.01 and 0.05 mg/kg nicotine reflect attenuation of anxiety-like behavior rather than blockade
of locomotor suppression. The administration of 0.032 mg/kg of the highly selective β2*nAChR
agonist 5I-A85380 resulted in reduced exploration of the brightly-lit chamber during the lightdark assay and increased time spent in the closed arms of an elevated plus maze without
significantly affecting movements per second in the dark chamber or number of entries made in
the closed arms of the elevated plus maze, suggesting that selective activation of β2*nAChRs
promotes anxiogenic-like behavior without significantly affecting gross locomotor activity.
Taken together, these data support the interpretation that the antagonist-like effects of preinjections of nicotine and DHβE prior to 0.5 mg/kg nicotine reflect attenuation of anxiogeniclike behavior and not merely the locomotor suppressive effects of a high dose of nicotine.
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The impact of nicotine on anxiety in humans appears to depend upon many variables including
predisposition for anxiety and smoking histories. Individuals with diagnosis of anxiety disorder
are 2X more likely to smoke than otherwise healthy smokers (Lasser et al., 2000). It is not
known whether β2*nAChR expression correlates with anxiety-disorder diagnosis, but smokers,
compared to non-smokers, show significant elevations in high-affinity β2*nAChR binding
(Benwell et al., 1988; Breese et al., 1997; Cosgrove et al., 2009) and are more anxious overall
than nonsmokers (Gilbert et al., 2008; Tsuda et al., 1996). Nicotine patch compared to placebo
alleviated negative affect in smokers, but not non-smokers in a picture-attention task (Gilbert et
al., 2008). Nicotine patch has been shown to reduce the functional connective strength between
the amygdala with insular and anterior cingulate cortices in smokers, but to increase this
connectivity in non-smokers (Sutherland et al., 2013). Similar reductions in the activation of
amygdalar networks were observed in human smokers following pre-injection with the partial
α4β2*nAChR agonist varenicline (Sutherland et al., 2013). These findings are particularly
germane considering that human imaging studies show increased activity in both the amygdala
and pre-frontal cortex in subjects presenting with trait anxiety (Britton et al., 2011; Sehlmeyer et
al., 2011) and provide a mechanistic explanation to the hypothesis that people suffering from
anxiety-related disorders may be using cigarette smoking as a means of self-medication. For
individuals who are motivated to smoke to relieve anxiety, it appears that low doses of nicotine
may be sufficient to support nicotine intake. This is highly relevant to smokers given current
policy measures being considered to reduce nicotine in cigarettes (Pearson, Abrams, Niaura,
Richardson, & Vallone, 2013) as even low doses of nicotine are capable of binding nearly 80%
of β2*nAChRs in brain (Brody, Mandelkern, Costello, et al., 2009).
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The light-dark and elevated plus maze assays are animal models with good predictive validity for
the anxiolytic effects of drugs. Using these assays, these genetic and pharmacological data show
that the anxiolytic-like effects of nicotine are regulated via inhibition of β2*nAChRs and suggest
that activation of β2*nAChRs contribute to increased anxiety-like behavior. These preclinical
studies further demonstrate the efficacy of low doses of nicotine to promote anxiolytic-like
behavior and to prevent increases in anxiety-like behaviors resulting from activation of the
cholinergic system with high doses of nicotine. Whereas the precise confirmation of nicotinic
receptors regulating this behavior remains to be determined, these preclinical studies indicate
that partial agonists or negative allosteric modulators of β2*nAChRs may be helpful therapeutic
strategies for the treatment of smoking cessation in smokers with anxiety-related co-morbidities.
Taken together, these data collectively support the hypothesis that low doses of nicotine promote
anxiolysis-like behavior in mice via inactivation of the high affinity β2*nAChRs. Further
studies are necessary to determine the subunits assemble with β2 to support the anxiolytic and
anxiogenic effects of nicotine. β2*nAChRs can be further divided into two subclasses that are
sensitive or insensitive to α-conotoxin MII. To test if nicotine is acting in part via
α6β2*nAChRs to exert anxiolytic-like effects, the anxiety phenotype of mice with a gain of
function single point L9’S mutation in the α6 subunit (L9S) and with genetic deletion of
α6*nAChRs (α6KO) could be used to determine if cholinergic persistent activation or genetic
deletion of α6*nAChRs are sufficient to promote anxiogenic and/or anxiolytic-like behavior.
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Chapter 4 – Assessment of the contribution of α6β2*nAChRs to anxiety-like behavior

INTRODUCTION

Many smokers indicate that they smoke to relieve anxiety. Although it has proved difficult to
detect that anxiety measures provoke smoking episodes throughout the day, a number of studies
suggest that smokers experience anxiety more intensely than non-smokers (Fidler & West, 2009;
Parrott, 1999; Perkins & Grobe, 1992). Reports of stress are correlated with escalation of
cigarette use (Byrne et al., 1995; Byrne & Mazanov, 2003; Finkelstein et al., 2006; Siqueira et
al., 2000; Skara et al., 2001) and stress is a major precipitating factor in relapse to smoking
(Shiffman et al., 1997). Studies also show that craving and exposure to smoking-related cues
underlie maintenance of smoking behavior (Chandra, Scharf, & Shiffman, 2011; Shiffman et al.,
2013; Shiffman, Dunbar, Scholl, & Tindle, 2012). This is consistent with escalation models of
drug use and dependency, wherein the positive effects of drugs of abuse contribute to their initial
use, but avoidance of the negative effects of withdrawal promotes escalated drug use, leading to
dependency (Koob & Volkow, 2010). The mechanism of nicotine-mediated relief of anxiety and
elevated anxiety-phenotype experienced by smokers is not clearly understood.

Preclinical studies assessing anxiety phenotype in rodents show that nicotinic agonists, including
nicotine, produce a bimodal effect on anxiety-like behavior with low doses promoting anxiolytic
phenotypes and high doses promoting anxiogenic phenotypes (Anderson & Brunzell, 2012;
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Cheeta, Irvine, et al., 2001; Cheeta, Tucci, et al., 2001; File et al., 2000; File et al., 1998; Irvine
et al., 1999; McGranahan et al., 2011; Ouagazzal et al., 1999; Varani et al., 2012; Zarrindast et
al., 2008). Anxiolytic effects of nicotinic antagonists in these behavioral measures suggest that
nicotine may promote anxiolysis via desensitization of nAChRs (Anderson & Brunzell, 2012;
Dawson et al., 2013; Newman et al., 2002; Newman et al., 2001; Roni & Rahman, 2011). Once
activated, the heteromeric nicotinic receptors revert to a stable desensitized state that renders
them incapable of further activation for upwards of 90 min (Fenster et al., 1997; R. A. Lester &
Dani, 1995; Mansvelder et al., 2002; Pidoplichko et al., 1997). In vitro studies reveal that low
concentrations of nicotine in the nM range that are subthreshold for activation of most nicotinic
receptor subtypes can result in preferential desensitization of these receptors (Fenster et al.,
1997; Grady et al., 2012; Kuryatov et al., 2011; Lu et al., 1999). Although nicotine
concentrations can vary in temporal waves, the steady-state concentration of nicotine in the
brains of smokers is thought to be 200-400 nM (Rose et al., 2010), within a range that would
preferentially desensitize the β2 subunit containing nAChRs (β2*nAChRs; *denotes that other
subunits assemble with β2 to form a functional receptor) which have been implicated in
promoting the anxiolytic-like effects of nicotine (Anderson & Brunzell, 2012; McGranahan et
al., 2011). Capable of activation by 300 nM nicotine (Drenan et al., 2010; Kuryatov &
Lindstrom, 2011; L. Liu et al., 2012; Zhao-Shea et al., 2011), and slower than other subtypes to
desensitize (Grady et al., 2012; Kuryatov & Lindstrom, 2011), the α4α6β2*nAChRs appear to
be an exception to this rule.

Previous studies show that, like low doses of nicotine, the β2*nAChR-selective antagonist,
dihydro-beta-erythroidine (DHβE) significantly attenuates conditioned inhibition in a CER task,
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increases time spent in the open arms of an elevated plus maze and decreases marble-burying
behavior without affecting locomotor activity (Anderson & Brunzell, 2012). Although largely
driven by the availability of an α4 subunit, DHβE antagonizes α4β2*nAChRs and
α6β2*nAChRs with similar potency (Grady et al., 2010; Papke et al., 2008).

Compared to the more ubiquitous expression of α4β2*nAChRs, α6β2*nAChRs have a more
selective expression pattern in the brain. Enriched on the soma and axon terminals of
catecholaminergic DA and NE neurons as well as in the visual circuitry (Champtiaux et al.,
2002; Marks et al., 2010; Whiteaker et al., 2000), the α6β2*nAChRs are not highly expressed in
brain regions such as the amygdala, cingulate cortex and lateral septum (Champtiaux et al., 2002;
Clarke et al., 1985; Marks et al., 2010; Whiteaker et al., 2000) that are well-known for their
contributions to anxiety and fear behaviors. Recent studies, however, indicate that the
anxiolytic-like efficacy of a low dose of nicotine was reduced in mice with a selective genetic
deletion of the α4 subunit from VTA DA neurons, suggesting that the anxiolytic efficacy of
nicotine is mediated in part by α4β2*nAChRs on DA neurons in the VTA. It is not clear if VTA
α4α6β2*nAChRs contributed to this phenotype. Given their high affinity for activation by
nicotine and their resistance to desensitization, it is possible that activation, rather than
inhibition, of this subclass of β2*nAChRs supports anxiolytic effects of nicotine (L. Liu et al.,
2012; McGranahan et al., 2011). Albeit at low levels, α6β2*nAChRs are expressed in the
hippocampus, a brain region where excessive cholinergic signaling is implicated in supporting
anxiety-like behavior (Luo, Wei, Niu, Wang, & Wang, 2013; Mineur et al., 2013). Inhibition of
α6β2*nAChRs in the locus coeruleus (LC) could also dampen neuroanatomical signals which
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support fight or flight responses that are downstream of this NE-enriched nucleus (Fu, Matta,
James, & Sharp, 1998; Fu, Matta, McIntosh, & Sharp, 1999).

To test the contributions of α6β2*nAChRs to anxiety phenotype, these studies assessed the
anxiety-like behaviors of mice with a genetic gain of function or loss of function to their
α6β2*nAChRs. Gain of α6β2*nAChR function mice were generated by a single leucine to
serine point mutation in the M2 pore-forming region of the α6 subunit (L9S), which renders their
α6β2*nAChRs highly hypersensitive to both nicotine and ACh as compared to wild type (WT)
littermates (Drenan et al., 2010; Drenan, Grady, et al., 2008). If stimulation of α6β2*nAChRs is
sufficient to support anxiogenesis, then L9S mice ought to show increased latency to enter and
less total time spent in the light chamber of a light-dark apparatus and spend less time in the open
arms of an elevated plus maze. If stimulation of α6β2*nAChRs is necessary for anxiogenesis,
then mice with a null mutation of their α6 subunit (α6KO) ought to display an anxiolysis
phenotype in these tasks, showing shorter latencies to enter and spending more time than their
WT littermates in the open, brightly-lit regions of the experimental apparatus during
performance of these tasks. Conversely, if activation of α6β2*nAChRs is sufficient to promote
anxiolysis, then L9S mice ought to show less anxiety-like behavior in these tasks. As these tasks
are sensitive to horizontal movement, locomotor activity was assessed across genotypes during
bright light and low light conditions. These studies also compared footshock sensitivities and
HPA-axis responses following novel cage exposure observed in L9S, α6KO and WT mice.
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MATERIALS AND METHODS

Subjects
A total of 148 mice participated in these studies: 43 L9S and 53 WT littermates; 26 α6KO mice
and 26 WT littermates. All mice were derived in a Virginia Commonwealth University breeding
colony. A single allele for the L9S transgene produces the L9S genotype and hypersensitive
α6β2*nAChR phenotype (Drenan, Grady, et al., 2008) so that breedings to C57BL/6J mice
(Jackson labs, Bar Harbor, ME) resulted in 50% L9S transgenics and 50% non-transgenic or WT
offspring. α6KO mice were derived from heterozygous matings of mice backcrossed at least 10
generations on a C57BL/6J background. Offspring were group-housed (2-5 per cage),
maintained in the animal colony (20 - 22 ˚C) with a 12h light/dark cycle (lights on at 0600) and
had ad libitum access to both food and water throughout these studies. All mice were habituated
to experimenter handling for 3 days and the experimental room for 1 day prior to any
experimentation. All experiments were approved by the VCU Institutional Animal Care and Use
Committee and were in compliance with the Guide for Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources, 2010).

Apparatus

Behavioral Procedures

Assessment of α 6*nAChR contributions to Anxiety-Like Behaviors
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Light-dark assay
Light-dark experiments were conducted in modified place conditioning chambers (Med
Associates, St. Albans, VT). A small, enclosed, dark chamber with a black ceiling (L 16.8 cm x
W 12.7 cm x H 12.7 cm) was adjacent to a larger, open, brightly-lit chamber (L 26.5 cm x W
12.7 cm x H 26.2 cm) that was illuminated by a single 23W fluorescent light bulb. Manual
opening of a door (W 5 cm x H 5.9 cm) at the beginning of the test provided mice with free
access to explore both the dark and light chambers. White and black plastic inserts (L 16.8 cm x
W 12.7 cm) were placed in the stainless steel dropping trays in the respective light or dark
chambers to increase the brightness of the light chamber and reduce the glare of light that might
reach the dark chamber from the light chamber. Data was collected using Med Associates
software.

Elevated plus maze assay
A wooden elevated plus maze 68 cm above the floor had white plastic flooring on two (5 x 30
cm) open arms that were perpendicular to two equivalent arms with the exception that these
closed arms had 15.25 cm black Plexiglas wall enclosures. Experimentation took place under
overhead fluorescent light illumination.

Open field locomotor assay
Locomotor tests took place in a polycarbonate cage (33 cm× 21 cm × 9 cm high). The
polycarbonate cage was placed within a white plastic enclosure that surrounded all 4 walls and
the floor. Testing took place under overhead room lighting conditions or with overhead lights
off and infrared illumination provided by 500 mA intensity infrared lights emitting an 830 nM
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frequency (Wisecomm, Cerritos, CA). A ceiling-mounted camera was interfaced to a PC for
collection of elevated plus maze and locomotor data using ANY-maze tracking software by
Stoelting (Wood Dale, IL).

Assessment of α 6*nAChR contributions to acute foot shock sensitivity

Flinch, vocalize and jump experiments were conducted in mouse operant chambers (21.6 cm x
17.8 cm x 12.7 cm; Med Associates, St. Albans, VT). A 2.24 watt incandescent house-light was
positioned 9.5 cm from the floor of the operant chamber. The floor consisted of steel rods (0.32
cm in diameter placed 0.79 cm apart) connected to a Med Associates shock generator/scrambler.

Assessment of α 6*nAChR contributions to HPA axis activity

Exposure to a novel cage is a stressor to mice that is demonstrated to activate the HPA-Axis
(Hennessy, 1991; Hennessy & Foy, 1987). Mice were thus exposed to a novel cage prior to
having blood drawn for assessment of corticosterone levels. Clean polycarbonate cages (33 cm×
21 cm × 9 cm high) with filtered cage tops and 1/8 corn cob bedding like that in the home cage
were used for these studies. Novel cage exposure took place under standard fluorescent room
lighting conditions.

Drugs
Injections of 0.9% sterile saline were delivered i.p. in volumes of 0.1 ml/30 g. Mouse weights
were taken approximately 1 h prior to behavioral assays.
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Behavioral Procedures

Assessment of α 6*nAChR contributions to Anxiety-Like Behaviors

Light-dark assay
On test day, the experimental room was dark other than illumination required for the light-dark
apparatus. In order to assess α6β2*nAChR contributions to anxiety-like behavior following
exposure to a stressor, adult male L9S, α6KO mice and their corresponding WT controls (n =
13-14 per genotype) received i.p. sterile 0.9% saline immediately prior to evaluation in the lightdark assay. A separate cohort of L9S and WT mice received no injection immediately prior to
evaluation in the light-dark apparatus (n = 8 per genotype). The light-dark assay was conducted
as described in Chapter 3. Latency to enter the light chamber, % time spent in the light chamber
and movement counts per second spent in the light and dark chambers were separately calculated
as described in Chapter 3. Between animals, feces, urine and animal dander were removed and
all apparatus were thoroughly wiped with 2% Nolvosan between trials (Pfizer Animal Health,
Madison, NJ).

Elevated-plus maze
Saline-injected L9S, α6KO mice and their corresponding WT controls (n = 12-15 per genotype)
were returned to their home cage for a 5 minute post-injection period before placement on the
center of an elevated plus maze apparatus facing the closed arms. Behavior was evaluated for a
period of 10 minutes. Subjects were scored for time spent in the open arms, entries made into
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the open arms, distance traveled in the open arms and latency to explore the terminal zones (the
extreme 5 cm) of the open arms. Time spent in the open arms, entries made in the open arms and
distance traveled in the open arms were separated into two 5 min time bins.

Locomotor assessment
Untreated L9S, α6KO mice and their corresponding WT controls (n = 6-8 per genotype) were
removed from their home cage and placed into the polycarbonate cage facing one of the corners.
Behavior was evaluated for a period of 15 minutes. Total distance traveled, latency to enter the
central zone (6 cm x 6 cm), central zone entries and time spent in the corners (6 cm x 6 cm) were
evaluated. Experimentation took place under infrared lighting or overhead fluorescent lighting
conditions (n = 6-8 per genotype and lighting condition).

Assessment of α 6*nAChR contributions to acute foot shock sensitivity

Non-injected L9S (n = 10), WT (n = 15), α6KO mice (n = 11) and their WT controls (n = 11)
were evaluated for footshock thresholds for 4 responses in Med Associates mouse operant
chambers as described previously (Brunzell & Kim, 2001; Kim, DeCola, Landeira-Fernandez, &
Fanselow, 1991). Briefly, mice received footshocks 1 sec in duration every 30 sec. Mice were
scored for flinching, scrambling, vocalization and jumping responses to footshock. A flinch was
defined as an observable reaction to the shock (e.g., typically an orienting response of the head,
usually directed at the grid floor). A scramble was defined as movement of front or hind paws in
response to the shock. A vocalization was noted when the foot shock resulted in any audible
vocalization by the mouse. A jump was recorded when a leaping response to the shock was
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observed. The initial footshock intensity was 0.1 mA and was increased in increments of 0.1 mA
every 30 sec. The test ended when each of the four responses measures were observed or when 1
mA was reached. A value of 1 mA was recorded in the event that a mouse did not record a
visible jump response during the assay. Experimenters were blinded to the genotype of the
subject during testing.

Assessment of α 6*nAChR contributions to HPA axis activity

Novel cage exposure
Untreated L9S, α6KO mice and their corresponding WT controls were exposed to a clean, novel
polycarbonate cage for a period of 15 (n = 8-10 per genotype) or 30 (n = 9-10 per genotype) min.
Subjects were then removed and were euthanized via rapid decapitation. Control mice (n = 5-6
per genotype) were removed from their home cage immediately prior to decapitation. Trunk
blood was collected in 1.5 mL centrifuge tubes containing 15 µl of heparin, which were
immediately placed on ice. Subsequently, samples were centrifuged at 4° C at a speed of 15,000
rpm for 15 minutes. Serum was removed and stored at -80° C until evaluation of serum
corticosterone levels. Mice were sacrificed between 1000 and 1700 hours and were
counterbalanced across genotype and cage exposure time to minimize the impact of circadian
fluctuations of serum corticosterone levels on test results.

Determination of serum corticosterone via ELISA
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Serum corticosterone was determined using the Corticosterone HS EIA kit by Immunodiagnostic
Systems (Scottsdale, AZ). The assay was performed according to manufacturer instructions and
curve-fitting was determined using ReaderFit software (Hitachi Solutions America Ltd, USA).

Statistical Analysis
A 2-Way ANOVA comparing saline-injected and non-injected mice returned no significant
effects of injection for any behavioral measure in the light-dark assay and hence these groups
were combined for subsequent analyses (F’s < 1). Student’s t-tests were used to determine
genotype-specific effects in the light-dark assay. A repeated measures ANOVA analyzed
between-subject effects of genotype and within-subject repeated measures for exploratory
behavior across 5 min time bins (within subject repeated measures) in the elevated plus maze.
Latency to explore the terminal 5 cm of the open arms was analyzed via Student’s t-tests. A
two-way (genotype x light condition) ANOVA was used to analyze the effects of genotype and
light condition on locomotor activity and anxiety-like behavior in the open field test. Significant
interactions were followed by Student’s t-tests to identify the specific nature of the interaction.
Serum corticosterone values were analyzed using a 2 x 3 (genotype x exposure time) ANOVA.
Planned comparisons assessed genotype-specific effects on basal serum corticosterone levels
obtained from control L9S, WT, α6KO and their corresponding WT mice. Planned comparisons
analyzing genotype effects of HPA-axis activity in animals with 15 and 30 min of novel cage
exposure were assessed via Student’s t-tests using a Bonferrroni correction. Student’s t-tests
were used to detect genotype-specific threshold differences for each response in the Flinch,
Scramble, Vocalize and Jump test. For all analyses, P values < 0.05 were reported as significant.
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RESULTS

Assessment of α 6*nAChR contributions to Anxiety-Like Behaviors

Light-dark assay
There was an effect of genotype for time spent in the light chamber (t41 = 3.837, P < 0.001; Fig
4.1a) revealing that L9S mice spent less time in this more aversive area than their WT
counterparts. Despite similar trends, there was no effect of genotype on latency to enter the light
chamber (t41 = 1.395, P = 0.171; Fig 4.1b). L9S mice further showed less movements per second
in both the light (t41 = 4.387, P < 0.001; Fig 4.1c) and dark chambers (t41 = 5.151, P < 0.001; Fig
4.1d), suggesting that decreases in locomotor activity may have contributed to these findings. In
contrast, there were no significant differences between WT and α6KO mice for these measures
(t25 = 1.924, 1.206, 0.398, 0.109; P’s > 0.05; Fig 4.1e-h).

Elevated plus maze
Repeated measures ANOVAs detected significant time bin x genotype interactions for time spent
in the open arms (F1,27 = 6.114, P < 0.05) and distance traveled in the open arms of an elevated
plus maze (F1,27 = 7.729, P < 0.05). Post-hoc t-tests revealed that L9S mice spent less time in the
open arms (t27 = 2.341, P < 0.05; Fig 4.2a) and traveled shorter distances on the open arms
during the first 5 minutes (t27 = 2.745, P < 0.05; Fig 4.2b), but not the second 5 minutes
compared to WT littermates (t27 = 1.424, P = 0.166; Fig 4.2a, t27 = 0.899, P = 0.377; Fig 4.2b).
Additionally, t-tests revealed that L9S mice required more time to explore the terminal 5 cm of
the elevated plus maze compared to their WT controls (t27 = 2.812, P = 0.009; Fig 4.2d). A
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Figure 4.1 - Mice with gain of function α6*nAChRs (L9S) express anxiogenic-like
phenotype in the light-dark assay. a) Mice with a single point L9S mutation in α6*nAChRs
(L9S) spent less time in the light chamber compared to wild type (WT) controls, suggestive of an
anxiogenic-like phenotype in this assay. b) Although latencies did not significantly differ
between genotypes, L9S mice showed reduced exploration of both the c) light and d) dark
chambers than WT controls, suggesting that changes in locomotion may have contributed to
genotype differences in light-dark activity. e-h) Mice with genetic deletion of α6 subunit
(α6KO) did not significantly differ from WT mice in any of these measures, suggesting that
increased activation, but not inhibition of α6*nAChRs promotes anxiety-like behavior in the
light-dark assay. Data are represented as means ± SEM. *P < 0.05 vs. WT.
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Figure 4.2 - L9S mice also express increased anxiety-like behavior in an elevated plus maze
assay. During the first 5 minutes of elevated plus maze activity, wild type (WT) controls a)
spent more time in the open arms, b) traveled a greater distance on the open arms than mice
expressing gain of function α6*nAChRs (L9S). d) Finally, WT mice required less time to
explore the terminal 5 cm of the open arms than L9S animals. e-h) As in the light-dark assay,
there were no differences between the behavior of WT and α6KO mice on an elevated plus
maze. These data suggest that increased cholinergic activation of α6*nAChRs is also anxiogenic
in the elevated plus maze. Data are represented as means ± SEM. *P < 0.05 vs. WT.
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repeated measures ANOVA revealed that mice made fewer entries into the open arms of the
elevated plus maze during the second 5 minutes independent of genotype (F1,27 = 13.04, P =
0.001). These data suggest that L9S mice showed higher levels of anxiety-like behavior than
WT controls during the elevated plus maze assay. Repeated measures ANOVAs revealed that
mice spent more time in the open arms, traveled greater distances and made more entries into the
open arms during the first 5 minutes of the elevated plus maze assay independent of genotype
(F1,23 = 27.53; F1,23 = 18.32; F1,23 = 16.93, P’s < 0.001), but no significant effects of genotype
were detected between WT and α6KO mice evaluated in the elevated plus maze for measures of
time spent in the open arms, distance traveled in the open arms or number of entries made in the
open arms (F1,23 < 1, P = 0.423; F1,23 = 1.052, P = 0.316; F1,23 = 1.087, P = 0.308).
Furthermore, α6KO did not show different latencies to explore the terminal 5cm of the open
arms compared to WT mice (t23 = 0.240, P = 0.814).

Locomotor activity
Two-way ANOVA revealed a genotype x light condition interaction for latency to enter the
central zone and total distance traveled during a locomotor test for L9S mice compared to their
WT littermates (F1,26 = 10.630, P = 0.003; F1,26 = 4.356, P < 0.05). Post-hoc tests revealed that
L9S mice showed higher levels of anxiety-like behavior than WT mice under fluorescent lighting
conditions, having longer latencies to enter the central zone of the arena (t12 = 3.218, P = 0.007;
Fig 4.3a). WT mice showed greater distance traveled than L9S mice under infrared, but not
fluorescent lighting conditions (t14 = 2.296 P < 0.05; Fig 4.3d), suggesting that the increased
latencies to enter the center zone expressed by L9S mice under fluorescent lighting conditions
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Figure 4.3 - Mice with L9S gain of function α6*nAChRs are more sensitive to lighting
conditions than wild type (WT) mice regarding anxiety-like but not locomotor activity.
L9S gain of function mice (L9S) showed higher levels of anxiety-like behavior during a
locomotor activity test than wild type (WT) mice. a) Under full room lighting, (Room lights on
+), L9S had higher latencies to enter the central zone of the locomotor chamber. b) L9S mice
also made fewer center zone entries and c) spent more time in the corners of a locomotor activity
chamber than WT mice, suggestive of increased anxiety-like behavior. d) Compared to L9S
mice, WT mice showed greater distance traveled under infrared lighting conditions. There were
no differences between WT and L9S mice for distance traveled under fluorescent lighting
conditions, suggesting that differences in open field activity expressed by L9S mice under full
room lighting conditions reflect increased anxiety-like behavior. e-h) Both WT and α6-null
mutant (α6KO) mice g) spent more time in the corners and h) showed greater distance traveled
under infrared lighting conditions. However, no effects of genotype were detected between WT
and α6KO mice during an open field locomotor assay. Data are represented as means ± SEM.
*P < 0.05 vs. WT, **P < 0.05 compared to Room lights on +.
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did not reflect an overall decrease in locomotor activity of L9S mice. Main effects of genotype
revealed that L9S made fewer number of entries into the central zone and spent more time in the
corners of the locomotor apparatus compared to WT mice (F1,26 = 10.630, P = 0.003; Fig 4.3b,
F1,26 = 4.356, P < 0.05; Fig 4.3c), suggestive of an anxiogenic-like phenotype. There were no
main effects of genotype between WT and α6KO mice for any of the behavioral measures in the
locomotor assay (F1,27 = 1.645, P = 0.211; F1,27 = 1.698, P = 0.204; F1,27 <1.645, P = 0.862; F1,27
= 1.292, P = 0.266). Unexpectedly, main effects of lighting condition revealed that all mice
spent more time in the corners under infrared lighting conditions than under fluorescent lighting
(F1,27 = 19.48, P < 0.001; Fig 4.3g). WT and α6KO mice also traveled greater distances (F1,27 =
5.817, P = 0.023; Fig 4.3h) under infrared lighting conditions than under normal room lighting
conditions independent of genotype.

Assessment of α 6*nAChR contributions to foot shock sensitivities

Student’s t-tests revealed dichotomous effects of genotype on footshock thresholds that
depended upon the measure in L9S mice. Compared to WT controls, L9S mice had lower
thresholds to vocalization (t23 = 2.849, P = 0.009; Fig 4.4a) but higher thresholds for the jump
response (t23 = 2.856, P = 0.009; Fig 4.4a). There were no significant effects of genotype
detected for footshock thresholds for the flinch (t19 = 0.641, P = 0.529) or scramble responses (t19
= 0.195, P = 0.848). α6KO mice did not differ from WT controls in any measure of footshock
threshold in this assay (t20’s < 1, P’s > 0.5; Fig 4.4b).

Assessment of α 6*nAChR contributions to HPA axis activity
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Figure 4.4 - Mice expressing hypersensitive α6*nAChRs (L9S) show different footshock
thresholds than wild type (WT) mice in flinch, scramble, vocalize and jump assay. a) L9S
mice had lower footshock thresholds for vocalization but increased thresholds before expressing
a jump response than WT mice. b) Animals with genetic deletion of α6 subunit (α6KO) did not
significantly differ from WT mice in any of these measures, suggesting that increased activation,
but not deletion of α6*nAChRs affects the thalamic response to a footshock stimulus. Data are
represented as means ± SEM. *P < 0.05 vs. WT.
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Student t-tests did not detect baseline differences in serum corticosterone levels across genotypes
at the zero time point showing that basal HPA-axis activity was not different between L9S and
non-transgenic WT mice (t8 = 0.031, P = 0.976; Fig 4.5a) or between α6KO mice and their WT
controls (t10 = 0.464, P = 0.653; Fig 4.5b). ANOVA analyses revealed main effects of time (F2,40
= 32.620, P < 0.001) and genotype for corticosterone levels in L9S (F1,40 = 5.629, P < 0.05).
Planned comparison t-tests showed that serum corticosterone levels were lower in L9S mice after
30 (t17 = 3.011, P = 0.008; Fig 4.5a), but not 15 min novel cage exposure (t15 = 1.496, P = 0.155;
Fig 4.5a). Post-hoc Dunnett’s tests revealed elevated corticosterone levels in mice exposed to the
novel cage for 15 (P < 0.001; Fig 4.5a) or 30 min (P < 0.001; Fig 4.5a) compared to controls
independent of genotype. In assessment of corticosterone levels of α6KO mice, there was a
main effect of exposure time (F2,44 = 20.700, P < 0.001), revealing that serum corticosterone
levels were higher in mice after 15 and 30 min of novel cage exposure compared to control mice
independent of genotype (P’s < 0.001; Fig 4.5b). As in other assays, no differences in serum
corticosterone levels were detected between WT and α6KO mice after 15 (t16 = 0.085, P = 0.933;
Fig 4.5b) or 30 min of novel cage exposure (t18 = 1.187, P = 0.251; Fig 4.5b).

DISCUSSION

In the present studies, gain-of-function L9S mice showed increased anxiety-like behavior
compared to WT controls in the light-dark, elevated plus maze and open field locomotor assays,
suggesting that stimulation of α6β2*nAChRs is sufficient to promote anxiogenic-like behavior.
In contrast, anxiety-like behavior did not differ between WT animals and mice with a genetic
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Figure 4.5 - L9S mice show a blunted HPA-axis response following 30 minutes of exposure
to a novel cage. a) Compared to controls (0), serum corticosterone levels were elevated after 15
or 30 min of exposure to a novel cage independent of genotype. After 30 min of novel cage
exposure, compared to WT mice, L9S mice showed lower serum corticosterone levels, reflective
of a blunted HPA-axis response. b) Compared to controls, serum corticosterone levels were
elevated in all mice after 15 and 30 min exposure to a novel cage independent of genotype. As
in other assays, serum corticosterone levels did not significantly differ between WT and α6KO
mice at any time point tested. These data suggest that activation, but not deletion of
α6β2*nAChRs regulates the HPA-axis response to novel cage exposure. Data are represented as
means ± SEM. *P < 0.05 vs. WT; **P < 0.05 vs. 0 min novel cage exposure time.
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deletion of the α6 subunit (α6KO) in these measures, revealing that α6β2*nAChRs are not
necessary for expression of anxiety-like behavior.

An accumulation of data suggest that cholinergic hyperactivity promotes anxiety- and
depression-like behavior in rodent animal models (Kolasa, Fusi, Garattini, Consolo, & Ladinsky,
1982; Luo et al., 2013; Mineur et al., 2013; Power & McGaugh, 2002). Reduced AChE activity
is inversely correlated with elevated trait anxiety and is thought to contribute to depression in
humans (Saricicek et al., 2012; Sklan et al., 2004). Candidate brain areas for this include the
amygdala, where cholinergic lesions reduces anxiety-like behavior (Power & McGaugh, 2002)
and the hippocampus, where local reductions in AChE function increases cholinergic activation
along with anxiety and depression phenotype (Luo et al., 2013; Mineur et al., 2013).
Additionally, reductions in serum AChE were shown to be inversely correlated with increased
trait anxiety in humans, and in fMRI human imaging studies, activation of the anterior cingulate
cortex and the amygdala is implicated in anxiety-like behavior (Sutherland et al., 2013). α6β2*
nAChRs are not greatly enriched in these brain areas, suggesting that neuroanatomical systems
outside of the amygdala circuitry contribute to anxiety-like behaviors. The administration of the
anxiolytic buspirone to mice led to reduced acetylcholine levels in both the dorsal and ventral
striatum, suggesting that reduced cholinergic tone in these brain regions may in part attenuate
anxiety-like behavior (Kolasa et al., 1982).

α6β2*nAChRs are also enriched on the soma of NE projection neurons in the LC. Exposure to
stressors activates the LC, resulting in norepinephrine release at thalamic nuclei involved with
processing noxious stimuli as well as the PVN, leading to increases in serum cortisol (Condes-
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Lara, 1998; Voisin, Guy, Chalus, & Dallel, 2005; C. Zhang, Guo, Qiao, & Dafny, 1998).
Although smokers in abstinence require shorter times to report pain following exposure to a cold
pressor task that is negatively correlated with expression of β2*nAChRs, abstinent smokers
express higher levels of antinociception following a social stress test that corresponded with
increased levels of NE compared to non-smokers (Cosgrove et al., 2010; Girdler et al., 2005;
Pomerleau, Turk, & Fertig, 1984). L9S mice showed both lower footshock thresholds for the
vocalization response and higher thresholds for the jump response than WT mice. It is possible
that exposure to subsequent footshocks led to activation of NE projection neurons in the LC,
resulting in NE release in the thalamus and higher thresholds for the jump response in L9S mice
(Condes-Lara, 1998; Voisin et al., 2005; C. Zhang et al., 1998). These higher thresholds
required for the jump response are similar to the increased antinociception shown by smokers
after stress exposure. Considering that monoamine reuptake inhibitors with greater selectivity at
NE or serotonin transporters are typically more efficacious at reducing pain-stimulated
behaviors, such as acid-induced stretching, than reuptake inhibitors with preferential activity at
DA transporters, the differences in footshock thresholds observed in L9S mice in these
experiments may have been mediated via activation of α6β2*nAChRs on NE neurons, rather
than on DA neurons (Aoki et al., 2006; Ardid et al., 1992; Leventhal et al., 2007; Rojas-Corrales,
Casas, Moreno-Brea, Gibert-Rahola, & Mico, 2003; Rosenberg, Carroll, & Negus, 2013).
Recent studies in transgenic mice with their α4 subunit specifically knocked down in VTA DA
neurons suggest that mesolimbic DA neurons support the anxiolytic-like effects of nicotine in the
elevated plus maze tasks (McGranahan et al., 2011). The selective deletion of the α4 subunit
from DA neurons resulted in an attenuation of the anxiolytic efficacy of 0.01 mg/kg i.p. nicotine
in an elevated plus maze. The results of these studies suggest that persistent activation of
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α6β2*nAChRs promotes, rather than attenuates anxiety-like behavior. If low doses of nicotine
in these studies exerted their effects via desensitization of α4β2*nAChRs, as has been proposed
elsewhere (Anderson & Brunzell, 2012), the present data in L9S mice suggest that low doses of
nicotine may in part mediate their anxiolytic-like effects via inhibition of α4α6β2*nAChRs.

Previous studies demonstrate that low doses of nicotine and broad-spectrum antagonists of
nAChRs promote anxiolysis-like behavior in rodents in a number of preclinical models with
predictive validity for anxiolysis, suggesting that low dose nicotine may reduce anxiety-like
behavior via inactivation of the high affinity β2*nAChRs (Anderson & Brunzell, 2012;
McGranahan et al., 2011; Newman et al., 2002; Roni & Rahman, 2011; Varani et al., 2012).
Varenicline and DHβE administration results in reduced time to eat palatable food in a novel
environment in the novelty induced hypophagia assay, reversal of suppressed operant responding
in the presence of conditioned stimulus paired with a footshock during a conditioned emotional
response assay, reduced digging in a marble burying task and increased exploration of the open
arms of an elevated plus maze (Anderson & Brunzell, 2012; Dawson et al., 2013; Turner et al.,
2010). Both drugs have similar affinities for β2*nAChRs comprised of either α4 or α6 subunits,
suggesting that α4β2*, α6β2*, and or α4α6β2*nAChRs may contribute to these effects (Grady
et al., 2010; Papke et al., 2008). The present studies in α6KO and L9S mice reveal that although
α6β2*nAChRs do not appear to be necessary for expression of anxiety-like behavior in the lightdark task, elevated plus maze, or open field assay, α6β2*nAChRs may contribute to anxiety-like
behavior when stimulated by exogenous compounds such as nicotine under conditions in which
endogenous cholinergic tone is elevated.
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One theory suggests that expression of β2*nAChRs contributes to anxiety and depression
phenotype (Picciotto et al., 2002). Chronic nicotine self-administration results in up-regulation of
α4β2*nAChRs in mice (Even et al., 2008; Metaxas et al., 2010; Nashmi et al., 2007; Nuutinen,
Ahtee, & Tuominen, 2005; Pakkanen, Jokitalo, & Tuominen, 2005; Pauly, Marks, Robinson, van
de Kamp, & Collins, 1996; Perez et al., 2008; Pietila, Lahde, Attila, Ahtee, & Nordberg, 1998;
Sparks & Pauly, 1999; Turner et al., 2011; C. Xiao et al., 2009), rats (Abdulla et al., 1996;
Barrantes, Rogers, Lindstrom, & Wonnacott, 1995; Collins, Romm, & Wehner, 1990; el-Bizri &
Clarke, 1994; Flores, Davila-Garcia, Ulrich, & Kellar, 1997; Nguyen, Rasmussen, & Perry,
2003, 2004; Perez et al., 2008; Walsh et al., 2008; F. Wang, Chen, Steketee, & Sharp, 2007;
Yates, Bencherif, Fluhler, & Lippiello, 1995) non-human primates (Kassiou et al., 2001;
McCallum et al., 2006; Perez et al., 2012; Perez et al., 2013; Slotkin, Pinkerton, Auman, Qiao, &
Seidler, 2002) and human smokers (Benwell et al., 1988; Breese et al., 1997; Brody et al., 2013;
Cosgrove et al., 2009; Mamede et al., 2007; Metaxas et al., 2010; Mukhin et al., 2008; Staley et
al., 2006; Staley et al., 2005; Wullner et al., 2008). This is consistent with preclinical models
which suggest that selective inhibition of β2*nAChRs promotes anxiolysis-like behavior and
anti-depressant activity (Anderson & Brunzell, 2012; Dawson et al., 2013; Mineur et al., 2013).
In contrast to the α4β2*nAChRs, a preponderance of the evidence suggests that chronic nicotine
results in a down-regulation of α6β2*nAChRs (Perez et al., 2008; Perez et al., 2012; Perez et al.,
2013) (but see (Parker et al., 2004)). More recent studies showed reduced binding of the E11A
analog of the α6/α3*nAChR antagonist α-conotoxin MII, believed to have greater affinity for
α4α6β2*nAChRs than α6(non-α4)β2*nAChRs, in rats following chronic oral nicotine selfadministration. Compared to oral consumption of saccharin, chronic oral nicotine selfadministration in mice resulted in a reduction in α-conotoxin MII binding in WT but not in

120

α4KO mice, suggesting that reductions in α6β2*nAChRs appear to be predominantly of the
α4α6β2*nAChR subtype, whereas upregulation of α6(non-α4)β2*nAChRs is reported in the
striatum (Baker et al., 2013; Lomazzo et al., 2011; Metaxas et al., 2010; Moretti et al., 2010;
Perez et al., 2008; Perez et al., 2013; C. Xiao et al., 2009). Future studies in L9S mice bred to
α4KOs could help clarify if α4α6β2* or α6β2*nAChRs contribute more or less to this
phenotype. Basal or nicotine exposure-dependent differences in nAChR expression may in part
account for affective behavior observed during nicotine withdrawal. Intracerebroventricular
infusions of the selective α6/α3β2*nAChR antagonist α-conotoxin [H9A;L15A] at doses that had
no effect on elevated plus maze activity on their own attenuated reductions in open arm time
expressed by mice in spontaneous withdrawal from nicotine (Jackson et al., 2009). This lack of
anxiolytic efficacy of α-conotoxin [H9A;L15A] in nicotine-naïve mice is consistent with results
of the present genetic studies wherein α6KO mice did not show any significant differences in
either anxiety-like behavior or responses to external stimuli compared to WT controls. In light
of the anxiogenic behavior exhibited by L9S mice in these present studies, the anxiolytic efficacy
of α-conotoxin [H9A;L15A] in mice experiencing spontaneous withdrawal from nicotine
suggests that activation of α6β2*nAChRs on DA neurons by ACh during spontaneous
withdrawal may contribute to the increased anxiety and sensitivity to external stressors reported
by smokers in abstinence (Cosgrove et al., 2010; Jackson et al., 2009; Swan, Ward, & Jack,
1996).

Considering the anxiogenic-like phenotype expressed by L9S mice observed in various
behavioral models, the blunted HPA-axis response in L9S mice following 30 min novel cage
exposure was surprising, since novel cage exposure results in elevated serum corticosterone, a
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biomarker of increased anxiety (Armario et al., 2012; Hennessy, 1991; Hennessy & Foy, 1987).
However, these results are similar to the HPA-axis dysregulation observed in abstinent smokers
following exposure to stress assays such as the Trier Social Stress Test (Childs & de Wit, 2009;
Kudielka & Wust, 2010; Swan et al., 1996). The HPA-axis response in humans diagnosed with
depression is also muted following social stress, further suggesting that L9S mice might express
a depression-like phenotype, which warrants further experimentation to determine the effect of
the L9’S mutation on depression-like behavior. This is not surprising, since depression is also
associated with increased cholinergic tone (Saricicek et al., 2012).

Taken together, these studies suggest that activation of α6β2*nAChRs promotes anxiety-like
behavior. They do not eliminate the possibility that the anxiolytic-like efficacy of low doses of
nicotine are in part via inactivation of α6(non-α4)β2*nAChRs. They further suggest that L9S
mice may provide insight into the neurocircuitry that regulates the rewarding and reinforcing
effects of nicotine, but also how activation of α6β2*nAChRs may contribute to the symptoms of
nicotine withdrawal and possibly depression-like behavior.
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Chapter 5 – α4β2*nAChR contributions to affective behavior during adulthood and aging

INTRODUCTION

As of 2009, those aged 65 years or older comprised approximately 13% of the total population of
the United States (Administration on Aging, 2009). Anxiety disorders overall are lower in the
elderly than in the general population (Flint, 1994). While reductions in nicotinic acetylcholine
receptors (nAChRs) are a part of the normal human aging process (Mitsis et al., 2009),
pathologic reductions in nAChRs are associated with cognitive declines and the emergence of
psychological co-morbidities, such as increased anxiety (Brodaty et al., 2012; Sabbagh et al.,
2006; Wolitzky-Taylor et al., 2010).

nAChRs are pentameric, ligand-gated ion channels that promote neuronal activity. nAChRs
containing the α4 and β2 subunits (α4β2*nAChRs; *denotes possible assembly with other
subunits) have a high affinity for the endogenous ligand, ACh. The activation and expression of
α4β2*nAChRs is neuroprotective (Zanardi et al., 2007); increased age-dependent
neurodegeneration is observed in mice with a genetic null mutation of β2*nAChRs (Zoli et al.,
1999).

Brain areas that may regulate anxiety include the hippocampus, amygdala, anterior cingulate
cortex and lateral septum. The hippocampus, amygdala and anterior cingulate cortex are
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predominantly excitatory nuclei, whereas the lateral septum is a GABA-ergic projection nucleus.
In addition to vasopressin inputs from the amygdala that promote anxiety-like behavior, the
lateral septum receives a convergence of excitatory afferents from brain areas known to regulate
motivational salience, such as dopamine from the ventral tegmental area and glutamate from the
hippocampus and anterior cingulate (Beckstead, 1979; Buchanan, Thompson, Maxwell, &
Powell, 1994; Caffe, van Leeuwen, & Luiten, 1987; Calderazzo, Cavalheiro, Macchi, Molinari,
& Bentivoglio, 1996; Canteras, Simerly, & Swanson, 1995; De Vries & Buijs, 1983; Lindvall,
1975; Numan & Numan, 1996; Risold & Swanson, 1997a, 1997b). Exposure to both restraint
and chronic social stress results in lower levels of phosphorylated, or activated extracellular
regulated kinase (pERK) in the lateral septum, and thus reduced pERK in the lateral septum may
serve as a cellular biomarker for increased anxiety (Sheehan et al., 2003; Singewald et al., 2009).

Activation of nAChRs promotes growth factors (Belluardo, Mudo, Blum, et al., 1999; Belluardo
et al., 2000; Belluardo, Mudo, Caniglia, et al., 1999; Ying et al., 2002), supports release of
neurotransmitters that regulate adenylyl cyclase and results in an increase in intracellular
calcium, which can indirectly activate ERK via the Raf/Ras/MEK/ERK pathway. In its active
form, pERK is capable of phosphorylating several downstream substrates leading to activation of
RSK, c-Fos, MSK and the transcription factor cAMP response element-binding protein (CREB)
(Nakayama et al., 2001). Inactivation of α4β2*nAChRs on GABA interneurons in the ventral
tegmental area promotes activation of dopamine neurons via disinhibition, leading to increased
pERK (Graupner, Maex, & Gutkin, 2013; Mansvelder et al., 2002; Valjent et al., 2005). Thus,
reduced cholinergic tone promoted via α4β2*nAChRs can result in dopamine release in the
lateral septum, leading to elevated pERK and increased lateral septum activity.
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These studies used genetic and pharmacologic manipulations to study the age-dependent effects
of reduced basal expression of α4β2*nAChRs on anxiety-like behavior in mice using numerous
ethological tests. Mice heterozygous for a null mutation in their α4 nAChR subunit (α4HET)
have a 50% reduction in α4β2*nAChR expression (Gotti et al., 2008). Using the light-dark
assay, the elevated plus maze, and the open field test, these studies assessed anxiety-like
behavior in 6-8 month (Adult) and 22-24 month (Aged) wild type (WT) and α4HET mice. Adult
and aged mice received a challenge dose of the selective α4β2*nAChR antagonist dihydro-betaerythroidine (DHβE) to further determine how inhibition of α4β2*nAChRs affects anxiety-like
behavior during adulthood and aging. Immunoprecipitation assays on brain samples taken from
the lateral septum, amygdala, anterior cingulate cortex and hippocampus confirmed reduced
α4β2*nAChR expression in these brain areas during adulthood and assessed if there was a
decline of α4β2*nAChR expression during aging. Following a challenge injection of either
saline or a behaviorally relevant dose (3 mg/kg i.p.) of DHβE, the lateral septum and anterior
cingulate cortex were extracted from mice for western blot analysis of levels of total ERK and
pERK and total CREB and pCREB of Adult and Aged WT, α4HET and α4 knockout (α4KO)
mice.

MATERIALS AND METHODS

Animals
68 WT-Adult, 17 WT-Aged, 70 α4HET-Adult, 23 α4HET-Aged, 30 α4KO-Adult and 20
α4KO-Aged male mice back-crossed against the C57BL/6 background over ten generations were
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used for these studies. Mice were generated in a breeder colony at Virginia Commonwealth
University. Animals received ad libitum access to food and water and were group-housed (2-5
per cage) with 1/8 inch corncob bedding in an environmentally controlled, AALAC-approved
vivarium with a 12h light/dark cycle (lights on 0600). To promote hydration and nutrition, the
diets of aged mice were supplemented with Clear H2O Diet Gel (Pharmaserv, Framingham,
MA). Mice were habituated to experimenter handling for 3 days and the experimental room at
least one day prior to any training or testing. All experiments were conducted with approval of
the Institutional Animal Care and Use Committee at Virginia Commonwealth University in
compliance with the Guide for Care and Use of Laboratory Animals (Institute of Laboratory
Animal Resources, 2010).

Drugs
Dihydro-beta-erythroidine (DHβE) (Tocris, Bristol, UK) was dissolved in 0.9 % sterile saline.
DHβE doses are expressed as hydrogen bromide salt. Injections were delivered i.p. in volumes
of 0.1 ml/30 g. After DHβE injection, animals were returned to their home cages for 15 minutes
before evaluation in the light-dark assay. Weights were taken approximately 1 h prior to
behavioral assays.

Apparatus
Light-Dark Apparatus
Light-dark experiments were conducted in modified place conditioning chambers (Med
Associates, St. Albans, VT) so that a small, enclosed, dark chamber with a black ceiling (L 16.8
cm x W 12.7 cm x H 12.7 cm) was directly adjacent to a larger, open, brightly-lit chamber (L
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26.5 cm x W 12.7 cm x H 26.2 cm) that was illuminated by a single 23W fluorescent light bulb.
Mice had free access to both light and dark chambers of the apparatus via a door (W 5 cm x H
5.9 cm) that was opened at the beginning of the test. The stainless steel dropping trays had
plastic inserts (L 16.8 cm x W 12.7 cm) in the respective light or dark chambers to enhance the
brightness of the light chamber and reduce brightness and glare in the dark chamber. Data were
collected on a PC computer and calculated using Med Associates software.

Open Field
Open field experiments were conducted in a polycarbonate cage (33 cm× 21 cm × 9 cm high)
under ambient room lighting conditions provided by overhead fluorescent lights. The apparatus
was covered with clear Plexiglas to permit tracking but to prevent escape of mice. Holes drilled
in this lid allowed ventilation during the test. During experiments when additional illumination
was provided by a 23W fluorescent light bulb (No injection/bright room lighting), the
polycarbonate cage was placed within a white plastic enclosure that surrounded all 4 walls and
the floor.

Elevated Plus Maze
An elevated plus maze raised 68 cm above the floor had two arms with white plastic flooring that
were enclosed with 15.25 cm black Plexiglas walls (5 x 30 cm) that were perpendicular to two
equivalent (5 x 30 cm) exposed arms also with white flooring. Experimentation took place under
overhead fluorescent light illumination. For both the open field and elevated plus maze assays,
data was collected by a ceiling-mounted camera that was interfaced to a PC for collection of data
using ANY-maze tracking software (Stoelting, Wood Dale, IL).
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Experimental Procedures
Experiment 1: Behavioral assessment of α4β2*nAChR expression and aging on anxiety-like
behavior.

Light-dark assay
Untreated Adult and Aged α4HET and WT mice (n = 9-15 per age group and per genotype) were
brought to the experimental room at least one hour prior to testing. The room was dark with the
exception of lighting required for the apparatus. Mice were started in the dark chamber of the
apparatus with the door closed. This enabled the use of latency to enter the light chamber as a
measure of anxiety-like behavior while preventing the potential confound of freezing that occurs
when rodents are started in the light chamber. Mice moved freely throughout the apparatus for a
period of 10 min. Latency and % time spent in the light chamber were calculated as described in
Chapter 3. Movement counts per second spent in the light and dark chambers were separately
calculated over 1 min time bins.

Open field locomotor assay
Untreated Adult and Aged α4HET and WT mice (n = 6-7 per age group/genotype) were placed
in the open field facing the left corner of the apparatus farthest from the experimenter and were
allowed to freely explore he entire apparatus for 15 min (No injection/bright room lighting).
Latency to first entry into the center zone (6 x 6 cm), the number of entries made into the center
zone and time spent in the corners (6 x 6 cm each corner) were evaluated. A separate cohort of
α4HET-Adult, α4HET-Aged, WT-Adult and WT-Aged mice (n = 5-9 per age and genotype)
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received i.p. delivery of 0.9% sterile saline as a stressor immediately before evaluation in the
open field locomotor assay in novel polycarbonate cages containing corncob bedding (Saline
injection/normal room lighting).

Elevated plus maze
Untreated Adult and Aged α4HET and WT mice were placed on the center of an elevated plus
maze apparatus facing one of the closed arms (n = 6-11 per age group/genotype). Mice were
evaluated for number of open arm entries, time spent in the open arms and latency to explore the
terminal zones (the extreme 5 cm) of the open arms for a period of 10 min as described
previously (Anderson & Brunzell, 2012). Between animals, feces, urine and dander were
removed and behavioral apparatus was cleaned with 2% Nolvosan (Pfizer Animal Health,
Madison, NJ).

Experiment 2: Assessment of α4β2*nAChR expression on anxiety-like behavior following
pharmacological antagonism of β2*nAChRs.

α4HET-Adult and WT-Adult mice received between-subject delivery of 0 or 3 mg/kg of the
selective β2*nAChR antagonist DHβE i.p. (n = 18 per genotype/dose) 15 minutes prior to
evaluation in the light-dark assay as described above.

Experiment 3: Serum corticosterone determination by ELISA
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Immediately following completion of the open field locomotor assay described above in
Experiment 1, mice underwent rapid decapitation between 1000 and 1700 hours and were
counter-balanced by age and genotype to minimize the effect of circadian fluctuations of serum
corticosterone levels on test results. Trunk blood was collected in 1.5 mL centrifuge tubes
containing 15 µl of heparin, which were immediately placed on ice. Samples were centrifuged at
4° C at 13000 g for 15 minutes. Serum was decanted and stored at -80° C until thawed on ice
for corticosterone ELISA determined using the Corticosterone HS EIA kit by Immunodiagnostic
Systems (Scottsdale, AZ). The assay was performed according to manufacturer instructions and
serum corticosterone concentrations were determined using ReaderFit curve-fitting software
(Hitachi Solutions America Ltd, USA).

Experiment 4: nAChR immunoprecipitation: Assessment of age-related expression of

α4*nAChRs

Brains from α4HET-Adult, α4HET-Aged, α4KO-Adult, α4KO-Aged, WT-Adult and WT-Aged
mice (n = 6-8 per genotype and age) were harvested following rapid decapitation. Brains were
removed, placed in ice-cold PBS and sliced in a plastic matrix chilled with dry ice. Coronal
slices were floated in ice-cold PBS and anterior to posterior hole punches were taken of the
amygdala (1.20 mm; approx. -1.06 to -1.94 from Bregma, with the dorsal hippocampus as the
primary anterior and posterior landmarks), anterior cingulate cortex (1.50 mm; approx. +1.94 to
+0.14 from Bregma, with the anterior commissure as the primary landmark) and septum (1.50
mm; approx. +1.18 to +0.14 from Bregma, with the anterior commissure aligning with the lateral
ventricles as the anterior landmark, and crossing midline as the posterior landmark) . The
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anterior dorsal hippocampus was hemi dissected with the right lobe retained for processing.
Tissue samples were fast frozen in ice-cold isopentane and stored at -80º C until the expression
of α4 nAChR subunits was determined via immunoprecipitation.

nAChR antibody generation
All nAChR antibodies were targeted against the cytoplasmic loop region of mouse nAChR
subunits as previously published (David et al. 2010). The immunoprecipitation (IP) efficacy and
specificity of the antibodies has previously been tested with recombinant receptors expressed in
HEK-293 cells, and by comparing the IP results in the SCG of α5β2 and α5β4 double KO mice
(which express pure α3β4 and α3β2 receptors, respectively) with polyethylene glycol
precipitation of all solubilized receptors. We furthermore took advantage of nAChR-KO mice in
order to exclude false-positive reactions (see supplemental Fig. 1, David et al. 2010).

Immunoprecipitation of [³H]-epibatidine labeled receptors
Receptors were solubilized in 2 % Triton X-100 lysis buffer: 50 mM Tris-HCl pH = 7.5, 150
mM NaCl, 2 % Triton X-100, supplemented with one complete mini protease inhibitor cocktail
tablet (Roche) per 10 ml buffer. Following one ultrasound pulse of 5 seconds duration at 30 %
energy level, samples were left for 2 hours at 4°C and thereafter centrifuged at 16000 g for 15
min at 4°C. 130 µl clear supernatant from were incubated with 20 µl 10 nM [³H]-epibatidine and
5 µg antibody in 30 µl phosphate-buffered saline (PBS: 10 mM Na2HPO4, 1.8 mM KH2PO4,
2.7 mM KCl, 140 mM NaCl, pH = 7.4) on a shaking platform at 4°C overnight. Unspecific
binding was determined by adding 300 µM nicotine to half of the samples.
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Heat-killed, formalin-fixed Staphylococcus aureus cells carrying protein A (Standardized
Pansorbin-cells, Calbiochem) were centrifuged at 2300 g for 5 min at 4°C. Pansorbin-pellets
were washed twice with IP-High (50 mM Tris-HCl pH = 8.3, 600 mM NaCl, 1 mM EDTA, 0.5
% Triton X-100), once in IP-Low (50 mM Tris-HCl pH = 8.0, 150 mM NaCl, 1 mM EDTA, 0.2
% Triton X-100), and re-suspended with IP-Low. 20 µl of this suspension of Pansorbin cells
were added to the above mentioned cocktail containing the antibody, solubilized receptors, and
[³H]-epibatidine for 2 hours at 4°C on a shaking platform. Samples were centrifuged at 2300 g
for 5 min at 4°C and washed twice with IP-High and once with IP-Low at 2300 g for 1 min at
4°C. Pellets were re-suspended in 200 µl 1 M NaOH and subjected to liquid scintillation
counting. All protein quantifications were performed using the BCA Protein Assay Reagent Kit
(Pierce) following the manufacturer‘s instructions.

Experiment 5: Assessment of α4β2*nAChR-associated changes in intracellular signaling:
Regulation of ERK and CREB in the lateral septum and anterior cingulate cortex.

Western blot analysis
Adult and Aged α4HET (n=43), α4KO (n=33) and WT mice (n=51) were placed in a novel cage
x 15 minutes after administration of 3 mg/kg DHβE or 0.9% sterile saline i.p. Brains were then
harvested via rapid decapitation and brain sections were collected as described previously
(Brunzell et al., 2003). For collection of the lateral septum, the medial portion of the septal
region was removed via a 0.75 mm brain punch and discarded prior to collection of the septal
region with a 1.5 mm punch. Tissue samples were fast frozen on dry ice and stored at -80º C
until the expression of ERK, pERK, CREB, pCREB and alpha tubulin were determined via
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western blot analysis. Samples were sonicated while on ice in a 1% SDS homogenization buffer
containing 50 mM Tris (pH 7.5), 1 mM EDTA, 1 mM EGTA, 1 mM PMSF supplemented with a
protease inhibitor cocktail tablet (Roche, Indianapolis, IN) and Phosphatase Inhibitor Cocktails 2
and 3 (Sigma, St. Louis, MO) at a 1:100 dilution. Samples were centrifuged at 13000 g for 15
min. The supernatant fluid was removed and stored at -80° C. Protein concentrations were
determined in duplicate using Bio-Rad DC protein detection reagent (Bio-Rad, Hercules, CA).
10µg of protein was loaded per lane to determine immunoreactivity for ERK, pERK, CREB,
pCREB and alpha tubulin. Protein was run on a 4-15% gradient SDS-polyacrylamide gel (BioRad, Hercules, CA) and then transferred to a nitrocellulose membrane in chilled Tris-glycine
buffer for 55 minutes at 100 V.

All incubation steps were performed on a rocker. Membranes were rinsed in Tris-buffered saline
(TBS), then blocked in Odyssey Blocking Buffer (1:5 in 1X PBS) for 1.5 h at room temperature.
Membranes were washed briefly in TBS-T and incubated overnight at 4° C in primary antibody
diluted in 3% BSA in TBS-T. Primary antibodies to detect ERK and pERK (threonine
183/tyrosine 185) were used at a dilution of 1:5000 in mouse and rabbit respectively (MAB1576;
R&D Systems, Minneapolis, MN; CS4376; Cell Signaling Technology, Beverly, MA) CREB in
rabbit (CS9197) at 1:500, pCREB in mouse (CS9196) at 1:1000 (Cell Signaling Technology,
Beverly, MA) and alpha tubulin in chicken (SAB35000023; Sigma, St. Louis, MO) diluted
1:5000 was used as a loading control. Blots were washed for 30 min in TBS-T and incubated for
50 min at room temperature in 1:15000 affinity-purified anti-rabbit IgG IRDye fluorescent
(800CW) for pERK, 1:20000 anti-mouse IgG IRDye fluorescent (680LT) for ERK, 1:15000
affinity-purified anti-mouse IgG IRDye fluorescent (800CW) for pCREB, 1:20000 affinity-
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purified anti-rabbit IgG IRDye fluorescent (680LT) for CREB and 1:20000 affinity-purified antichicken IgG IRDye fluorescent (680LT) for alpha tubulin (LI-COR Biosciences, Lincoln, NE)
secondary antibody in 3% BSA in 0.01% SDS/PBS-T. After exposure to secondary antibodies,
blots were protected from light to prevent degradation of the fluorescent signal of the secondary
antibody. Blots were scanned on an Odyssey Infrared Imaging System (LI-COR Biosciences,
Lincoln, NE). Integrated densities were analyzed and quantified using ImageJ software (NIH).
Relative protein expression values were normalized to alpha tubulin in these experiments, and
each subject was further normalized to % of WT-Adult saline-injected subjects on each blot.

Statistical Analysis

2 x 2 ANOVA assessed genotype x age or genotype x treatment effects in behavioral and
corticosterone assays. For the light-dark assays, % time spent in the light was initially analyzed
using a repeated measures ANOVA, with a within-subject factor of 5 min time bins. 3 x 2
ANOVA analyzed genotype x age or genotype x treatment effects on α4 nAChR subunit
expression or levels of ERK, pERK, CREB, pCREB and alpha tubulin. Tukey’s post hoc tests
were used to identify main effects of genotype. Significant interactions were followed with post
hoc Student’s t-tests to determine the nature of the interaction. For Experiment 1, detection of a
significant genotype x age x time bin interaction for movements per second in either the light or
dark chamber were followed by a repeated measures ANOVA for each age group, to determine
the genotype-specific nature of the interaction. In Experiment 2, a repeated measures ANOVA
was performed for each genotype after detection of a significant effect of drug treatment.
Planned comparisons to evaluate the effect of a stressful saline-injection on anxiety-like behavior
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in the light-dark and open field assays between WT-Adult and α4HET-Adult mice were
performed via Student’s t-tests. Planned comparisons to assess age-dependent changes in α4
nAChR subunit expression in WT mice were performed using Student’s t-tests. For all analyses,
P values < 0.05 were reported as significant.

RESULTS

Basal expression of α4β2*nAChRs affects age-dependent changes in anxiety-like behavior
Light-Dark Assay
There was a significant genotype x age interaction for movements per second in the light (F1,49 =
13.096, P = 0.001), but not the dark chamber (F1,49 = 2.444, P = 0.124). Post hoc analyses
revealed that α4HET-Adult mice showed significantly more exploration of the light chamber
than their age-matched WT littermate controls (F1,27 = 4.384, P < 0.05; Fig 5.1a). The absence
of any genotype effect on dark chamber activity suggests that this difference was not due to
general changes in locomotor activity. Interestingly, this genotypic effect was reversed in Aged
mice. α4HET-Aged mice showed reduced movements per second in the light chamber compared
to Aged-WT mice (F1,22 = 12.070, P = 0.002; Fig 5.1b). A significant genotype x age
interaction was also observed for latency to enter the light chamber (F1,49 = 10.670, P = 0.002),
revealing that α4HET-Aged mice showed significantly higher latencies to enter the light
chamber than their WT-Aged counterparts (t22 = 2.930, P < 0.01; Fig 5.2a). This observation was
not evident in Adult mice. α4HET mouse latencies increased with age as evidenced by a
significant difference between α4HET-Adult and α4HET-Aged mice (t27 = 2.847, P < 0.01; Fig
5.2a). As with exploratory behavior of the light chamber, there was a non-significant trend for
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WT-Aged mice to require less time to explore the light chamber than WT-Adult controls (t22 =
1.839, P = 0.079; Fig 5.2a).

There was a significant genotype x age x time bin interaction (F1,49 = 4.701, P < 0.05) for time
spent in the light chamber. A subsequent two-way ANOVA detected a significant interaction of
genotype x age for this measure during the first 5 minutes (F1,49 = 12.359, P = 0.001) but not the
second five minutes of the 10 min light-dark assay (F1,49 < 1, P = 0.351). Consistent with other
light-dark measures, post hoc tests showed that WT-Aged mice spent more time in the light
chamber than WT-Adult mice (t22 = 2.206, P < 0.05; Fig 5.2b), whereas α4HET-Aged mice
spent less time in the light chamber than both α4HET-Adult mice (t27 = 2.819, P < 0.01; Fig
5.2b) and their WT-Aged counterparts (t22 = 3.350, P < 0.01; Fig 5.2b).

Open Field Test
Two-way ANOVA analyses revealed significant genotype x age interactions for latency to enter
the central zone (F1,27 = 15.068, P = 0.001), number of entries made into the central zone (F1,22 =
5.757, P = 0.025) and time spent in the corners of the open field locomotor assay under bright
lighting conditions (F1,22 = 5.757, P = 0.025). α4HET-Aged mice required longer to enter the
central zone (t10 = 3.606, P < 0.01; t11 = 3.736, P < 0.01; Fig 5.3a), made significantly fewer
entries into the central zone (t10 = 4.622, P = 0.001; t11 = 2.336, P < 0.05; Fig 5.3b) and spent
more time in the corners than both α4HET-Adult mice and WT-Aged mice, respectively (t10 =
3.501, P < 0.01; t11 = 3.274, P < 0.01; Fig 5.3c). These differences in open field behaviors are
also graphically represented by group occupancy plots in Figure 5.4, with blue representing the
lowest center zone group occupancy. In contrast to these age-dependent effects observed in
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Figure 5.1 - Basal expression of α4β2*nAChRs regulates anxiety-like behavior in an agedependent manner. a) Compared to age-matched wild type (WT) mice, exploration of the light
chamber was higher in 6-8 month (Adult) mice with 50% basal expression of α4β2*nAChRs
(α4HET), suggestive of an anxiolytic-like phenotype. b) In contrast, light chamber activity was
reduced in 22-24 month (Aged) α4HET mice compared to WT-Aged mice, suggesting that
anxiety phenotype increases as α4HET mice age. c-d) There were no effects of genotype on
movements per second spent in the dark chamber, suggesting that the age- and genotype-specific
differences in behavior were reflective of changes in anxiety-like behavior. Data are represented
as means ± SEM.
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Figure 5.2 - Age-dependent changes in anxiety-like behavior regulated by basal expression
of α4*nAChRs during the light-dark assay in mice. a) Compared to 6-8 month (Adult) mice
of the same genotype, anxiety-like behavior was increased in 22-24 month (Aged) mice with
heterozygous expression of α4*nAChRs (α4HET) and reduced in Aged wild type (WT) mice, as
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measured by increased latencies to enter the light chamber compared to both α4HET-Adult and
age-matched WT mice. Additionally there was a non-significant trend for WT-Aged mice to
show lower latencies to enter the light chamber than WT-Adult controls (P = 0.079). b) WTAged mice spent more time in the light chamber than WT-Adult mice, while α4HET-Aged mice
spent less time in the light chamber than both α4HET-Adult and WT-Aged mice during the first
5 minutes of the light-dark assay, suggesting that basal expression of α4*nAChRs differentially
regulates age-dependent changes in anxiety-like behavior in this assay. c) No age or genotypespecific effects were observed for time spent in the light chamber during minutes 6-10,
suggesting that all mice habituated to the apparatus after 5 minutes. Data are represented as
means ± SEM. *P < 0.05; **P < 0.01 vs. Adult mice of same genotype; ††P < 0.01 vs. WTAged mice.
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α4HET mice, WT-Aged mice did not differ from WT-Adult mice in center zone latency time (t12
= 0.025, P = 0.980; Fig 5.3a), center zone entries (t12 = 0.253, P = 0.805; Fig 5.3b), or time spent
in the corners during the open field locomotor assay (t12 = 0.343, P = 0.738; Fig 5.3c).

Although two-way ANOVA did not reveal any significant genotype x age interactions for
latency to enter the center zone (F1,22 = 2.760, P = 0.111), number of entries made into the center
zone (F1,22 < 1, P = 0.932) or time spent in the corners during the open field locomotor assay
under normal lighting conditions (Saline injection/normal room lighting; F1,22 < 3.216, P =
0.087), planned comparison t-tests revealed that α4HET-Adult mice spent significantly less time
in the corners than WT-Adult controls (t13 = 2.873, P < 0.05; Table 5.1). There was also a nonsignificant trend for α4HET-Adult mice to make more entries into the center zone than agematched WT mice (t13 = 2.072, P = 0.059; Table 5.1). Data from 2 subjects were excluded due
to inconsistent video tracking. Data from an additional mouse was excluded due to total distance
traveled being 4 standard deviations from the mean.

Elevated Plus Maze
Two-way ANOVA tests revealed main effects of age for number of open arm entries (F1,29 =
5.937, P < 0.05), time spent in the open arms (F1,29 = 4.839, P < 0.05) and latency to explore the
terminal 5cm of the open arms of an elevated plus maze (F1,29 = 14.652, P = 0.001). Aged mice
made fewer entries into the open arms, spent less time in the open arms and had higher latencies
to explore the terminal zone of the open arms of an elevated plus maze compared to Adult mice
independent of genotype (Table 5.2). There was no effect of genotype or interaction of genotype
with age in the elevated plus maze task.
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Figure 5.3 - Age-dependent increases in anxiety-like behavior also observed in α4HET mice
during open field test. a) Unlike wild type (WT) mice, whose behaviors did not differ between
141

6-8 (Adult) and 22-24 month (Aged) mice, anxiety-like behavior was increased in Aged α4
heterozygous (α4HET) mice during an open field test. α4HET-Aged mice had higher latencies
to enter the center zone, b) made fewer entries into the center zone and c) spent more time in the
corners than both α4HET-Adult controls and age-matched WT mice. Data are represented as
means ± SEM. **P < 0.01 vs. α4HET-Adult mice; †P < 0.05; ††P < 0.01 vs. WT-Aged mice.

142

WT

Aged

Adult

α
!4HET

Figure 5.4 - Group occupancy plots for 6-8 (Adult) and 22-24 month (Aged) wild type (WT)
and α4 heterozygous (α4HET) mice during open field locomotor test. α4HET-Aged mice
made the fewest number of entries into the center zone as represented by the color blue (lowest
occupancy) and spent the most time in the corners of the open field apparatus, represented as the
color red (highest occupancy) among all groups tested.
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Table 5.1 - Mice with reduced expression of α4β2*nAChRs (α4HET) show less anxiety-like
behavior in open field locomotor task following i.p. saline.
Genotype

Age

Latency to
enter center (s)

Center zone
entries

Time spent in
corners (s)

n size

WT
WT
α4HET
α4HET

Adult
Aged
Adult
Aged

71.68 ± 42.3
37.64 ± 16.4
15.19 ± 5.0
94.40± 34.6

16.50 ± 2.8
10.20 ± 1.5
25.71 ± 3.3#
14.33 ± 3.5

364.54 ± 33.3
249.34 ± 48.0
248.51 ± 14.8*
248.00 ± 21.7

8
5
9
7

After i.p. delivery of 0.9% sterile saline, mice were allowed to explore a novel polycarbonate
housing cage under normal fluorescent lighting conditions that was not surrounded by a white
enclosure and x 15 min. α4 heterozygous (α4HET) 6-8 month (Adult) mice spent less time in
the corners and showed trends for more entries made in the center zone than age-matched wild
type (WT) controls, showing that the reduced expression of α4β2*nAChRs protects against
increased anxiety-like behavior following an i.p. saline injection. Key: WT = wild type; α4HET
= α4 heterozygous; Adult = 6-8 months; Aged = 22-24 months. All data represented as Mean ±
SEM. *P < 0.05, #P = 0.059 compared to WT-Adult.
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Pharmacological antagonism of α4β2*nAChRs increases anxiety-like behavior in α4HET, but
not WT mice
Planned comparison t-tests revealed that Saline-treated α4HET mice showed shorter latencies
compared to saline-injected WT mice, suggesting that reduced expression of α4β2*nAChRs
reduced the stress of injection during this assay (t36 = 2.788, P < 0.01; Fig 5.5a). Despite this
basal reduction in anxiety-like behavior observed in α4HET mice, a genotype x treatment
interaction was observed for latency (F1,72 = 7.547, P = 0.008), revealing that α4HET mice
administered 3 mg/kg i.p. DHβE required more time to enter the more aversive light chamber
compared to α4HET saline-injected controls (t36 = 2.335, P < 0.05; Fig 5.5a). There was also a
significant genotype x treatment interaction for percentage of time spent in the light chamber
during the first 5 minutes (F1,72 = 3.984, P = 0.05). Despite the appearance of DHβE injection to
increase time spent in the light chamber in WT mice and for α4HET mice to spend less time in
the brightly-lit chamber than saline-injected α4HET animals, post hoc tests did not detect any
significant effects of treatment on either genotype in this measure (t36 = 1.461, P = 0.153; t36 =
1.363, P = 0.181; Fig 5.5b). No significant treatment x genotype interaction was observed
during the final 5 minutes of the light-dark assay (F1,72 < 1, P = 0.754).

A repeated measures ANOVA revealed a main effect of time bin (F9,72 = 17.134, P < 0.001) and
a non-significant trend for a main effect of DHβE treatment on movements per second in the
light chamber (F1,72 = 3.344, P = 0.072). Post hoc tests revealed that unlike WT mice, which
were unaffected by DHβE treatment (F1,36 < 1, P = 0.865; Fig 5.6a), α4HET mice receiving
DHβE showed reductions in movements per second in the brightly illuminated chamber
compared to saline-injected controls (F1,36 = 5.238, P < 0.05; Fig 5.6b). Although between
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Table 5.2 - Aged mice express higher levels of anxiety-like behavior than Adult mice on an
elevated plus maze independent of genotype.

Genotype

Age

WT
WT
α4HET
α4HET

Adult
Aged
Adult
Aged

Open arm
entries

Time in
open arms
(s)

Latency to
explore terminal
5cm of open
arms (s)

4.56 ± 0.90
2.29 ± 0.75

32.70 ± 7.94
15.17 ± 4.54

303.00 ± 7.94
572.40 ± 19.75

4.18 ± 1.05

55.45 ± 18.88

392.15 ± 69.49

10
7
11

1.67 ± 0.71

10.25 ± 7.07

600.00 ± 0.00

6

n size

22-24 month (Aged) mice expressed higher levels of anxiety-like behaviors than 6-8 month
(Adult) mice, suggesting that Aged mice are more anxious than Adult mice independent of
genotype during an elevated plus maze assay. Key: WT = wild type; α4HET = α4 heterozygous;
Adult = 6-8 months; Aged = 22-24 months. All data represented as Mean ± SEM.
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Figure 5.5 – Dihydro-beta-erythroidine (DHβE) administration results in anxiogenic-like
behavior in α4HET mice. a) Despite the fact that α4HET saline-injected mice showed lower
latencies than vehicle-treated wild type (WT) controls, latencies were increased in α4HET mice
receiving 3 mg/kg i.p. dihydro-beta-erythroidine (DHβE) than their saline-injected (DHβE=0)
α4HET counterparts. b) Although there was a treatment x genotype interaction for time spent in
the light chamber (F1,72 = 3.984, p = 0.05), post hoc tests did not detect any specific effects of
DHβE administration on time spent in the light chamber. Taken together, these data suggest that
although lower basal expression of α4β2*nAChRs may protect against the anxiogenic-like
effects of a saline vehicle injection, further antagonism of α4β2*nAChRs promotes an
anxiogenic-like response in α4HET mice. Data are represented as means ± SEM. *P < 0.05 vs.
saline-injected mice of same genotype (DHβE=0); ††P < 0.01 vs. saline-injected WT mice
(DHβE=0).
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Figure 5.6 - α4HET mice with lower expression of α4*nAChRs are more sensitive to
anxiogenic-like effects of dihydro-beta-erythroidine (DHβE). a-b) Exploration of the light
chamber was reduced in α4 heterozygous (α4HET) mice administered 3 mg/kg i.p. of the
selective β2*nAChR antagonist dihydro-beta-erythroidine (DHβE) compared to saline-injected
(SAL) α4HET mice. c-d) Compared to saline injection, administration of 3 mg/kg i.p. DHβE did
not affect movements per second in the dark chamber in either genotype. These data suggest that
the observed behavioral effects of DHβE treatment in α4HET mice reflect increases in anxietylike behavior and not changes in general locomotion. Data are represented as means ± SEM.
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subject ANOVA tests revealed a trend for a treatment x genotype interaction for movements per
second spent in the dark chamber (F1,72 = 3.060, P < 0.085), post hoc tests did not reveal any
significant between subject effects of drug treatment for movements per second in the dark
chamber for WT (F1,36 = 1.129, P > 0.1; Fig 5.6c) or α4HET mice (F1,36 = 1.946, P > 0.1; Fig
5.6d).

Expression of α4β2*nAChRs does not regulate HPA-axis activity after 15 min exposure to an
open field locomotor assay

Two-way ANOVA analyses did not reveal any significant effects of genotype, age or
interactions of genotype x age for serum corticosterone levels following the open field assays
conducted under either bright (F1,26 < 1, P = 0.504; F1,26 < 1, P = 0.605; F1,26 < 1, P = 0.434;
Table 5.3) or normal room lighting conditions (F1,23 = 1.054, P = 0.315; F1,23 < 1, P = 0.852;
F1,23 < 1, P = 0.353; Table 5.3).

α4 nAChR subunit expression
nAChR immunoprecipitation confirmed that α4 nAChR subunit expression was significantly
reduced in α4HET compared to WT mice. Two-way ANOVA analyses detected main effects of
genotype for α4 nAChR subunit expression in the amygdala (F2,19 = 32.278, P < 0.001),
cingulate cortex (F2,19 = 33.652, P < 0.001), hippocampus (F2,19 = 13.802, P < 0.001) and lateral
septum (F2,19 = 22.963, P < 0.001). Tukey’s post hoc tests revealed that compared to WT mice,
α4 nAChR subunit expression was significantly reduced in α4HETs (P’s < 0.05) and essentially
absent in α4KO mice in all brain areas evaluated (P’s < 0.001). Planned comparisons revealed a
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Table 5.3 - No effects of genotype or age on serum corticosterone
levels observed after 15 minutes of exposure to a novel cage.
Genotype
WT
WT
α4HET
α4HET
WT
WT
α4HET
α4HET

Age

Serum corticosterone
(ng/ml)
No injection/bright room lighting
Adult
303.5 ± 27.5
Aged
286.3 ± 15.4
Adult
305.2 ± 21.1
Aged
330.9 ± 22.5
Saline injection/normal room lighting
Adult
299.2 ± 32.6
Aged
289.6 ± 44.2
Adult
295.1 ± 29.8
Aged
342.0 ± 33.6

n size
7
7
7
7
10
5
8
7

Untreated mice were allowed to explore a polycarbonate cage that was
brightly lit and surrounded by a white plastic enclosure x 15 min (No
injection/bright room lighting). A separate cohort of mice received i.p.
saline immediately prior to exploration of a novel polycarbonate housing
cage that was not surrounded by a white plastic enclosure under normal
fluorescent lighting conditions x 15 min (Saline injection/normal room
lighting). Key: WT = wild type; α4HET = α4 heterozygous; Adult =
6-8 months; Aged = 22-24 months. All data represented as Mean ± SEM.
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Figure 5.7 - Trends observed for an age-dependent increase in the amygdalar expression of
the α4 nAChR subunit in wild type (WT) mice. Two-way ANOVA analyses detected that the
expression of the α4 nAChR subunit was higher in wild type (WT) mice than both α4
heterozygous (α4HET) mice and mice with genetic deletion of the α4 subunit (α4KO) in all
brain areas evaluated. a) A non-significant trend for increased α4 subunit expression in the
amygdala in 22-24 month (Aged) WT mice compared to 6-8 month (Adult) WT mice (P =
0.073) likely contributed to reduced amygdalar α4 subunit expression in α4HET-Aged mice
compared to WT-Aged mice. Data are represented as means ± SEM (n = 3-4 experiments per
genotype and age). †P < 0.05 vs. aged-matched WT.
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non-significant trend for increased amygdalar α4 nAChR subunit expression in Aged WT mice
compared to Adult WT controls (t4 = 3.423, P = 0.073; Fig 5.7a).

Effects of Age and α4β2*nAChR expression on regulation of ERK and CREB
ANOVA analyses detected significant age x genotype interactions for levels of pERK42 (F2,52 =
4.795, P = 0.012) and pCREB (F2,52 = 4.446, P = 0.017) in the lateral septum following saline
vehicle injection. Compared to WT-Adult mice, post hoc tests revealed that pERK42 was
significantly higher in α4HET-Adult mice (t22 = 2.766, P < 0.05; Fig 5.8a) with a trend for
elevated pERK42 in WT-Aged mice (t25 = 2.033, P = 0.052; Fig 5.8a). pERK42 was lower in
α4HET-Aged mice compared to α4HET-Adult mice (t15 = 2.152, P < 0.05; Fig 5.8a). Compared
to WT-Adult controls, pCREB was significantly higher in both WT-Aged mice (t25 = 3.902, P <
0.001; Fig 5.8a) and α4HET-Adult mice (t22 = 2.228, P < 0.05; Fig 5.8a). Age-dependent
changes in pERK42 or pCREB were not observed in α4KO mice. No significant age x genotype
interactions were detected for total ERK42 (F2,48 = 1.280, P > 0.2), ERK44 (F2,46 < 1) or total
CREB in the lateral septum (F2,53 < 1; Fig 5.8b).

Regulation of ERK and CREB phosphorylation observed in the lateral septum in α4HET mice
following antagonism of α4β2*nAChRs
A trend for a genotype x treatment interaction (F2,97 = 2.868, P = 0.062) revealed that levels of
pERK44 were reduced in α4HET mice administered DHβE compared to saline-injected α4HET
mice (t30 = 2.232, P < 0.05; Fig 5.9a), whereas injections of DHβE did not affect pERK44 in WT
or α4KO mice (t41 = 0.8309, P = 0.411; t26 = 0.044, P = 0.965). A main effect of genotype (F2,96
= 2.868, P = 0.0034) as well as a similar trend for an interaction of genotype x treatment (F2,96 =
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2.413, P = 0.094) revealed that pCREB levels in the lateral septae of saline-injected α4HET
mice were significantly higher than saline-treated WT controls (t36 = 3.266, P = 0.002; Fig 5.9a).
Post hoc t-tests also identified a non-significant trend for reduced pCREB in α4HET mice
receiving DHβE compared to α4HET mice administered saline (t30 = 2.029, P = 0.051; Fig 5.9a).
As with pERK, DHβE injections did not affect pCREB in WT or α4KO mice, compared to their
saline-injected counterparts (t40 = 0.365, P = 0.717; t26 = 0.306, P = 0.762). A trend for a
genotype x treatment interaction (F2,92 = 2.780, P = 0.067) revealed that DHβE–injected α4HET
mice showed significant reductions in total ERK 42 compared to saline-injected α4HET mice
(t29 = 2.384, P < 0.05; Fig 5.9b). A trend for a main effect of treatment for total ERK 44 (F1,92 =
2.780, P = 0.067) was likely due to similar trends for reduced total ERK 44 in DHβE–injected
α4HET mice, suggesting that reduced ERK phosphorylation in the lateral septum following
DHβE injections may have been due to downregulation of total ERK protein, rather than
regulation of ERK phosphorylation.

DISCUSSION

In these studies, we evaluated the effects of reduced basal expression of α4β2*nAChRs on agedependent anxiety-like behaviors in mice. During the light-dark assay, a genetic reduction of
α4β2*nAChRs promoted anxiolysis-like behavior in untreated 6-8 month old α4HET-Adult
mice compared to controls, as measured by increased exploration of a brightly-lit chamber and
shorter latencies to enter that chamber compared to age-matched WT controls. Adult α4HET
mice also spent less time in the corners and showed trends for increased entries into the center
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Figure 5.8 - Opposing age- and genotype-specific changes in anxiety-like behavior are
associated with regulation of ERK and CREB phosphorylation in the lateral septum. a)
Compared to 6-8 month (Adult) WT controls, reductions in anxiety-like behavior observed in
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α4HET-Adult mice were associated with elevated phosphorylation of ERK 42 (pERK42) in the
lateral septum. Conversely, the increased anxiety-like behavior observed in 22-24 month (Aged)
α4HET mice was associated with reduced pERK42. There was also a non-significant trend for
increased pERK42 in WT-Aged mice (P = 0.052) compared to WT-Adult controls. These data
suggest that the age- and genotype-dependent changes in anxiety-like behavior may have been
regulated via phosphorylation of ERK in the lateral septum. Similar trends were observed for
pCREB. Compared to WT-Adult animals, pCREB was significantly higher in both WT-Aged
mice and α4HET-Adult mice. Age-dependent changes in pERK42 or pCREB were not observed
in α4KO mice, suggesting that the changes in pERK and pCREB require α4β2*nAChRs. b) No
significant age x genotype interactions were detected for the expression of total ERK42, ERK44
or total CREB in the lateral septum. Data are represented as means ± SEM. *P < 0.05 vs.
α4HET-Adult mice; ***P < 0.001; †P < 0.05 vs. WT-Adult mice.
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Figure 5.9 - Increased anxiety-like behavior following i.p. DHβE in α4HET mice is
associated with reduced ERK and CREB phosphorylation in the lateral septum. a)
Consistent with results from the aging study, the dose of DHβE (DHβE) that promoted
anxiogenic-like behavior in α4HET mice in the light-dark assay (3 mg/kg i.p.) also regulated
phosphorylation of ERK44 (pERK44) in the lateral septum, as α4HET mice receiving DHβE
expressed lower levels of pERK44 than saline-injected (SAL) α4HET animals. Compared to
wild type (WT) SAL mice, phosphorylation of CREB (pCREB) was higher in α4HET mice. A
non-significant trend for reduced CREB phosphorylation (pCREB) in DHβE-injected α4HET
mice was also observed (P = 0.051). The administration of DHβE did not affect anxiety-like
behavior, or levels of either pERK or pCREB in WT mice, suggesting that 3 mg/kg i.p. DHβE
may have promoted anxiogenic-like behavior in α4HET mice by reducing ERK and CREB
phosphorylation in the lateral septum. b) DHβE-injected α4HET mice showed reduced levels of
total ERK 42 than vehicle-injected α4HET animals. Data are represented as means ± SEM. *P
< 0.05 vs. α4HET i.p. saline (SAL) mice; †P < 0.05, ††P < 0.01 vs. WT SAL mice.
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Figure 5.10 Representative western blots from aging and DHβE challenge studies.
Key: Genotype- WT = Wild type, HET = α4HET, KO = α4KO. Age: Adult = 6-8 months old,
Aged = 22-24 months old at time of harvest.
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zone of a novel cage than age-matched WT mice. These genetic studies complement
pharmacological studies suggesting that inhibition of α4β2*nAChRs promotes anxiolysis-like
behavior during the conditioned emotional response, light-dark, elevated plus maze, novelty
induced hypophagia and marble burying assays (Anderson & Brunzell, 2012; Dawson et al.,
2013; Newman et al., 2002; Newman et al., 2001; Roni & Rahman, 2011; Turner et al., 2010).
In contrast to these observations in Adult mice, reduced basal expression of α4β2*nAChRs
promoted anxiogenic-like behavior in 22-24 month Aged mice. α4HET-Aged mice showed
increased anxiety-like behaviors in both the light-dark and open field locomotor assays compared
to α4HET-Adult mice and aged-matched WT controls. An opposing effect was observed in WTAged mice, which exhibited reduced anxiety-like behavior compared to WT-Adult controls in
the light-dark and compared to α4HET-Aged mice in both the light-dark and open field assays.
These genotype-specific effects in Aged mice were not likely due to global differences in
locomotor activity, since there were no differences between aged WT and α4HET mice in either
dark chamber activity during the light-dark assay or distance traveled in the open field locomotor
assay. Injections of the selective β2*nAChR antagonist DHβE increased anxiety-like behavior
in α4HET, but not WT mice during the light-dark assay. Antagonism of β2*nAChRs did not
significantly affect dark chamber activity in α4HET mice, suggesting that the resultant behaviors
reflected anxiogenic-like behavior in the light-dark assay. These data suggest that while reduced
basal expression of α4β2*nAChRs may promote an anxiolytic-like phenotype in α4HET-Adult
mice, it renders them more sensitive to age-dependent increases in anxiety-like behaviors.

The results of the aging studies were surprising in the context of previous work showing that
α4β2*nAChR receptor expression decreases with aging in brain areas that support anxiety,
159

including the hippocampus (Gahring et al., 2005; Mitsis et al., 2009; S. W. Rogers et al., 1998).
In these studies WT mice showed a decrease in anxiety that would be consistent with reduced
expression of α4β2*nAChRs. However, our immunoprecipitation studies showed trends for
increases in α4 subunit expression in WT mice with aging. The previous studies analyzed the
number of neurons staining positive for the expression of the α4 nAChR subunit via
immunohistochemistry and nicotinic agonist binding assays to detect changes in the number of
high affinity α4β2*nAChR binding sites. Unfortunately, we did not have the animals to perform
agonist binding studies to quantify the number of available binding sites across age groups. It is
possible for the expression of α4 subunits to remain relatively unchanged or even increase with a
coincident reduction in the number of receptors. This would favor the assembly of the lower
affinity α4(3)β2(2)nAChRs and reduce, rather than increase, the α4β2*nAChR-mediated
response of these brain regions to nicotine and ACh. It is possible that aged WT mice have an
increase in expression of the α4(3)β2(2) low sensitivity receptors and hence show a phenotype
that is more like a4HET adults (Moroni et al., 2006; Zwart & Vijverberg, 1998). If this is true in
a4HETs as well as WT mice, then cholinergic tone at these receptors could explain the
dichotomy in effects of aging on anxiety-like behavior in WT vs. a4HET mice, with a4HETAged mice showing elevations in anxiety that resembled a4HET-Adult animals following
antagonism of α4β2*nAChRs. Our immunoprecipitation studies may have also detected α4
subunits sequestered in the endoplasmic reticulae of neurons, which would also result in an
increase in the expression of α4 subunit protein without a corresponding increase in functional
receptors (H. A. Lester et al., 2009; Wanamaker & Green, 2007).
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Little is known regarding the neuroanatomical circuitry wherein α4β2*nAChRs exert their
effects on anxiety-like behavior. Elevated cholinergic tone in the hippocampus is associated
with increased anxiety and depression-like behavior in mice and humans (Luo et al., 2013;
Mineur et al., 2013; Saricicek et al., 2012). Excitotoxic lesions of cholinergic inputs to the
basolateral amygdala reduce anxiety-like behavior in rats (Power & McGaugh, 2002), and fMRI
studies show that amygdalar activation is associated with negative affect in humans (Sutherland
et al., 2013). The lateral septum is a predominantly GABA-ergic projection area that receives a
convergence of excitatory input from brain regions known to be important for determining the
salience of external stimuli such as the ventral tegmental area, hippocampus, amygdala and
anterior cingulate cortex (Risold & Swanson, 1997a, 1997b) (for review, see (Sheehan et al.,
2004)). Studies in rodents show that electrical stimulation of the lateral septum protects against
stress-induced ulceration, and that administration of the anxiolytic chlordiazepoxide results in
increased neuronal activity in the lateral septum (E. Thomas et al., 2005; E. Thomas & Yadin,
1980; E. Thomas et al., 1991; Yadin & Thomas, 1996).

These studies explored the effect of nAChR expression and aging on ERK and CREB in the
lateral septum and found that these pathways were regulated in a fashion that correlated with
anxiety-like behavior. ERK is an intracellular signaling protein that is known to be critical in
neuronal plasticity related to learning and memory, and the rewarding properties of drugs of
abuse, including nicotine (Brunzell et al., 2009; Sweatt, 2001; Valjent et al., 2006; Valjent et al.,
2004). pERK is reduced in the lateral septum following restraint stress (Sheehan et al., 2003),
whereas the overexpression of Pyk-2, an activator of the Raf/Ras/MEK/ERK pathway, in the
lateral septum promotes an anti-depression-like phenotype in rats (Sheehan et al., 2003). The
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opposing effects of increased lateral septum activity following the administration of anxiolytic
drugs and reductions of pERK in the lateral septum after restraint stress suggest that increased
pERK in the lateral septum may be an important molecular mechanism underlying the reduced
anxiety-like behaviors observed in these studies. Reduced anxiety-like behaviors in α4HETAdult mice were associated with increased pERK in the lateral septum compared to both WTAdult and α4HET-Aged mice. Likewise, WT-Aged mice showed reduced anxiety-like
behaviors and trends for increased pERK compared to WT-Adult controls. Unlike previous
studies, wherein antagonism of β2*nAChRs reduced anxiety-like behavior (Anderson &
Brunzell, 2012; Dawson et al., 2013), we did not observe significant effects of DHβE
administration in WT mice on anxiety-like behavior during the light-dark assay. It is possible
that the 3 mg/kg DHβE dose used in these studies is on the descending arm of the dose-response
curve for DHβE in the light-dark assay. We observed anxiogenic-like behavior and associated
reductions in pERK in the lateral septum in α4HET mice following the administration of 3
mg/kg DHβE, suggesting that while reduced expression of α4β2*nAChRs may promote
anxiolysis-like behavior via activation of ERK in the lateral septum, further antagonism of
α4β2*nAChRs in mice with already reduced α4β2*nAChRs has the opposite effect, increasing
anxiety-like behavior and reducing pERK in the lateral septum. The effects of DHβE on ERK
phosphorylation in α4HET mice may have been due to downregulation of total ERK, rather than
regulation of kinases or phosphatases upstream of ERK. We also observed age- and genotypespecific changes in pCREB in the lateral septum following an i.p. saline challenge. CREB is a
transcription factor that is activated by several intracellular kinases, including ERK. The
overexpression of CREB in the nucleus accumbens, another GABA-ergic nucleus, reduced
anxiety-like behaviors in both the open field (Barrot et al., 2002) and elevated plus maze assays
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(Barrot et al., 2005). In these present studies, we observed increased levels of pCREB in both
WT-Aged and α4HET-Adult Adult mice compared to WT-Adult controls. However, pCREB
was not reduced in the lateral septae of α4HET-Aged mice, suggesting that activation of CREB
by pERK in the lateral septum may be an important for the promotion of anxiolysis-like behavior,
but that other downstream targets of pERK may be critical in regulating the increased anxietylike behaviors observed in Aged α4HET mice.

Although the incidence of anxiety-related disorders is typically lower in healthy, elderly subjects
than young adult human subjects (Flint, 1994), it is elevated in those with co-morbidities
associated with abnormal neurodegenerative processes such as AD or dementia (WolitzkyTaylor et al., 2010). β2*nAChRs protect against age-related neurodegeneration and hypergliosis
in mice (Zoli et al., 1999) as well as damage resulting from excitotoxic lesions (Zanardi et al.,
2007). In vitro studies show that activation of β2*nAChRs and the ERK pathway inhibits
neuronal toxicity associated with AD (Kawamata & Shimohama, 2011; Kihara et al., 1998),
although the role of α7nAChRs cannot be excluded (Kawamata & Shimohama, 2011). In the
present studies, anxiogenic-like behaviors observed in α4HET-Aged mice were associated with
reduced pERK in the lateral septum. Furthermore, direct antagonism of β2*nAChRs increased
anxiety-like behavior and reduced pERK in the lateral septum in α4HET mice, but not WT mice.
Taken together these data suggest that impaired ERK signaling in the lateral septum of α4HETAged mice may have accelerated age-related neurodegeneration, contributing to increased
anxiety-like behaviors. These present studies are consistent with human studies showing that
anxiety-like behavior decreases in an age-dependent manner, while elderly subjects with
advanced neurodegeneration associated with pathologic reductions of nAChRs actually
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demonstrate increased anxiety. Finally, these studies suggest that pathological reductions of
α4β2*nAChRs in non-elderly human subjects may be a biomarker of the onset of
neurodegenerative processes such as AD.
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Chapter 6 – Concluding discussion

In these experiments, we first demonstrated that low doses of nicotine (0.01, 0.032 and 0.05
mg/kg) and a selective antagonist of β2*nAChRs, DHβE, reduced anxiety-like behavior in mice
using four independent behavioral models with predictive validity for evaluating the anxiolyticlike properties of drugs, namely the conditioned emotional response assay, the marble burying
task, the elevated plus maze assay, and the light-dark assay. The administration of 0.001 mg/kg
of the selective β2*nAChR agonist 5I-A85380 also promoted anxiolysis-like behavior in the
elevated plus maze assay. Conversely, injections of a high dose of nicotine (0.5 mg/kg) and 5IA85380 (0.032 mg/kg) promoted an anxiogenic-like phenotype in the light-dark and elevated
plus maze assays. These results are consistent with previous studies showing that nicotine has a
bimodal effect on anxiety-like behavior (Anderson & Brunzell, 2012; Cheeta, Irvine, et al., 2001;
Cheeta, Tucci, et al., 2001; File et al., 2000; File et al., 1998; Irvine et al., 1999; McGranahan et
al., 2011; Ouagazzal et al., 1999; Varani et al., 2012). Additionally, anxiolytic-like doses of
nicotine, DHβΕ or 5I-A85380 did not significantly affect locomotor activity, suggesting that the
observed behaviors reflected an attenuation of anxiety-like behavior rather than increased
locomotion.

Pre-injections of both anxiolytic-like doses of nicotine (0.01 and 0.05 mg/kg i.p.) and a dose of
DHβΕ previously shown to block nicotine place preference and reduce anxiety-like behavior (2
mg/kg i.p.) blocked the anxiogenic-like effects of 0.5 mg/kg i.p. nicotine during the light-dark
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and elevated plus maze assays (Anderson & Brunzell, 2012; Grabus et al., 2006; Walters et al.,
2006). Based upon previous pharmacokinetic studies in mice, the concentrations of nicotine
achieved in the brains of mice following the anxiolytic-like doses of nicotine used in these
studies (0.01 – 0.05 mg/kg i.p.) would likely be between 25-125 nM (Crooks, Li, & Dwoskin,
1995; Petersen et al., 1984; Zhou et al., 2010). These concentrations are sub-threshold of the
EC50 values of nicotine for the high affinity β2*nAChRs (Fenster et al., 1997; R. A. Lester &
Dani, 1995; Mansvelder et al., 2002; Pidoplichko et al., 1997), but are concentrations of nicotine
that in in vitro studies result in preferential desensitization of α4β2*nAChRs and α6β2*nAChRs
(Fenster et al., 1997; Grady et al., 2012; Kuryatov et al., 2011; Lu et al., 1999), but not
α4α6β2*nAChRs (L. Liu et al., 2012). Presently available radioligands to study nAChR binding
in human SPECT studies are not selective for subclasses of β2*nAChRs and are unable to
determine if nAChRs are in an activated or desensitized state. While we did not confirm the
activity of nAChRs in awake, behaving animals after injections of low doses of nicotine, the fact
that both low doses of nicotine and DHβE displayed anxiolytic-like efficacy across behavioral
models and similarly blocked the anxiogenic-like effects of a high dose (0.5 mg/kg) of nicotine
suggests that low doses of the anxiolytic properties of low dose nicotine were promoted via
inhibition, rather than activation, of β2*nAChRs.

Although compounds highly selective for β2*nAChRs were used in these experiments,
pharmacological studies are limited. We therefore performed genetic studies in β2KO mice with
a null mutation of the β2 or α4HET mice with a 50% reduction of the α4 subunit. The
anxiolytic-like behavior observed in WT mice receiving 0.05 mg/kg i.p. nicotine in the light-dark
assay was absent in β2KO mice, confirming that β2*nAChRs are required for the anxiolytic-like
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efficacy of low doses of nicotine. 6-8 month α4HET-Adult mice showed reduced anxiety-like
behavior compared to WT-Adult mice in the light dark and open field assays, suggesting that
reduced cholinergic tone mediated via α4β2*nAChRs is required for the attenuation of anxietylike behavior. L9S mice with hypersensitive α6β2*nAChRs showed an anxiogenic-like
phenotype across several behavioral assays, whereas genetic deletion of the α6 subunit did not
significantly affect the expression of anxiety-like behavior in α6KO null mutant mice,
suggesting that activation of α6β2*nAChRs is sufficient for the promotion of anxiety, but that
inhibition of α6β2*nAChRs is not required for the expression of anxiolytic-like behavior.

Although the pharmacologic and genetic studies suggest that the low doses of nicotine used in
these studies were selective for β2*nAChRs, the use of L9A and L9S mice with hypersensitive
α4β2*nAChRs or α6β2*nAChRs would confirm if these nAChR subclasses are sufficient to
promote the anxiolytic efficacy of nicotine. If the anxiolytic effects of nicotine are promoted by
sub-activating concentrations of nicotine that favor desensitization of β2*nAChRs, then the
anxiolytic-like behaviors observed in WT mice should be absent in L9A or L9S mice. We could
also compare the efficacy of pre-injections of nicotine to dose-dependently block CPP to 0.09
mg/kg i.p. nicotine in WT, L9S and L9A mice. Pre-injections of low-dose nicotine ought to
block CPP in WT, but not in either the L9S or L9A mice, since low doses of nicotine would
activate α4β2*nAChRs in L9A mice or α6β2*nAChRs in L9S mice, but not in WT animals.
Using localized optogenetic activation of nAChRs in Chat-CRE mice co-expressing channel
rhodopsin, we could activate cholinergic neurons in the amygdala, hippocampus or lateral
septum to directly determine if activation of nAChRs in these brain regions promotes an anxiety
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phenotype. Lesions of cholinergic neurons projecting to the amgydala attenuated fear response
in rats (Power & McGaugh, 2002). Genetic deletion of the prototoxin Lynx2, an endogenous
negative allosteric modulator of α4β2*nAChRs highly expressed in the amygdala, results in
increased anxiety-like behavior in mice (Tekinay et al., 2009), suggesting that increased
cholinergic tone in the amygdala promotes anxiety-like behavior. Local infusions of the AChE
inhibitor physostigmine and siRNA knock-down of AChE in the hippocampus resulted in
elevated anxiety-like and depression-like behavior (Mineur et al., 2013). Additionally, exposure
to the synthetic compound bisphenol a results in elevated anxiety-like behavior and reduced
activity of hippocampal AChE (Luo et al., 2013), suggesting that elevated cholinergic tone in the
hippocampus also increases anxiety-like behavior in rodents. Reduced levels of pERK are
observed in the lateral septum following restraint stress and chronic social stress, and our studies
reveal that increased anxiety-like behavior is associated with reduced pERK in the lateral septum
(Sheehan et al., 2003; Singewald et al., 2009). These three brain regions form part of the
circuitry that regulates emotive responses to external stimuli. Once we identify a
neuroanatomical locus wherein optogenetic activation of cholinergic neurons promotes an
anxiogenic phenotype, we would test whether local infusions of nicotine and/or DHβE would
attenuate these effects. Using in vivo electrophysiology technology, we could also measure the
neuronal activity of the amygdala, hippocampus or lateral septum during CER. This would
provide tremendous insight into what neuronal pathways are involved when mice are responding
for a reinforcer in the presence or absence of an aversive CS, or what neuronal pathways are
upregulated or downregulated following the presentation of a footshock, for example.
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β2KO mice were also less sensitive than WT mice to the anxiogenic-like effects of 0.5 mg/kg
i.p. nicotine, suggesting that they were protected from the behavioral effects of 0.5 mg/kg i.p.
nicotine. Locomotor suppression was observed in both WT and β2KO mice during the lightdark assay following 0.5 mg/kg nicotine. An anxiogenic-like dose of 5I-A85380 did not
significantly affect measures of locomotion, further confirming that activation of β2*nAChRs in
mice promotes anxiogenic-like behavior and that activation of some other subclass of nAChRs
likely contributed to the locomotor depressive effects of high dose nicotine, possibly
α3β4*nAChRs (Jackson et al., 2010; Marubio et al., 2003; Salas et al., 2003). We want to
pharmacologically and genetically confirm that the 0.032 mg/kg dose of 5I-A85380 is selective
for β2*nAChRs by assessing if the anxiogenic-like effects of this dose of 5I-A85380 can be
blocked by DHβE and if these effects are present in β2KO mice. Administration of 0.5 mg/kg
nicotine to β4KO mice during the light-dark and elevated plus maze assays would further
determine if the anxiogenic and/or locomotor depressive effects of this dose of nicotine are in
part mediated via α3β4*nAChRs.

Interestingly, a dose of nicotine shown to promote conditioned place preference (0.1 mg/kg i.p.)
(Brunzell et al., 2009; McGranahan et al., 2011; Mineur et al., 2009), which requires the
activation of β2*nAChRs (Brunzell et al., 2010; Corrigall et al., 1994; Gotti et al., 2010; Grabus
et al., 2006; Jackson et al., 2009; X. Liu et al., 2003; Maskos et al., 2005; McGranahan et al.,
2011; Picciotto et al., 1998; Pons et al., 2008; Tapper et al., 2004; Walters et al., 2006), did not
affect anxiety-like behavior in either the light-dark or CER assays. Unlike the opposing effects
of nicotine and nAChR antagonists that are observed for the reward-like and reinforcing
properties of nicotine, pre-injections of anxiolytic-like doses of nicotine and DHβΕ did not
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accumulate with anxiogenic-like effects of 0.5 mg/kg nicotine or block the anxiolytic efficacy of
low doses of nicotine, further confirming that low doses of nicotine promote anxiolysis via
inactivation of β2*nAChRs.

Pre-injections of 0.01 mg/kg nicotine were more effective at blocking the anxiogenic-like effects
of high dose nicotine than pretreatment with 0.05 mg/kg nicotine during the elevated plus maze
assay. This leftward shift in the “antagonist-like” efficacy of nicotine is possibly reflective of
nAChRs being in a “smoldering” state, wherein their conversion to an irreversible Bound and
Desensitized state or to the Bound and Activated state is concentration dependent (Kuryatov et
al., 2011; Williams, Wang, & Papke, 2011). Lower nicotine concentrations prior to the delivery
of 0.5 mg/kg nicotine promoted by pre-injections of 0.01 mg/kg nicotine would favor
desensitization, whereas higher concentrations following 0.05 mg/kg pretreatment would be
more likely to promote activation, leading to increased anxiety-like behavior associated with the
administration of 0.5 mg/kg nicotine.

We also observed age-dependent reductions in anxiety-like behavior in 22-24 month WT-Aged
mice compared to Adult 6-8 month controls during the light-dark assay. In contrast to these
findings, α4HET-Aged mice showed higher levels of anxiety-like behavior than α4HET-Adult
mice and WT-Aged mice in both the light-dark and open field assays. The administration of
DHβE promoted anxiogenic-like behavior in α4HET-Adult, but not WT-Adult mice during the
light-dark assay, suggesting that the age- and genotype-specific changes in anxiety-like behavior
may have been due to further reductions in α4β2*nAChRs. However, the immunoprecipitation
assays performed herein determined that there were no further age-dependent reductions in the
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expression of the α4 subunit in the amygdala, anterior cingulate cortex, lateral septum or dorsal
hippocampus. These findings contrast with previous studies demonstrating age-dependent
reductions in α4β2*nAChRs in mice (Gahring et al., 2005; S. W. Rogers et al., 1998). It is
possible that the antibodies used to detect α4β2*nAChRs in the former studies were less specific
than the antibodies used in these experiments. Also, previous studies were performed using
immunohistochemistry and [3H] nicotine binding assays, which determined the total number of
cells expressing α4β2*nAChRs and/or nicotine binding sites, whereas the immunoprecipitation
experiments detected the expression of α4 subunit protein present in each sample. A large
proportion of nAChR subunits remain sequestered in the endoplasmic reticulum, and are not
expressed on the cell membrane (H. A. Lester et al., 2009; Wanamaker & Green, 2007). Another
possibility is that there was an age-dependent reduction in the expression of the β2 subunit,
which would favor the assembly of α4β2*nAChRs in a lower-affinity α4(3)β2(2) stoichiometry,
resulting in a reduction in α4β2*nAChR-mediated cholinergic tone (Anand et al., 1991; Buisson
& Bertrand, 2001; Cooper et al., 1991; Covernton & Connolly, 2000; Gotti et al., 2008; Khiroug
et al., 2004; Moroni et al., 2006; Nelson et al., 2003; Zwart & Vijverberg, 1998). Unfortunately,
we did not have sufficient animals to perform either immunoprecipitation assays to determine the
expression of the β2 subunit or binding studies to detect potential age-dependent changes in the
number of nicotine binding sites. We also did not detect any age or genotype-specific
differences in serum corticosterone levels following 15 min exposure to a novel cage. These
data suggest that basal expression of α4β2*nAChRs regulated anxiety-like behavior in Adult
animals, but that some factor other than age-dependent changes in nAChR regulation contributed
to age-associated reductions in anxiety-like behavior in Aged WT mice and the inverse
elevations in anxiety-like behavior observed in Aged α4HETs.
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Extracellular regulated kinase is a cellular signaling protein that is important for synaptic
plasticity related to learning and memory and the addictive properties of drugs of abuse (Brunzell
et al., 2009; Brunzell et al., 2003; S. Davis et al., 2000; Schafe et al., 2000; Schafe et al., 2008;
Sweatt, 2001; Valjent et al., 2006; Valjent et al., 2004). In the present studies, elevated levels of
pERK in α4HET-Adult and WT-Aged mice in the lateral septum were associated with reduced
anxiety-like behavior compared to their counterparts of the same genotype. Additionally,
significant decreases in pERK in the lateral septum were associated with the anxiogenic-like
behavior observed in α4HET-Adult mice following 3 mg/kg i.p. DHβE. These data are
consistent with previous studies showing reduced pERK in the lateral septum following exposure
to restraint stress or chronic social stress (Sheehan et al., 2003; Singewald et al., 2009). We did
not observe any effects of age or DHβE administration on pERK in α4KO mice, suggesting that
the changes of pERK in the lateral septum observed in these aging and pharmacological studies
were mediated via α4β2*nAChRs. They further suggest that ERK phosphorylation in the lateral
septum may regulate the age-related changes in anxiety-like behaviors that were observed in
Aged WT and α4HET mice in these studies.

The preponderance of evidence suggests that pERK serves a neuroprotective role (Al Rahim et
al., 2008; Hetman, Kanning, Cavanaugh, & Xia, 1999; Karmarkar, Bottum, Krager, & Tischkau,
2011; Kihara et al., 1998; Yim et al., 2009), but can also promote neuronal death (Chen, Rusnak,
Lombroso, & Sidhu, 2009), showing that dysregulation of ERK signaling is deleterious to
cellular health, including neurons. pERK is regulated either by changes in the activity of
MEK ,the only known kinase of ERK, or by phosphatases that inactivate ERK. The phosphatase
STEP can inactivate ERK, and outside of the striatum, STEP expression is highest in the lateral
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septum, suggesting its importance as a regulator of pERK in this brain region (Boulanger et al.,
1995; Lombroso et al., 1993). STEP expression is increased in the cortex in various transgenic
rodent models of AD and in the PFC of humans diagnosed with AD, suggesting that its increased
expression may contribute to premature neurodegeneration (Chin et al., 2005; Kurup et al., 2010;
Xu, Kurup, Nairn, et al., 2012; Y. Zhang et al., 2010). Perhaps there was an age-dependent
increase in STEP activity in α4HET animals leading to decreased ERK phosphorylation in the
lateral septum and elevated anxiety-like behavior. Additional western blot analyses could be
performed to quantify the expression of STEP in the lateral septum of Aged and Adult WT and
α4ΗΕΤ mice. If the western blots indicate that STEP is elevated in the lateral septum of
α4ΗΕΤ−Aged mice, one could then knock-down STEP in the lateral septum of
α4ΗΕΤ−Aged mice via siRNA to reverse the anxiety phenotype.

The studies conducted herein demonstrate that pERK in the lateral septum is inversely associated
with anxiety-like behavior. We are unable to determine whether the changes in pERK are
downstream of α4β2*nAChRs or are the result of reduced anxiety. Data from the Aged mice
suggests the latter, since α4β2*nAChRs are not differentially expressed in the hippocampus,
anterior cingulate cortex, amygdala or lateral septum compared to Adult mice. However, we did
observe reduced pERK and increased anxiety-like behavior in α4HET mice after the
administration of DHβE, suggesting that basal expression of α4β2*nAChRs may have regulated
pERK in Adult animals. Compared to WT-Adult controls, α4HET-Adult mice showed elevated
levels of pERK in the lateral septum. These mice would likely have a 50% reduction of
α4β2*nAChRs on the terminals of GABA interneurons in the VTA. Compared to WT mice,
ACh release in the VTA would favor disinhibition of VTA DA neurons in α4HET mice,
173

facilitating DA release in the lateral septum, leading to increased pERK in that brain region,
supporting a reduction in anxiety (Graupner et al., 2013; Mansvelder et al., 2002; Mineur et al.,
2009; Pidoplichko et al., 1997). Determining the effects of infusions of the MEK inhibitor
U1026 into the lateral septum on anxiety would directly assess if reduced ERK phosphorylation
in this brain region promotes anxiety-like behavior. Additionally, with new technology available
in our lab, we would also be able to determine in vivo electrophysiological changes in the brains
of awake, behaving mice in real time following MEK inhibition. The administration of the
benzodiazepine chlordiazepoxide activates the lateral septum and inhibits activity within the
amygdala (Yadin & Thomas, 1998), suggesting that the opposing activities of these two brain
regions may be coordinated to regulate the emotive response to an aversive stimulus. Therefore,
this technology would also provide us the ability to evaluate how infusions of U1026 into the
lateral septum may affect neuronal activity in the amygdala. It is unknown if the nAChRs
affected by nicotine and/or nicotinic antagonists in the lateral septum are pre or post-synaptic.
Mice receiving nicotine or DHβE challenge could be sacrificed and probed for pERK
immunoreactivity using immunohisotochemistry, which would also allow dual-labeling of
α4β2*nAChRs, to help determine if nAChR ligands are regulating pERK levels pre or postsynaptically.

Human SPECT imaging studies and in vivo studies in rodents show that reduced levels of AChE
promote both anxiety and depression-like behavior (Luo et al., 2013; Mineur et al., 2013;
Saricicek et al., 2012). Reduced serum AChE is associated with increased trait anxiety and
SPECT imaging studies in humans suggest that lower levels of AChE activity are associated with
depression (Saricicek et al., 2012; Sklan et al., 2004). In contrast to the lateral septum, which
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has low levels of AChE staining, AChE staining in the amygdala is dense (Paxinos & K.P.J.,
2003). As stated above, elevated levels of ACh favor desensitization of α4β2*nAChRs in the
presence of nanomolar concentrations of nicotine (Graupner et al., 2013). This would suggest
that higher endogenous levels of ACh might be sustained in the lateral septum than the
amygdala, favoring enhanced nicotine-mediated desensitization of α4β2*nAChRs in the lateral
septum in comparison. However, changes in endogenous AChE activity would have a greater
potential to regulate anxiety-like behavior directly within the amygdala, as increased ACh levels
would support increased amygdalar activity, potentially leading to increased fear and anxietylike responses to aversive stimuli. Human PET imaging studies measuring levels of AChE
activity by metabolism of [14C] MP4A, a radioactive substrate of AChE, show reduced AChE
activity in the amygdala of subjects with mild cognitive deficits, a population that also
demonstrates increased anxiety and amgydalar activity (Herholz et al., 2000; Herholz et al.,
2004; Irie et al., 1996; Iyo et al., 1997; Y. D. Li et al., 2013; Ota et al., 2010). Combined with
activation of the lateral septum, desensitization of α4β2*nAChRs in the amygdala could
potentially coincide to enhance the anxiolytic effects of initial nicotine exposure.

Human studies measuring displacement of the selective β2*nAChR agonist 2-F-A85380 by
nicotine show that there is enough nicotine in a single cigarette to occupy 80% of β2*nAChRs in
the brain of a smoker for hours (Brody, Mandelkern, Costello, et al., 2009; Brody et al., 2006).
Although higher spikes are possible, steady-state concentrations of nicotine achieved in the
brains of human smokers are estimated to be between 200-400 nM, concentrations that ought to
favor desensitization of β2*nAChRs, suggesting the likelihood that many of the β2*nAChRs
would be desensitized for hours (Fenster et al., 1997; Grady et al., 2012; Kuryatov et al., 2011;
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R. A. Lester & Dani, 1995; Lu et al., 1999; Mansvelder et al., 2002; Pidoplichko et al., 1997;
Rose et al., 2010). However, slice electrophysiology studies show that nanomolar concentrations
of nicotine activate α4α6β2*nAChRs, and that this nAChR subclass shows slower rates of
desensitization than other β2*nAChRs (L. Liu et al., 2012). Nonetheless, anxious individuals
smoking for the first time may experience more relief from stressors than non-anxious subjects
following initial nicotine exposure due to desensitization of a large population of α4β2*nAChRs
in brain areas such as the amygdala or lateral septum. As nicotine levels drop, α4β2*nAChRs in
these brain regions would return to the resting state, where they are activated in the presence of
stressful stimuli (Carter et al., 2006; Lazev et al., 1999; Littel & Franken, 2007; McDonough &
Warren, 2001). Additionally, human imaging studies suggest that β2*nAChRs may be critical
for nicotine’s ability to curb anxiety in smokers (Benowitz, 2008; Sharma & Brody, 2009).
Thus, hours after consumption of the first cigarette, people with an underlying propensity for
anxiety-related disorders may be motivated to smoke again in order to return their
α4β2*nAChRs to a desensitized state.

Unfortunately, in addition to being a leading risk factor for the development of most chronic
diseases, repeated nicotine use leads to upregulation of nAChRs, especially β2*nAChRs and
α7nAChRs. Human PET imaging studies suggest that nicotine-facilitated DA release is
increased in the NAcc of smokers, likely due to upregulation of β2*nAChRs (Baker et al., 2013;
Brody, Mandelkern, Olmstead, et al., 2009; Brody et al., 2004; Domino et al., 2013; Domino et
al., 2009; Lomazzo et al., 2011; Metaxas et al., 2010; Moretti et al., 2010; Perez et al., 2008;
Perez et al., 2013; Takahashi et al., 2008; C. Xiao et al., 2009). Studies in rodents show that
chronic nicotine administration results in a downregulation of the high affinity α6α4β2*nAChRs
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on DA neurons, whereas the expression of α4β2*nAChRs on GABA interneuron terminals is
increased (Baker et al., 2013; Lomazzo et al., 2011; Metaxas et al., 2010; Moretti et al., 2010;
Perez et al., 2008; Perez et al., 2013; C. Xiao et al., 2009). This dichotomous up and
downregulation of subclasses of β2*nAChRs has the potential to affect not only the rewarding
effects of nicotine use, but also anxiety. Upregulation of α4β2*nAChRs in the amygdala would
enhance the nAChR-mediated cholinergic tone in this brain region, increasing anxiety in
response to ACh release in the amygdala when these receptors are in the Resting and Unbound
state. Similarly, upregulation of α4β2*nAChRs in the lateral septum would facilitate greater
release of anxiogenic neuropeptides such as CRF, if these nAChRs are positioned on the
terminals of CRF projection neurons. Taken together with data showing that repeated
administration of nicotine results in a downregulation of AChE activity in the brains of rats,
circulating levels of ACh would increase, facilitating greater nicotine-mediated desensitization of
α4β2*nAChRs. Furthermore, as nicotine levels drop, populations of β2*nAChRs in brain
regions that regulate anxiety such as the amygdala, cingulate cortex and septum become
available for activation by increased levels of ACh in response to stressful stimuli such as
cigarette/tobacco cues (Carter et al., 2006; Lazev et al., 1999; Littel & Franken, 2007;
McDonough & Warren, 2001), contributing to escalation of tobacco use in order to alleviate the
negative consequences of upregulation of α4β2*nAChRs in these brain regions (Koob &
Volkow, 2010).

This would also suggest that smokers might be more sensitive to the anxiety-relieving properties
of nicotine. In fact, human imaging studies show that the nicotine patch alleviates negative
affect in smokers, but not non-smokers, in a picture attention task (Gilbert et al., 2008) and
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reduces the functional connectivity between the amygdala and the insular and cingulate cortices
in smokers, but increases it in non-smokers (Sutherland et al., 2013). Similar effects are
observed in smokers following administration of the selective α4β2*nAChR agonist varenicline
(Sutherland et al., 2013), suggesting that the nicotine delivered via the application of a nicotine
patch may be inactivating α4β2*nAChRs in the amygdala in smokers. Furthermore, elevated
cued fear conditioning responses in human subjects with trait anxiety correlate with increased
activation of the amygdala and anterior cingulate cortex, brain regions also important regulators
of fear conditioning in rodents (Britton et al., 2011; Craske et al., 2008; Delgado et al., 2006;
Lang & McTeague, 2009; Sehlmeyer et al., 2011; Waters et al., 2009). Thus, when in the resting
state, upregulation of α4β2*nAChRs in the amygdala and/or lateral septum could contribute to
enhanced perception of environmental stressors, signaling subsequent smoking episodes,
contributing to the perceived anxiety relief provided by nicotine use (Parrott, 1999). In fact,
heightened perception of stress is linked with escalation of smoking behavior from occasional to
daily use (Byrne et al., 1995; Byrne & Mazanov, 2003; Finkelstein et al., 2006; Siqueira et al.,
2000). Studies suggest that smokers are more anxious than non-smokers, perhaps due to
upregulation of nAChRs in the cortex or striatum. Unfortunately, human imaging studies have
not determined if the expression of β2*nAChRs is regulated in the amygdala of smokers
(Benwell et al., 1988; Breese et al., 1997; Cosgrove et al., 2009; Gilbert et al., 2008; Staley et al.,
2006; Staley et al., 2005; Tsuda et al., 1996).

To test the hypothesis that reduced elevated cholinergic tone due to reduced AChE activity
would render one more sensitive to the initial anxiolytic-like effects of low doses of nicotine, one
could first evaluate the anxiolytic-like efficacy of between-subject delivery of 0, 0.01 or 0.032
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mg/kg i.p. nicotine. After the conclusion of the behavioral test, the mice would then be
sacrificed and the amygdala and hippocampus would be harvested. These tissues could then be
assayed for AChE activity. From this, one could determine if there is a negative correlation
between AChE activity and initial sensitivity to the anxiolytic-like efficacy of nicotine. We
would then determine if the administration of physostigmine and/or siRNA knock-down of
AChE in either the amygdala or hippocampus would result in a leftward shift in the anxiolyticlike efficacy of nicotine.

Although the results of the genetic studies conducted in Chapter 5 suggest that reduced basal
expression of α4β2*nAChRs promotes anxiolytic-like behavior in Adult mice, they also
demonstrate that α4HET mice are sensitive to age-dependent increases in anxiety-like behavior.
This is consistent with human studies, showing that pathological reductions in nAChRs are
associated with elevated prevalence of anxiety-related disorders in geriatric subjects with
advanced cognitive deficits and AD (Brodaty et al., 2012; Mitsis et al., 2009; Sabbagh et al.,
2006). A preponderance of the research concerning cognitive deficits and AD is centered around
the homomeric α7nAChRs. These studies suggest that α4β2*nAChRs may also be important
modulators of molecular changes related to age-dependent changes in anxiety. Additionally, the
pharmacological studies revealed that selective antagonism of β2*nAChRs promoted anxietylike behavior in α4HET mice in the light-dark assay, but the administration of DHβΕ resulted in
reduced anxiety-like behavior in WT mice in a number of assays for anxiety-like behavior.
These results are consistent with increased cholinergic tone improving affect in individuals with
advanced cognitive deficits that are associated with pathological reductions in nAChRs (S. L.
Rogers et al., 1998; Sabbagh et al., 2006) and promoting increased anxiety and depression-like
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behavior in younger humans and rodents (Mineur et al., 2013; Saricicek et al., 2012). The
administration of repeated injections of physostigmine or nicotine to Aged α4HET mice might
reverse age-dependent changes in anxiety-like behavior observed in these studies. We could
further assess if optogenetic stimulation of cholinergic neurons in the lateral septum would
promote anxiolysis-like behavior in Aged α4HET mice.

The activation of α6β2*nAChRs regulates nicotine-induced release of DA in the dorsal striatum
and NAcc, and is thought to chiefly be responsible for the reinforcing effects of nicotine
(Brunzell et al., 2009; Drenan et al., 2010; Drenan, Grady, et al., 2008; Pons et al., 2008).
Persistent activation of α4α6β2*nAChRs promoting sustained DA release in the NAcc is
thought to be a mechanism by which nanomolar concentrations of nicotine may support cigarette
smoking throughout the day and may also reduce anxiety in smokers (L. Liu et al., 2012).
Additionally, the anxiolytic effects of 0.01 mg/kg i.p. nicotine observed in the elevated plus
maze were absent in mice with a selective deletion of the α4 subunit from VTA DA neurons,
suggesting that activation of α4α6β2*nAChRs by nanomolar concentrations of nicotine may
also promote anxiolysis in mice in this behavioral model (McGranahan et al., 2011). However,
the genetic studies performed herein demonstrate that, compared to WT controls, L9S mice with
a gain-of-function single point L9’S mutation in the M2 pore-forming region of the α6 subunit
showed an anxiogenic-like phenotype across multiple behavioral assays, whereas no behavioral
differences were observed between α6KO mice and their WT counterparts. These data suggest
that persistent activation of α6β2*nAChRs by nicotinic agonists would heighten rather than
attenuate anxiety-like behavior. Taken together with data demonstrating that antagonism of
α6β2*nAChRs attenuates both anxiety-like behavior and conditioned place aversion during
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nicotine withdrawal, these present data highlight that α6β2*nAChRs may be important for both
the reinforcing effects of nicotine as well as the relief from stress reported by smokers during
abstinence periods (Jackson et al., 2009). The discrepancy between L9S mice expressing an
anxiogenic phenotype and the lack of an anxiety phenotype in α6KO animals may have been due
to the fact that the paradigms used in these studies were not stressful enough to uncover an
anxiolytic phenotype in α6KO mice. Future studies will evaluate if genetic deletion of
α6β2*nAChRs will promote anxiolysis in the light-dark, elevated plus maze or open field
locomotor assays following restraint stress compared to WT control animals. The suppression of
HPA-axis activity following 30 min exposure to a novel cage observed in L9S mice could be
reflective of reduced HPA-axis responses observed in human smokers exposed to a social stress
paradigm or with the depression-like behaviors exhibited by humans and mice with reduced
AChE activity (Childs & de Wit, 2009; Kudielka & Wust, 2010; Mineur et al., 2013; Saricicek et
al., 2012; Swan et al., 1996). Further studies would include evaluation of spontaneous nicotine
withdrawal in L9S mice. I predict that L9S mice would display more observable signs of
nicotine withdrawal than WT mice. Furthermore, I predict that there would be a left-ward shift
in the dose of chronic nicotine required to elicit observable signs of spontaneous withdrawal. I
also expect that there would a left-ward shift in the ability of α-conotoxin MII to attenuate the
reduced time spent in the open arms of an elevated plus maze in L9S mice. Considering that
HPA-axis suppression is also expressed in individuals diagnosed with depression, L9S mice
could be further evaluated for immobility time in the forced swim or tail suspension tests to
determine if they also express a depression-like phenotype in addition to an anxiety phenotype.
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With the exception of the conditioned emotional response and marble burying experiments,
wherein animals received within-subject delivery of multiple doses of nicotine and/or DHβE,
these experiments evaluated the effects of acute administration of nAChR ligands on anxiety-like
behavior. While acute administration is informative regarding mechanisms underlying initial
sensitivity to nicotine’s effect on anxiety-like behavior, tobacco use is typically chronic, leading
to nAChR upregulation and enhanced DA release in the NAcc (Baker et al., 2013; Brody,
Mandelkern, Olmstead, et al., 2009; Brody et al., 2004; Domino et al., 2013; Domino et al.,
2009; Lomazzo et al., 2011; Metaxas et al., 2010; Moretti et al., 2010; Perez et al., 2008; Perez et
al., 2013; Takahashi et al., 2008; C. Xiao et al., 2009). Chronic administration of nicotine in
mice promotes anxiolysis before withdrawal, but leads to anxiogenic-like behavior during
withdrawal (Jackson et al., 2009; Koob & Volkow, 2010; Turner et al., 2013). The
α4β2*nAChR partial agonist sazetidine-a and the selective α6β2*nAChR antagonist αconotoxin [H9A;L15A] attenuated these anxiogenic-like effects of nicotine withdrawal (Damaj,
Kao, & Martin, 2003; Jackson et al., 2009; Turner et al., 2013). Additionally, mice in
spontaneous withdrawal from nicotine are less sensitive to the anxiogenic-like effects of a high
dose of nicotine (0.5 mg/kg), which attenuates the anxiogenic-like behavior promoted by
spontaneous nicotine withdrawal (Damaj et al., 2003).

In light of these data and the results from these present acute studies, we will first administer
mice either 0.01 or 0.032 mg/kg i.p. nicotine prior to evaluation of anxiety-like behavior in the
elevated plus maze assay. These mice will then be administered chronic saline or nicotine via
osmotic mini-pumps. During nicotine withdrawal, I predict that mice showing more anxiolyticlike behavior after an acute dose of nicotine would be more sensitive the anxiogenic-like effects
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of nicotine withdrawal. Furthermore, we would observe a left-ward shift in the dose response
curve of sazetidine-a to attenuate anxiogenic-like behavior associated with nicotine withdrawal
in mice more sensitive to the anxiolytic properties of acute nicotine.

Due to their expression throughout the CNS, antagonism or partial agonism of α4β2*nAChRs
has the potential to promote many unwarranted side-effects in addition to possible relief of
anxiety and smoking behavior. With the exception of the partial agonist/preferential
α4β2*nAChR desensitizer sazetidine-a, chronic administration of nicotinic agonists and
antagonists results in upregulation of α4β2*nAChRs in in vitro and in vivo systems, which could
result in heightened negative affect during periods of withdrawal from the drug (Baker et al.,
2013; Lomazzo et al., 2011; Metaxas et al., 2010; Moretti et al., 2010; Perez et al., 2008; Perez et
al., 2013; C. Xiao et al., 2009). Although the expression of α6β2*nAChRs is more selective, the
paucity of ligands selective for α6β2*nAChRs that cross the blood-brain barrier makes it
difficult to evaluate the contributions that this nAChR subclass makes to nicotine’s effects on
anxiety. Efforts to develop ligands that selectively affect α4β2*nAChRs or α6β2*nAChRs are
hampered by the inability to express native α6*nAChRs in in vitro assays utilizing xenopus
oocytes without the use of concatomers (Kuryatov & Lindstrom, 2011). A therapeutic
alternative would be negative allosteric modulators (NAM) of nAChRs. NAMs of
α4β2*nAChRs would reduce cholinergic activation of nAChRs, rather than block it or
exogenously promote partial agonism of nAChRs. Thus, NAMs have the potential to be less
likely to promote unwarranted side effects than partial agonists or nAChR antagonists. The nonselective NAM UCI-30002 potently blocks both electrical stimulus and nicotine-evoked nAChRmediated currents, effectively crosses the blood-brain barrier, and dose-dependently reduces
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intravenous nicotine self-administration (Yoshimura et al., 2007). Although the α4β2 >>
α3β4/α7 selectivity of several molecules has been evaluated using in vitro systems, a negative
allosteric modulator selective at α4β2*nAChRs has not yet been identified (Henderson et al.,
2012; Henderson et al., 2010; Pandya & Yakel, 2011). It is not known whether chronic
administration of NAMs of nAChRs would affect nAChR expression, but the fact that chronic
administration of sazetidine-a does not increase the expression of nAChRs suggests that
upregulation of nAChRs may also be absent with chronic administration of nAChR NAMs,
reducing the negative effects of withdrawal that may accompany upregulation of α4β2*nAChRs.

In light of the data presented in these studies, it is critical to understand how high affinity
β2*nAChRs regulate changes in anxiety, whether their contributions are connected with tobacco
use or with changes resulting in age-depedent increases in anxiety. These studies also suggest
that it would be beneficial to determine if dysregulation of the basal cholinergic tone underlies
the tobacco use and/or anxiety disorder of the individual. Furthermore, since chronic anxiety can
contribute to an acceleration of cell death, including neuronal death, and the emergence of
anxiety in the geriatric population may signal the onset of cognitive degeneration and/or AD, it is
important to develop diagnostic tools to identify susceptible populations and select therapeutic
intervention strategies that address the needs of the individual. Presently, the selective
β2*nAChR agonist 5I-A85380 is the best available tool to determine expression levels of
β2*nAChRs via SPECT scans. Unfortunately, it does not distinguish between the subclasses of
β2*nAChRs, and its utility is limited. Also, it cannot determine if nAChRs are in an active or
desensitized state. The radioactive ligand of AChE [14C] MP4A is presently used to determine
endogenous AChE activity via PET scans, but the use of PET scans to determine basal AChE
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activity in the general population is cost prohibitive. However, combined with the emerging
molecular tools being presently employed in preclinical studies, improved methods to detect the
functional status of nAChRs and basal AChE activity in in vivo human assays may be developed.
By determining the specific dysregulated neurotransmitter system that may underlie symptoms
of anxiety and/or habitual tobacco use, a more precise pharmacological treatment regimen can be
prescribed that better meets the needs of the individual.
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